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Abstract 
Primary Aim: To describe the relationship between relapse and disability III 
multiple sclerosis. 
Introduction: The relationship between relapse and disability in multiple sclerosis is 
presently unclear. Whilst natural history studies have confirmed the disabling effects 
of insidious disease progression they have suggested that relapse. the clinically 
defining feature of the majority of cases multiple sclerosis, is largely unrelated to 
disability. However the major therapeutic strategies currently in use against multiple 
sclerosis are known only to ameliorate relapses and their ability to prevent long term 
disability is not presently based on evidence but faith in a long presumed, but 
unproven relationship between relapse, disease progression and disability. 
Method: A cross sectional study of 150 patients with multiple sclerosis was 
performed. Details of previous relapses and current impairment and disability were 
collected. Statistical analysis was performed to see if the character of preceding 
relapses correlated with the character of current disability. 
Main Results and Conclusions: Relapses do cause relevant chronic impairment, 
however for a number of disease and scale related reasons this fails to translate into 
chronic disability. Disease related reasons include an apparent extra resistance of 
motor pathways to relapse, whilst scale related reasons include the widespread use of 
disability scales that are heavily predicated upon motor pathway dysfunction and less 
sensitive to sensory pathway dysfunction. We conclude that many of the paradox 
observed in multiple sclerosis tell us as much if not more about the tools used to 
observe the disease, as they do about the disease itself. 
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Chapter 1: Introduction 
The aims of this thesis are as follows: 
1. To describe the relationship between relapse and disabilit)· in multiple 
sclerosis. 
2. To describe the neurological deficits encountered during relapses of 
multiple sclerosis. 
3. To describe in detail the neurological deficits at prevalence in a defined 
population of patients with multiple sclerosis. 
Multiple sclerosis is a disease of the central nervous system and frequently leads to 
chronic disability. lean-Martin Charcot was the first to recognise the basic clinico-
pathological spectrum of the disease in the latter half of the 19th century. 
Multiple sclerosis may occur at any age although onset is most common in the 3rd 
and 4th decades of life. It is approximately twice as common in females as males. It is 
recognised to be rare in equatorial regions and become progressively commoner as 
one moves towards the poles. Prevalence figures of approximately 1 in 1000 in 
Western countries I are typical. There are several commonly recognised temporal 
disease patterns including2 relapsing-remitting, secondary progressive and primary 
progressive disease sub-types. 
Several aspects of multiple sclerosis remain enigmatic, these include: 
• Pathogenesis. A combination of environmental and genetic factors is a 
correct but largely unhelpful solution. Exactly which environmental and 
genetic factors remain unknown. 
• Pathology. Whilst the pathology of the later stages of the disease have been 
described in minute detail and heavily implicate inflammatory demyelination. 
descriptions of the earliest MS lesion are rare) and suggest that intlammation 
may be a partially adaptive response to an alternative primary pathology4. 
• 
Clinical disease course. The relationship between relapse. disease 
progression and long ternl disability remains unclear. \\'e do know that the 
relapse free disease subtype (primary progressive disease) has the worst 
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prognosis
5 
and that the course of secondary progressive disease is unaffected 
by antecedent relapses6. However it remains received. although unproven. 
wisdom that relapses shape future disability"7 and consequently that reducing 
relapses will have long-lasting prognostic benefits8. 
• Treatment. Despite considerable research and investment there have been no 
cures and no treatments that have conclusively altered the long-tenn natural 
history of multiple sclerosis9. 
Whilst the principal dilemma remams with the pnmary pathology of multiple 
sclerosis we believe useful inferences can be derived from a purely clinical study. 
Whether or not inflammation is the primary pathology3, its clinical hallmark. the 
acute relapse, bears an uncertain relationship to the chronic disability. In order to 
understand the possible rationale for this it is necessary to look in further detail at the 
following areas of multiple sclerosis: basic tenninology. natural history. pathology, 
radiology and therapy with a special emphasis on the relationship between relapse 
and disability. 
(1) The basic terminology of multiple sclerosis 
The natural history of multiple sclerosis is heterogeneous with regard to the 
individual and can range from a fatal index relapse paralysing respiration to a pair of 
mild sensory relapses with no pennanent deficit. Although a comprehensive record 
of the natural history of multiple sclerosis has been difficult to achieve (for reasons 
which will be discussed later) there are basic clinical disease features and temporal 
sub-types that merit discussion. 
There are two basic clinical phenomena that underlie multiple sclerosis: th~ relapse 
and disease progression. Relapses are thought to be the clinical expression of acute 
inflammatory focal lesions disseminated in the central nernms system. \\ht:rt:as 
progreSSIOn is less wt:ll understood but is traditionally considered to reflect the 
occurrence of chronic demyelination. axonal loss. and gliosis. Indeed the 
relationship. or non-relationship. between these two entitit:s4;lo-L' and th~ reasons 
behind this are critical to the paradigm shift in multiple sclerosis theory. Clinically 
relapse and progression both refer to deterioration in a patient with multiple sdcwsis. 
13 
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the distinction is in the timing. In broad terms a rdapse occurs over days or weeks 
whilst progression occurs over months or years. 
The relapse has been defined as an . episode of neurological disturbance of the kind 
seen in MS, when clinicopathological studies hayc established that 'he causari .... ·(' 
lesions are inflammatory and demyelinating in nature. .4lthough there was some 
divergence of opinion, the group agreed that, for general diagnostic purposes, all 
attack, defined either by subjective report or by oNecri1'l! observation. should last/or 
at least 24 hoursJ3. This assumes that there is expert clinical assessment that the 
event is not a pseudo attack, such as might be caused hv a chGlwe in cor(' hOc/l' 
. 0 . 
temperature14 or infection. Whereas suspicion of an attack may be provided by 
sll~jective historical reports from the patient, objectil'e clinical jinding,\ oj a lesion 
are required to make a diagnosis of JIS Single paroxysmal episodes (eg. a tonic 
5pasm) do not constitute a relapse, but multiple episodes occurring Ol'er not less thall 
24 hours do,' 15 
Disease progression refers to an insidious deterioration of neurological function 
over time. The period of time over which progression must occur is not dependent 
upon known pathological correlates but rather varies according to purpose. Generally 
for secondary progression, where the diagnosis of multiple sclerosis is already made, 
a period of six months is acceptable JO;16. In progressive onset disease the differential 
diagnosis is wider and includes several treatable possibilities such as compressi\'l~ 
disc disease and vitamin B 12 deficiency, For this reason the McDonald criteria 
require a period of 12 months sustained disease progression (as well as positive 
oligoclonal bands) in order to make a diagnosis of primary progressive MS without 
the aid of MRI. Certainly a longer period of disease progression lessens the chances 
of confusing relapse and progression. 
An attempt to achieve international consensus on the varying temporal phenotypes 
within multiple sclerosis has highlighted inconsistencies~. Researchers frequently use 
different tenns for the same phenomenon and similar terms for different phenomena. 
Accepting that a democratic approach to defining the temporal course of multiple 
sclerosis is probably the best compromise we must also recognise that pathological 
processes are likel\' unaccountable to public opinion, The results of the surve\, 
1.t 
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suggested the following disease sub-types2: Relapsing-remitting. primary 
progressive, secondary progressive. progressive relapsing. benign and malignant 
multiple sclerosis (see figure 1-1). The term relapsing-progressive multiple sclerosis 
was agreed to be a variant of secondary progressive disease and the distinction was 
deemed to be unhelpful. 
(i) Relapsing-remitting multiple sclerosis 
This comprises 'clearly defined relapses with full recovery or with sequellae and 
residual deficit upon recovery; periods between disease relapses characterised by a 
lack of disease progression' . 
(ii) Primary progressive multiple sclerosis 
This comprises 'disease progression from onset with occasional plateaus and 
temporary minor improvements allowed'. Approximately 10-15% of patients with 
multiple sclerosis have primary progressive disease17. 
(iii) Secondary progressive multiple sclerosis 
This comprises an 'initial relapsing-remitting disease course followed by progression 
with or without occasional relapses, minor remissions, and plateaus'. With prolonged 
follow up approximately 10-150/017 of relapsing remitting patients do not enter the 
secondary progressive phase. 
(iv) Progressive-relapsing multiple sclerosis 
This comprises 'progressive disease from onset, with clear acute relapses, with or 
without full recovery: periods between relapses characterized by continuing 
progressIOn. 
Benign and malignant are additional terms that can co-exist with any of the ahove 
disease sub-types: 
15 
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(v) Benign multiple sclerosis 
This comprises ' disease in which the patient remaIn full fun ti nal In all 
neurological systems 15 years after di sease on et . 
(vi) Malignant multiple sclerosis 
This comprises ' disease with a rapid progress i e cour e leading t ignifi ant 
disability in mUltiple neurologic systems or death in a relati el hort tim ft r 
disease onset' . 
Figure 1-1: The four sub-types of multiple sclerosis 
(i) RelapSing-remitting MS (ii) Prima ry progre si e M 
Time Tim e 
(iii) Secondary progressive M (iv) Progre si e reJap ing M 
Time Time 
(2) The natural history of multiple sclerosis 
Th id al natural hi tory tudy would include a populati n- a d h rt Ing 
identifi ed at the n t and th n cI ly fo Il w d up D r th durati n f th di 
ral fI atur f multipl ha mad th i h II 
an rna impl n t att nd th ir 1 t I n 
rflrrdt a r t d r fI ITa I unit. Th ntinuin a f d finiti\ 
di gn ti t tm it imp 11 t th ir in ti n. lini Ian 
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para-clinical information increasingly allow for the creation of diagnostic criteria, of 
which the McDonald criteria15 are the most recent, but fulfilling these criteria is 
subtly different from actually having the disease. Often multiple sclerosis can only be 
confidently diagnosed retrospectively which hinders prospectiye observation. 
Hospital based series have a natural bias towards more severe disease. The chronicity 
of the disease makes follow up over many years very difficult. Whilst we cannot be 
sure that existing treatments are effective at altering the long term natural history of 
multiple sclerosis the obverse is also true. Therefore the opportunity for recording the 
natural history of multiple sclerosis may, hopefully, have already passed. 
Obtaining hard 'endpoints' has also been challenging. Multiple sclerosis is a disease 
principally of morbidity and not mortality so death is not a particularly enlightening 
endpoint. For this reason Kurtzke's disability status score18 (DSS) and subsequent 
expanded disability status score19 (EDSS) have proved popular. However although 
this scale ranges from zero to ten and the EDSS has introduced half points (a total of 
twenty different descriptions of disability), most natural history studies have used 
only four of these descriptions. These relate to impaired gait (4), the walking stick 
(6), wheelchair (7) and grave (10) (see figure 1-2). 
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4 Limited walking ability but able to walk for more than 500 metres 
without aid or rest. 
6 Ability to walk with unilateral support no more than 100 m without rest. 
7 Ability to walk no more than 10m without rest while leaning against a 
wall or holding onto furniture for support, 
10 Death due to multiple sclerosis. 
The advantages of these points are that they are relatively simple and bear 
translation. Whilst newer scales20 ;21 should undoubtedly be adopted for therapeutic 
trials in multiple sclerosis, the EDSS at present is the language of natural history in 
multiple sclerosis. 
Of the numerous natural history studies of multiple sclerosis two merit individual 
consideration. These are the London, Ontario and the Lyon cohorts. 
(i) The London, Ontario cohort 
A study of the natural history of untreated multiple sclerosis has been carried out in 
London, Ontario, Canada, over the past generation5:11 ;17;22-24 chiefly supervised by 
George Ebers. The MS clinic at the University Hospital in London. Canada, was 
established in 1972. This clinic has been able to study a geographically based 
population of patients longitudinally by means of regular follow up. Stringent effort 
has been made to follow up the benign and advanced disease courses, which are 
often lost to clinic based series due to apathy and institutionalisation respecti\dy. 
The study also benefits from an internal control suggesting near complete 
ascertainment. A geographical subgroup of their patients from \ t iddksex county 
were the subject of a fomlal prevalence study~5 that showed 90o~ ascertainment of 
multiple sclerosis cases There are now some 25.000 patient-years of follow-up in a 
cohort of 1099 individuals. 
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The data reveals that a number of factors are associated \\ith long-tenn outcome of 
multiple sclerosis. The Ontario study shows several clinical variables that can be 
used to evaluate prognosis. The two most important indicators of a poor prognosis 
are the development of a progressive deficit and time to onset of progressive deficit. 
In addition, and independently, a high number of relapses in the first and second year 
is associated with a significantly shorter time to EDSS 6, as is the development of 
early unremitting disability. 
The study also failed to find any available clinical features that distinguish primary 
progressive and secondary progressive multiple sclerosis (an assertion we seek to 
examine in Chapter 2) raising the question of whether these are fundamentally the 
same disease24. The clinical similarities between primary and secondary progressin~ 
disease would suggest that relapses, a preceding feature of secondary progressive but 
not primary progressive disease, do not detennine chronic disability. 
This leaves the problem of explaining the ultimately deleterious effect of a high 
number of relapses in the first and second year of the disease22 . One possibilityll is 
that relapses may be associated with, rather than the cause of disability in multiple 
sclerosis. By way of example as steroids are frequently used to treat relapses one 
might also expect to find a higher usage of steroids in association with a more severe 
disease course, but one could not reasonably propose that the steroids had caused the 
disability. If inflammation and their resultant relapses are an adaptive2h .27 (albeit 
frequently maladaptive) response to an as yet unidentified primary pathology3.4.2h.2x 
then, much as with steroids, we may expect to find an association between relapses 
and disability without causation. 
(ii) The Lyon, France cohort 
The Clinique de Neurologie in Lyons, France, has been patiently recording the 
clinical details of multiple sclerosis patients since 1976 under the guidance of 
Christian Confavreux. The European Database for Multiple Sclerosis (ED\1LS)29 
has been used to record the infonnation since 1990. At the patient's initial visit 
retrospective details of the disease were recorded but subsequent assessment was 
annual and prospectIve. A total of 1844 patients with clinicdly definite l)r rrobabk 
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multiple sclerosis as defined by the Poser criteria 13 were identified. The average 
disease duration was 11 years. 1562 of these patients had relapsing-remitting onset 
disease compared with 282 (15.3%) with primary progressiye disease. The 
relationship between relapse onset (relapsing-remitting and secondary progressiyc) 
and progressive onset (primary progressive) disease with regard to irreversible 
disability was examined 10. 
In the whole group the median time from disease onset to an EDSS of 4.6 and 7 was 
8.4, 20.1 and 29.9 years respectively. Subgroup analysis confirmed that primary 
progressive disease was associated with a much shorter time from onset to a score of 
EDSS 4. However this difference was lost once an EDSS score of -t was obtained 
(see figure 1-3). This suggests that once walking becomes limited the pathological 
processes are unrelated to previous disease activity including relapses6. In addition 
super imposed relapses on either primary or secondary progressive disease were not 
found to hasten disability progression. 
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Figure 1-3: The relationship between time from disease onset (i) and time from 
EDSS 4 (ii) until fIXed disabilitylO, 
(i) Median time from disease (ii) Median time from EDSS 
onset 4 
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Further analysis by the Lyon group6 found that many of the factors traditionally 
associated with a poor prognosis in multiple sclerosis were only relevant up until an 
EDSS score of 4 had been attained. Male sex, greater age at onset, incomplete 
recovery from the first relapse, shorter time to the second neurological episode, and 
an increasing number of relapses in the first 5 years of the disease were all as ociated 
with a significantly (p<O.05) shorter time from disease onset to an EDSS of 4. 
However none of the above factors had any significant (p>O.05) effect on time from 
EDSS 4 to EDSS 6. 
The author believe that this further indicates that mUltiple clero i a two- tag 
di ea e compri ing an initial phase of irregular duration influ n ed by lini al 
ariabl and a cond pha e that i independent of ba elin characteri ti cour 
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stages of the disease. Indeed some of the problems of multiple sclerosis research may 
result from the disease being defmed by its heterogeneous early and ultimately 
inconsequential phase rather than its uniform late phase. Whilst a diagnostic shift 
away from relapses to progression may cause an unacceptable delay in diagnosis it 
would undoubtedly increase specificity and help focus therapy on the most disabling 
component of the disease. 
With regard to the relationship between relapse and disability an important 
alternative view is provided by a studrO of 224 patients who served as placebo 
controls in therapeutic randomised multiple sclerosis trials. The aim of the study was 
to determine whether relapses contributed to fixed disability. It was found that 
residual deficits of 0.5 and > 1.0 EDSS points were present in 42% and 28% of the 
population respectively at an average of 64 days after a relapse. Subsequent follow 
up suggested that disability following a relapse was sustained over time. This study 
provides strong support for disability accruing in a 'stepwise' manner, consequent 
upon relapses, during the earlier disease phases. Clearly fixed disability does occur 
during the relapsing remitting disease phase in advance of classical secondary 
progression, but is it all from incomplete recovery from relapse? The only other 
conceivable way in which disability could be formed in the relapsing remitting phase 
is by concurrent early insidious disease progression. Ebers has suggested that all 
patients may begin progressing early in the course of the disease, but that this is 
extrememly difficult to measure i.e. EDSS 123. If progression does occur in the 
relapsing remitting phase it is likely to be at a slower rate than in classical 
progressive disease 10. Clinical experience combined with popular teaching2 showing 
horizontal plateaus rather than gentle inclines between relapses has rendered any 
relapsing-remitting progressive disease clinically undetectable. There are 2 reasons 
not to completely discount the possibility. 
Firstly, from experience with primary progressive disease we know that the earliest 
stages of progression are difficult for both patient and clinician to reliably detect and 
diagnose. The median time from onset of symptoms to diagnosis in the London, 
Ontario primary progressive cohort was initially 8 yearss. The median EDSS at 
presentation in the Lyon cohort of primary progressive disease was 410. One assumes 
that these patients had gradually ascended from EDSS 1 through to 4 over a 
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sufficient period of time so as to make the progression virtually invisible to patient 
and clinician. It is therefore possible that the earliest stages of relapsing-remitting 
disease are similarly affected by an undetected progressive phase. 
Secondly, when usmg disability measures such as the EDSS, which is heavilv 
"' 
predicated towards mobility, a gradual deterioration in non-motile neurological 
systems will probably not affect the EDSS score, giving the illusion of stable disease. 
Even without using scales such as the EDSS to monitor disease activity the clinician 
may be reluctant to diagnose the secondary progressive phase until it has become 
blatantly obvious. The reasons for this might include the associated poor prognosis 10 
effect on patient morale and the need to withdraw drug therapies3! :32. A parallel 
study32 of relapsing-remitting patients who had not suffered a clear relapse over 
similar time periods might have helped to show whether progression in addition to 
relapses contributes to fixed disability during the relapsing remitting phase. 
The studies and theories of Confavreux6:10 and Lublin30 are in fact not mutually 
exclusive. Together they indicate that in the classical relapsing-remitting disease 
disability can be accrued in a stepwise manner at a slower rate and then subsequently 
in a more rapid progressive manner. Lublin30 has suggested that Confavreux's results 
may indicate that it is the later stages of the EDSS!9 and not multiple sclerosis that is 
insensitive to early relapses although this is unproven. Clinical scales such as the 
EDSS are one-dimensional. Relapses as part of natural history studies are often 
recorded as a binary event: 0 - no relapse or 1 - relapse. Whilst simplicity is a 
common component of successful research, it is reasonable to believe that accurate 
assessment of complex, multi-dimensional phenomena such as disability and relapses 
may require a qualitative, as well as a quantitative, approach. 
A qualitative study of the nature of disability during relapses, and that in chronic 
progressive disease, is a powerful approach to answering the question of whether or 
not disability in multiple sclerosis is related to relapse. If relapse and chronic 
disahility are related then one would expect them to be of a similar quality within an 
individual. 
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(3) The pathology of multiple sclerosis 
The pathology of multiple sclerosis is the disease. For obvious ethical and practical 
reasons it is not possible to monitor the pathology of multiple sclerosis in vivo. 
Autopsy pathology is commonly available from end stage disease but even this is 
becoming a scarce commodity33;34. Opportunities to examine the earliest disease 
stages are as rare3 as they are informative. For these and other reasons radiological 
techniques have become necessary to aid the study of disease activity in \'iva. 
The basic clinical features of multiple sclerosis probably have a distinct pathological 
basis. Relapses are considered to be the clinical expression of acute inflammatory 
central nervous system demyelination whilst remission is probably due to resolution 
of inflammation, sodium channel redistribution and remyelination. Progression is 
likely to reflect chronic demyelination, gliosis and axonal loss35. Although first 
noticed by Charcot over 100 years ago the importance of axonal loss36;37 has recently 
been rediscovered. 
The most obvious macroscopIC feature of multiple sclerosis pathology is the 
demyelinating plaque whose plurality came to name the disease. Initial descriptions 
indicated that these were only to be found in white matter although it appears grey 
matter is also affected38. It does however remain the case that grey matter provides 
excellent camouflage for the grey demyelinating plaque. Away from the plaque all is 
probably not normal either. The normal appearing white and grey (NA WGM) is 
normal only in macroscopic appearance39-41 . Whilst the histopathological damage is 
evidently less in the NA WGM than in plaque matter it should be remembered that 
even in the central nervous system with a high lesion load there will be much more 
NA WGM than plaque matter. Therefore a minor functional deficit of NA WGM may 
be more disabling than even a severe functional deficit in the plaque matter. 
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(i) The multiple sclerosis plaque 
Demyelinating plaques may occur anywhere in the CNS. They are, however, more 
common in certain areas 7 . In the forebrain, the periventricular subependymal zone, 
the border between cortex and white sub cortex, the optic nerves and chiasm are 
preferentially demyelinated. The brainstem generally has the highest concentration of 
demyelinating plaques. In the spinal cord plaques are more frequent in the cervical 
segment. One reason for this distribution is likely related to the tendency for plaques 
to form around venules and veins and indeed the aforementioned areas have high 
densities of post capillary venules. 
Early in their evolution plaques display active demyelination whilst with time they 
tend to become inactive. Macroscopically the active plaque displays a pink 
discolouration and the tissue texture is sofe. Microscopically inflammatory cells that 
contain myelin debris are found throughout the acute plaque. More detailed 
microscopic examination of active demyelination reveals a need for sub-division. 
The pathology of the actively demyelinating MS plaque is fundamentally 
heterogeneous. A confusingly broad range of pathological phenomena has been 
revealed in the active plaque but the work of Claudia Lucchinetti and colleagues42 
identified four distinct patterns of active plaque pathology. It appears the 
pathological target (myelin or oligodendrocyte) and the mechanisms of 
demyelination are distinctly different in subgroups of the disease and at different 
stages of disease development42 • Whilst all actively demyelinating lesions exhibit 
infiltrates ofT lymphocytes and macrophages they can generally be segregated based 
on the distribution of: 
• Myelin protein loss. 
• Plaque geography and extension. 
• Pattern of oligodendrocyte destruction. 
• Immunopathological evidence of immunoglobulin and activated complement 
deposits. 
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Although full consensus has not yet been achieved, it appears that in the same 
individual at the same point in time there appears to be homogeneity with regard to 
the lesional pattern. Lesional pattern is however heterogeneous between individuals 
and possibly changes over time. Broadly the patterns can separated into those with 
close similarities to auto-immune encephalomyelitis (patterns I and ll) and those 
associated with oligodendrocyte dystrophy (patterns ill and 1V)42. 
Pattern I plaques are typically centred on small veins and show sharply demarcated 
edges with peri-venous extensions. Loss of all myelin proteins from damaged myelin 
sheaths appears to occur in a simultaneous manner. There is a diffuse 
immunoglobulin reactivity in the tissue and astrocyte cytoplasm throughout the 
lesion reflecting blood-brain barrier damage although there is no complement or 
immunoglobulin deposition. This suggests the destructive process is induced mainly 
by activated macrophage products such as tumour necrosis factor-a42• Pattern I 
plaques are relatively uncommon and have been found in relapsing-remitting, 
secondary and primary progressive disease. 
Pattern II plaques share the same peri-venous geographical distribution and other 
features as pattern I plaques. In addition, and exclusively to pattern ll, there is 
prominent deposition of immunoglobulin (mainly IgG) and complement at sites of 
active myelin destruction. This is associated with degenerate myelin at the active 
plaque edge and marked immunoglobulin reactivity of myelin degradation products 
within macrophages. Patterns I and II are associated with a high proportion of re-
myelinated shadow plaques. Pattern II was found to be the most common in the 
identifying research 42 and can be present in any of the main disease sub types and 
can also be found in chronic MS. 
Pattern III lesions are not centred on veins and venules. Instead there is often 
preservation of a rim of myelin around inflamed vessels within the active lesion. The 
lesional border is ill defined and merges with the surrounding white matter. This 
pattern shows a marked loss of oligodendrocytes at the active plaque border often 
extending into the normal appearing peri-plaque white matter. There are no 
remyelinated shadow plaques. Whilst the lesions also contain an inflammatory 
infiltrate composed of T -lymphocytes, macrophages and activated microglia there is 
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no immunoglobu~in or complement deposition. The striking feature of pattern III 
lesions is the preferential loss of myelin associated glycoprotein (MAG) with relative 
preservation of other myelin proteins. This is associated with changes suggestive of 
oligodendrocyte apoptosis. Pattern III lesions are relatively common in acute 
multiple sclerosis but rarely seen in chronic multiple sclerosis. This pattern of 
demyelination is not found in primary progressive disease. 
Pattern IV lesions are only found in primary progressive disease and are 
consequently relatively rare. This pattern is associated with a well-demarcated plaque 
of demyelination with radial expansion. There is no deposition of complement or 
immunoglobulin, nor any clear evidence of oligodendrocyte apoptosis. There are no 
remyelinating shadow plaques, nor evidence for a specific myelin protein target. 
These different patterns show the marked heterogeneity in the immunopathological 
profiles of lesions between different MS patients. Recent evidence suggests that the 
above pathological descriptions also appear to conform with expected therapeutic 
response43 • Of 19 patients with mUltiple sclerosis who had had a lesion biopsy and 
were treated with plasma exchange moderate or greater neurological improvement 
was observed in aU 10 patients who had pattern II (immunoglobulin and complement 
deposition) lesions, but none of the 9 patients with either pattern I or III lesions43• 
All of these four patterns show clear evidence of inflammation and lend further 
support to the extensive literature suggesting that the primary pathology in multiple 
sclerosis is inflammatory. In 2004, however, a potentially' profoundly important 
study by Barnett and Prineas3 suggested that the primary pathology in multiple 
sclerosis may not always, or indeed ever, be inflammation. The authors found 
extensive oligodendrocyte apoptosis in a hyperacute brainstem plaque (I7 hours 
old) that had caused the death and subsequent post-mortem examination of its 
tragically young host. There was no inflammation in the plaque. This remarkable 
finding led to the re-examination of autopsy material from other patients who also 
had relapsing-remitting MS with a rapid and aggressive course. A further nine 
lesions were found that were essentially identical to the fatal brainstem lesion in the 
first case. The earliest structural change shared by all these lesions was extensive 
oligodendrocyte apoptosis in tissue exhibiting early microglial activation but with 
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little or no infiltrating inflammatory cells. This is unlike any preceding laboratory 
model of the disease. 
This suggests3 that the earliest lesion in multiple sclerosis may be an apoptotic 
oligodendrogliopathy that, due to the copious nature of the oligodendrocyte, 
overwhelms the local mechanisms (microglia) for removing myelin debris. In turn 
activated macrophages and other inflammatory cells enter the central nervous sytem 
to augment the clearance of myelin debris. Therefore inflammation may be a 
secondary and partially adaptive response to oligodendrocyte apoptosis. The cause of 
any oligodendrocyte apoptosis is not known. 
This may suggest that pattern III lesions, which are common in acute MS and display 
evidence of oligodendrocyte apoptosis in addition to inflammation42 are in fact a 
slightly later stage of the pure oligodendrocyte apoptosis and microglial activation. 
Some caution should be observed in analysing this studr. In particular acute plaques 
that lead to the rapid provision of autopsy material, or necessitate biopsy, cannot be 
described as typical in multiple sclerosis. It is possible that these findings in acute, 
severe multiple sclerosis do not pertain to the disease as a whole. 
The individual plaque tends to lose all evidence of active inflammatory activity over 
time. The chronic plaque (commonly defined as one in which there is an absence of 
inflammatory cells and myelin breakdown products) can show a spectrum of 
appearances with two extreme forms at either end. The 'closed lesion' has numerous 
intact axons although fibrous astrocytic processes have invaded the space previously 
occupied by myelin. The 'open lesion' is relatively acellular with a prominent extra-
cellular space. It contains few surviving axons and relatively few astrocytes. 
Although the white matter plaque, largely for reasons of outlined defmition, is the 
most striking macroscopic pathology in MS it should be remembered that grey 
matter is by no means spared. Approximately a quarter of lesions44 affect the grey 
matter, most of these straddle the grey-white matter interface. Cortical lesions are 
characterized by demyelination as well as axonal damage and neuronal apoptosis4S 
although the degree of inflammation appears to be much less in lesions confined to 
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grey matter than in their white matter counterparts~5A6. The cortical lesion load 
appears to be light early in the disease and increase over time. In certain cases the 
cortical lesion load can involve over a quarter of the entire cortex and be greater than 
the white matter lesion load47. Cortical lesion load is approximately five times 
greater in progressive than relapsing-remitting disease~8 whilst the white matter 
lesion load does not seem to differ significantly between these groups. It may 
therefore be an important contributor towards progressive disease and fixed 
disability. 
(ii) The normal appearing white and grey matter 
Whilst MRl techniques39-41:49-51 have been most widely used in the identification of 
abnonnalities of NA WGM, pathological studies have also demonstrated this 
phenomenon. Several autopsy studies52-5~ have shown minor but widespread 
abnonnalities in the NA WM from MS patients. These changes include axonal 
damage, oedema, inflammatory cell infiltrates and astrocytic hyperplasia. 
An autopsy study of a patient even in the early relapsing remitting disease phase 
revealed extensive axonal loss in nonnally myelinated spinal cord54. Axonal loss in 
the guise of numerous intact but empty myelin sheaths was seen. In addition 
activated macrophages were observed to be effecting early myelin degradation. 
Interestingly the axonal loss was restricted to descending fibres only and suggests 
that axonal loss in NA WM may represent antero-grade Wallerian degeneration 
secondary to remote lesions. Further damage may be propagated by retrograde 
axonal degeneration resulting in apoptotic neuronal cell body death. In addition axon 
loss and degeneration, via a loss of trophic factors, may lead to further trans-synaptic 
axon loss. In this wayan 'atrophic positi ve feedback loop' may lead to widespread 
damage of the central nervous system in areas remote from obvious inflammatory 
. . 4'i4 
actIVIty .- . 
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(iii) Axonal loss in multiple sclerosis 
MS is historically considered to be a demyelinating disease in which axonal loss, 
although recognised, was insignificant both pathologically and clinically. It is now 
recognised that axonal loss is the foundation stone of disability in chronic multiple 
sclerosis55 . The development of immunological staining techniques for amyloid 
precusor protein (APP), a marker of acute axonal damage, revealed that axon damage 
and loss in the acute plaque was more severe than previously recognised36;3755;56. The 
extent of acute axonal injury also appears to correlate with the number of 
inflammatory cells in acute lesions57 . This finding suggests that axonal loss is an 
early feature of multiple sclerosis that co-incides with, and is likely the result of, 
inflammatory demyelination 55. 
Axon loss also occurs in chronic, inactive plaques. The rate of axon loss is much 
lower in chronic than acute plaques57, but since axonal loss is irreversible and 
multiple sclerosis is a disease of exceptional longevity it is a potentially more 
devastating process. Additionally it appears that the slow axonal loss within inactive 
chronic plaques accelerates slightly in the secondary progressive as compared with 
the relapsing-remitting disease phase57. This may explain the observed paradox of 
accelerating disability in the face of decelerating eNS inflammation in the 
progressive disease forms4. There is also likely to be significant luxury function 
within central nervous system pathways58. This limits the ability of pathology to 
cause disability. It is suggested that there is a threshold55 below which axonal loss 
does not cause disability. Axonal loss occurs in the acute and chronic plaque, but 
rather like the hare and the tortoise, it appears that the chronic plaque is often the first 
to cross the line of irreversible disability. 
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(4) MRI in multiple sclerosis 
The advent of magnetic resonance imaging (MRI), has allowed multiple sclerosis to 
be studied in vivo. Previous x-ray based imaging techniques such as CT were 
insensitive to all but the most obvious MS pathology. MRI is able sensitively to 
detect MS plaques50 and has been able to demonstrate the importance of MRI 
delineated acute plaques in causing acute focal neurological deficit50;59;60 and 
therefore clinical relapse. It has long been assumed that the accumulation of these 
chronic plaques, and continuing degeneration within them, over time accounts for the 
progressive deterioration witnessed in later stages of mUltiple sclerosis. MRI studies 
have on balance done more to challenge than support this assumption39;41;49;61. The 
concept of mUltiple sclerosis being a multi-focal disease of the central nervous 
system may only be correct in its earliest stages. The major utility of MRI in multiple 
sclerosis is diagnostic15, its value in prognosis and as a surrogate marker for 
disability is less clear62. 
As with histopathology, there is a functional heterogeneity to the plaques which MRI 
techniques are not able fully to reveal. It should be remembered that MRI depends 
not on the functional state of the nerve fibres but on the amount and distribution of 
water in the intra- and extra-cellular spaces in the affected area. 
(i) MRI of MS plaques 
The evidence for relapse being accompanied by appropriate changes on an MRI scan 
is strong. There is an excellent correlation between the development of symptomatic 
focal neurological dysfunction and the development of an acute plaque in the 
relevant pathway of the CNS. In 10 patients with acute optic neuritis studied59 with 
T I-weighted MRI, all 11 clinically affected nerves enhanced with gadolinium 
implying breakdown of the blood-optic nerve barrier and inflammation. Gadolinium 
enhancement was associated with abnormal visual acuity, colour vision, retro-orbital 
pain on eye movement, afferent pupillary defect and decreased visually evoked 
responses (VERs). Repeat MRI 4 weeks later revealed gadolinium enhancement had 
stopped in 9 of the 11 nerves and this corresponded with clinical improvement. 
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Further evidence for acute lesions causing relevant focal neurological deficit comes 
from a study60 of 121 patients with non-compressive spinal cord syndromes who 
were imaged with MRI. There was a good correlation between the neurological 
deficit and location of lesion. This was highlighted by the association between 
lesions in the cervical dorsal root entry zone of patients exhibiting the 'useless hand 
of Oppenheim'. Another important study50 showed that 35 of 40 patients with MS 
who presented with an acute brain stem syndrome had a lesion demonstrated in the 
brainstem by MRI. There was a good correlation between precise site of lesion and 
the clinical picture in the case of cranial nerve palsies, the one-and-a-half syndrome 
and internuclear ophthalmoplegias (INO), although the last observation should be 
tempered by the high frequency with which lesions of the floor of the 4th ventricle 
were found such that a lesion in the region of the medial longitudinal fasciculus 
could be found in patients without an INO. 
Whilst clinical dysfunction is often accompanied by appropriate lesion fonnation on 
MRI the reverse is not true. Clinically silent plaques are approximately ten to fifteen 
times as common as symptomatic plaques in multiple sclerosis 7;63. Whilst this may 
be in part due to lesions forming in clinically irrelevant locations this is not the whole 
answer as MRI frequently discloses asymptomatic lesions in clinically eloquent areas 
such as the spinal cord64• Family studies have revealed MRI changes typical of 
mUltiple sclerosis in unaffected relatives of MS patients65 . This is not just an MRI 
phenomenon. Post mortem evidence has revealed that the finding of the pathological 
features of mUltiple sclerosis in a patient who was asymptomatic in life is not 
uncommon66• This is not always due to lack of clinical eloquence of involved 
pathways: an extensive demyelinating lesion has been reported in the spinal cord of a 
patient asymptomatic in life67• For obvious reasons it is difficult to accurately assess 
the true incidence of 'asymptomatic' multiple sclerosis and more difficult still to 
know whether this is truly asymptomatic or merely pre-symptomatic MS68. The very 
concept of asymptomatic multiple sclerosis highlights that plaques are not 
synonymous with clinical dysfunction. 
The relationship between the chronic plaque and neurological dysfunction is not as 
obvious. Studies which have compared the total volume of brain occupied by T 2 
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lesions and compared this with clinical disability have variously found correlations 
ranging from none69 to modeseo and overall is felt to be weak7). T2-weighted 
imaging for assessment of mUltiple sclerosis pathology is therefore limited by its 
poor specificity for identifying dysfunctional plaques and non plaque white matter. 
MRI has revealed marked differences between primary and secondary progressive 
multiple sclerosis. In one study72 of 12 secondary and 12 primary progressive MS 
patients who were otherwise well matched there were an average of 18.2 new lesions 
per year in the secondary progressive group whilst there were only 3.3 new lesions 
per year in the primary progressive group on brain MRI. Another study of 91 patients 
found the brain T2 lesion load in primary progressive disease to be lower than in 
either secondary progressive or relapsing remitting disease73 • MRI techniques 
suggese4 that the spinal cord is more heavily involved than the brain in primary 
progressive multiple sclerosis. This spinal cord damage in primary progressive MS, 
however, is probably no greater than that seen in disability matched secondary 
progressive disease 75. 
Hypointense T) lesions, or 'black holes' do correlate with more severe tissue 
disruption, including axon loss and demyelination76• Initial studies77 showed a good 
correlation between T) lesion load and disability, however subsequent larger studies 
have found only a weak link78• 
This dissociation between disability and conventional MRI occurs with different 
disability rating scales2o• Thus MRI suggests that disability is largely unrelated to 
chronic lesion load and casts doubt on the theory that multiple sclerosis is a chronic 
multi-focal eNS disease. Therefore we need to consider the MRI evidence against 
the two remaining components of the diseased eNS: normal appearing eNS tissue 
(NAWGM) and disappearing CNS tissue (atrophy). 
(ii) MRI of normal appearing eNS tissue 
Modem MRI techniques, such as magnetization transfer ratio (MTR), magnetic 
resonance spectroscopy (MRS) and diffusion weighted imaging (OWl) can detect 
biochemical and structural change of the eNS invisible to conventional MRI. This 
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allows the in vivo quantification of the involvement of ~A WGM in \ISAI. Region of 
interest (ROI)41;79;79-83 and histogram80;81 studies have shown subtle degenerative 
change and altered metabolism within NA WGM in all of the \ciS sub-types. These 
changes are evident even in clinically isolated syndromes (CIS) suggestive of 
MS4184°85 'd' d'd h h . , , prOVI mg goo eVI ence t at c anges m NA WGM may not be secondary 
to discrete lesions. Abnormalities of NA WGM are however more marked in 
progressive disease compared to relapsing-remitting disease86;87. Primary and 
secondary progressive disease displays similar NA WGM abnormalities75;88. Unlike 
most conventional MRI techniques, MTR of the NA WGM can predict the 
accumulation of disability over a subsequent five-year period89;90. MRS has revealed 
that there are developing abnormalities of areas of NA WGM that subsequently 
develop into classical MS lesions91 . MTR, MRS and DWI have also shown that 
regional abnormalities in the pyramidal tracts92 , cerebellum93 and optic nerve 94 
produce clinically relevant impairment. 
(iii) The role of disappearing white and grey matter in multiple sclerosis 
(atrophy) 
It is easy to overlook what isn't there. Whilst the disability ensumg from an 
amputated leg is easy to envisage the concept becomes less obvious, although no less 
important, when considering the spaces formerly occupied by axons and myelin 
sheaths. It is slightly complicated by the partial restoration of volume that may result 
from remyelination, gliosis and oedema. Atrophy of the CNS as measured by MRI 
does correlate well with disability in multiple sclerosis95-97 . In keeping with the 
observations of axonal loss, it appears that atrophy of both plaque matter and 
NA WGM occurs37. There is evidence that plaques atrophy completely98 (personal 
communication - Trapp BD) which may partly explain the relatively poor 
relationship between lesion load and disability at a given point in time69 . In tum this 
makes the problem of identifying clinically symptomatic lesions for therapeutic 
purposes 99 more difficult: the clinically relevant lesion may have disappeared but left 
its resultant disability behind. In these cases areas of focal atrophyl00 may be the only 
clue to a pre-existent plaque. 
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In conclusion MRI studies of MS have confirmed or revealed the following: 
• Clinical relapse is often associated with relevant acute lesion formation. 
• Lesion formation is infrequently associated with clinical relapse. 
• The lesion load is only weakly related to chronic disability. 
• Atrophy of the CNS is closely related to disability. 
• The normal appearing white and grey matter is structurally and metabolically 
abnormal, even at the earliest stages of disease and these abnormalities 
correlate well with disability. 
Therefore it may be reasonable to conclude that normal appearing white and grey 
matter, and disappearing white and grey matter (atrophy) are more relevant to 
disability in MS than abnormal appearing white and grey matter (lesions). 
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(5) The treatment of multiple sclerosis 
The concept of multiple sclerosis as a primary inflammatory multi-focal disease of 
the central nervous system has not been strengthened by the deyeloping 
pharmacology of MS. An increasingly sophisticated array of pharmaceutical agents 
has yet to convincingly slow or stop long-term disease progression. This is despite 
clear evidence of a reduction in inflammatory activity in the central nervous system. 
Corticosteroids decrease inflammation and shorten relapse duration but do not 
appear to have any long-term beneficial effect in multiple sclerosis7, with the 
possible exception of improving spasticity temporarily in chronic progressive 
disease. Similarly steroid sparing immunosuppressive drugs such as azathioprine lol 
and methotrexate have had a disappointing risk:benefit ratio in MS. A common 
problem has been drugs that may confer a short-term benefit that is unsustained with 
prolonged follow up, sulphasalazine l02 being one example. Some treatments that are 
not presently considered to be practical or effective in multiple sclerosis may be 
useful in as yet unidentified sub-groups of MS patients. This is highlighted by the 
discovery that plasma exchange43 appears to be effective in MS patients with pattern 
II lesions but not pattern I or III. An evolving knowledge of MS may see previously 
ineffective drugs become effective when targeted appropriately. 
The spread of the Acquired Immunodeficiency Syndrome (AIDS) in the 1980s 
provided further evidence of a dissociation between inflammation and disability in 
multiple sclerosis. Although clearly not an intended treatment for MS, AIDS through 
its pathological ablation of immune function might have been expected to favourably 
affect MS. This was not the case. MS continued to progress in men whose immune 
systems had been seriously impaired by AIDS 103. 
The immunomodulatory drugs beta-interferon and glatiramer acetate have been 
shown in the 'pivotal' trials to be effective in reducing the relapse frequency hy 
about one third8;104-107 at two years. Two of these trials have claimed a statistically 
fll d· bOlo . 8"107 A t·" lOX d t significant e ect on Isa 1 Ity progressIOn·. systema IC revIew an me a-
analysis of the beta-interferon trials has produced rather more modest claims for the 
effects of these drugs. Despite access to 7 trials and complete data on 1215 patients 
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this study was only able to conclude that the beta-interferons were significantly 
associated (p=0.04) with a relative risk of relapse of 0.73 compared to placebo. There 
was no effect of beta-interferon on preventing disability108. Whilst it is not clear if 
this represents a failing of beta-interferon or trial methodology, it is clear that there is 
no good evidence that these drugs prevent disability in the longer term9. 
The effect of beta-interferons on MRI lesion activity is certainly greater than their 
clinical effect105;107 and is in keeping with the known poor association with lesion 
load and disability69. 
The role of immuno-modulatory drugs was taken to an extreme with the potent 
lymphocyte depleting antibody Campath-lH 12. In 25 patients with secondary 
progressive multiple sclerosis, treatment with Campath 1 H did produce a very 
impressive reduction in gadolinium enhancing lesions and T 2 lesion volume. 
However, it did not reduce T 1 hypo intense lesions and rate of CNS atrophy compared 
with an admittedly small control group of 4 patients. Perhaps most importantly the 
reduction in gadolinium enhancement and T2 lesion load did not reduce disability 
progression compared with controls. The only MRI indices correlated significantly 
with Expanded Disability Status Score (EDSS) in this study were spinal cord atrophy 
and infratentorial T 1 to T 2 ratio. There is some evidence to suggest that 
immunomodulatory treatment of the early stages in MS may be effective in slowing 
disability progression 109, whilst the progressive stages of the disease are likely less 
dependent upon inflammation, and therefore less amenable to immunomodulation. 
Natalizumab, an alpha4 integrin antagonist has a marked effect on new MRl lesion 
formation in MS (92.70/0 reduction in new lesion formation compared to placebo) and 
halves the number of patients experiencing relapses95 . Despite further promising 
results Natalizumab has been setback indefinitely by the co-occurrence of 
progressive multi-focal leukoencephalopathy (PML)llO;lll. 
From this we can see that despite the availability of potent immunomodulatory drugs 
that have confim1ed and substantial effects on \1RI markers of neuro-inflammation 
in M5 we have not been able to demonstrate a sustained effect on disability 
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progression9• This suggests the role of inflammation in producing disability in ~IS 
may not be primary, and furthennore may not be entirely deleterious. 
It seems counter-intuitive to suggest that inflammation might be anything other than 
deleterious, however whilst inflammation in multiple sclerosis clearly does cause 
CNS tissue destruction it has also been shown to produce effects beneficial to 
recoverl6 and repair of the central nervous system. Inflammation is known to 
stimulate remyelination in areas of chronic demyelination27. Whether inflammation 
overall in multiple sclerosis is a good or bad phenomenon is unkno\\n and it is likely 
to be heterogeneous between individuals. Clearly in aggressive disease, such as the 
Marburg variant, the negative aspects of inflammation probably exceed any benefits. 
More difficult to say is whether patients with benign, or even asymptomatic disease 
are actually benefited by cerebral inflammation. For this to be the case it would be 
likely that MS is due to an alternative primary pathology and that inflammation is an 
adaptive response to this primary pathology. Viral infection112 or failure of natural 
neuro-regenerative mechanisms leading to uncontrolled apoptosis3 may necessitate 
the involvement of the immune system. 
If inflammation was overall an evolutionarily preserved adaptive mechanism to 
ameliorate an as yet unidentified primary pathology then one might expect to see 
long tenn advantage in patients experiencing an appropriate level of eNS 
inflammation (benign or asymptomatic MS) as compared with those experiencing 
too much (relapsing-remitting and Marburg variant) or too little (primary 
progressive ). 
This returns us to our natural history studies that suggest that relapses and, by 
extension, inflammation may be associated but not causally related to disability 
progression 11. Technically proving a non-causal relationship oyer a disease that lasts 
decades is challenging. However if it were to be shown that in a significant 
population of MS patients the qualify of the preceding relapses do not match the 
quality of the subsequent disability then it would constitute a powerful argument to 
suggest that relapses, and inflammation, are not the true problem. 
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(6) Summary 
Our current understanding of chronic disability in multiple sclerosis is dominated 
by intuitively held assumptions of a strong relationship to acute inflammatory 
relapses. Treatments which prevent relapses are assumed to have useful long term 
benefit in reducing disability; we look at MRI scans of chronic .11S patients and try 
to establish which lesion might be responsible for some aspects of their disability; 
we even plan future myelin repair therapies on the basis of injecting cells into 
chronically 'disabling' lesions. And yet even the brief consideration outlined above 
casts doubt on this fundamental and near-universal assumption. The evidence 
from natural history, pathological and radiological studies increasingly suggest the 
relationship between relapse, inflammation, and chronic disability is non-linear 
and complex in MS. Consequently the contribution of acute lesions and relapses to 
progressive neurological deficits is open to question. This has been further 
emphasised by the continuing failure of novel immuno-modulatory therapies to 
have a proven effect on disease progression and disability. On the basis of this 
para-clinical evidence, a purely clinical study is merited to examine long held 
assumptions regarding the relationship of relapse to disability. This is what I have 
attempted. 
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Chapter 2: A cross sectional survey of neurological examination 
findings in 150 hospital based patients with multiple sclerosis 
Aim: To describe in detail the neurological deficits at pre\'alence 111 a dejined 
population of patients with multiple sclerosis. 
Introduction 
Multiple sclerosis, in common with many chronic diseases, is primarily a disease of 
morbidityl13 rather than mortality. The morbidity of multiple sclerosis principally 
occurs in the form of physical disability. There are many different techniques for 
assessing disabilityI9;114;115 in multiple sclerosis. Whilst each has distinct qualities on 
the whole they seek to give a quantitative assessment of disability. Often, despite the 
tremendous clinical heterogeneity of multiple sclerosis, an individual's disability is 
expressed in terms of a single figure score. Whilst reductive disability scales are 
fundamentally necessary in order to bring structure to natural history and therapeutic 
studies they provide only limited information. For instance an Expanded Disability 
Status Score (EDSS) of 6 means that a patient is dependent upon a walking stick. It 
makes no comment on whether this is because they are weak, ataxic (sensory or 
cerebellar), blind or perhaps a combination of these factors. 
McAlpine's original schematal16 demonstrating the temporal course of multiple 
sclerosis IS an accurate representation of how we traditionally perceive multiple 
sclerosis over time (see figure 1-1). It still forms the basis of patient and 
undergraduate education in multiple sclerosis. It starts with individual spikes III 
disability that often resolve completely. Sometimes however these spikes III 
disability do not resolve and this forms the basis of step wise disability progression 
throughout the relapsing remitting phase. With time relapses become less frequent 
and often give way to a relentless phase of progressive disability. Key to this percept 
is that the relapse rate is a key component in the formation of long-tenn disability III 
I 'I I . 117 mu tIp e sc erosls . 
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Thus multiple sclerosis was perceived as a relatively simple inflammatory disease of 
the central nervous system. It was widely felt that episodes of focal inflammatory 
demyelination produced acute relapses and that the burden of these lesions over time 
led to an inexorable progression of disability. If we were able to stop this 
inflammation then the disease should be prevented from causing further disability. 
These theoretical benefits of anti-inflammatory and, more recently, Immuno-
modulatory therapies continue to be substantially greater than their observed 
practical benefits. Corticosteroids have an effect on relapse severity but not 
prospective relapse rate or long term disability. Beta-interferons and glatiramer 
acetate have a prospective effect on relapses but conclusive proof of long-term 
disability prevention is still lacking. The anti-inflammatory strategy has been taken 
to greater extremes with the monoclonal antibody Campath-l HI2 which conclusively 
inhibited the inflammatory components of multiple sclerosis, but not progression of 
disability in secondary progressive patients. In short we can dramatically affect 
inflammation in multiple sclerosis but, to date, this has not translated into long-term 
disability prevention at a population level. 
Large natural history studieslO;11 have not shown the relationship between number of 
relapses, the degree of recovery from relapses and the rate of disability progression 
that one would intuitively expect from a primary inflammatory disease of the central 
nervous system. 
Histopathological studies have revealed four different patterns of demyelination in 
multiple sclerosis42:118. These are (I) T celUmacrophage mediated; (II) 
antibody/complement mediated; (III) oligodendrocyte dystrophy with myelin protein 
dysregulation and oligodendrocyte apoptosis; (IV) primary oligodendrocyte 
degeneration with features similar to viral infection or toxic oligodendrocyte damage. 
Whilst these processes are heterogeneous within patients, pattern IV was only 
observed in cases of primary progressive disease. It is unlikely all 4 types of 
demyelination will be susceptible to the same therapeutic agent, unless of cours~ we 
are m~rely observing the evolution of demyelination in a 'snap shot' fashion. If 
different types of demyelination exist perhaps they produce different clinical 
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phenotypes that will ultimately allow more targeted selection of therapeutic agents 
than is presently possible. 
A further recent pathological study suggested that different tracts within the nervous 
system of the MS patient sustain damage at different rates119. This is compatible \\'ith 
clinical experience that certain tracts within the nervous system, for example the 
optic nerves and medial longitudinal fasciculus, seem preferentially susceptible to 
acute relapses in multiple sclerosis. 
So there are variable types of demyelination and also perhaps variable resistances or 
susceptibilities of the different central nervous system pathways. Likely therefore 
there are qualitative differences in the way that different types of impairment and 
disability form. The secondary progressive phase for instance is defined purely in 
terms of disability progression. It is not clear from the literature whether all 
neurological pathways enter the secondary progressive phase at the same stage or 
whether we are in fact merely observing the stage at which pathways more crucial to 
disability, such as the corticospinal tracts, begin to degenerate. Quantitative disability 
studies tell us that primary and secondary progressive disease progress at the same 
rates JO;120 despite apparent differences in radiological studies in these patients. One 
group69 has reported profound MRI activity differences among several clinical 
categories of patients. Primary progressive patients had the lowest rate of activity at 
3.3 new T 2 lesions per patient per year. Next was benign MS at 8.8, followed by 
relapsing remitting MS and secondary progressive MS at 17.2 and 18.2 new lesions 
per year. 
A 'complete' neurological examination is used to examine the majority of patients 
who have multiple sclerosis at one stage or another. Whilst the term 'complete' 
neurological examination is unlikely to have identical connotations between all 
neurologists we believe there is a significant degree of overlap between the \'arious 
interpretations. Although there is little formal evidence base one assumes through its 
natural evolution that the findings of this neurological examination are useful. It is 
through this anecdotal experience that our perceptions of disease are largely fomled. 
But is our anecdotal experience of multiple sclerosis entirely accurate or are we 
subject to recall bias'! We can all remember a relapse in a patient with multiple 
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sclerosis that has clearly led to prolonged disability. So why then do large natural 
history studies tell us that disability is largely inconsequent on previous relapses? 
Perhaps our anecdotal observations are correct but incomplete. If there were a large 
proportion of patients whose relapses weakly preserved long-term function they 
could negate the effects of a small but highly visible minority with marked 
dysfunction in response to relapse. Are we subject to recall bias that is eliminated to 
a degree in these natural history studies 10;22 or does measurement of disability scores 
allow important long-term qualitative effects of relapses to be overlooked? 
Whilst a long term prospective study of clinical signs in multiple sclerosis would 
have been ideal it is also clear that the chronic disease course requires more than one 
research generation for follow up studies. A cross sectional approach to clinical signs 
however does mean that all the clinical data is essentially prospective. We were 
unable to find previous work detailing the systematic findings of a complete 
neurological examination in a population of patients with multiple sclerosis. 
Numerous previous works17;113;121;122 have reported summary fmdings from clinical 
examinations in these patients but the manner in which these studies summarise their 
findings is frequently heterogeneous. 
Our aim was to systematically report the findings of a complete neurological 
examination in a population of multiple sclerosis patients and identify whether there 
were predictable patterns in which certain clinical signs become evident. For 
instance: do individual clinical signs become significantly more evident with 
increasing disease duration or whether the patient has entered the secondary 
progressive phase? Are the clinical findings in primary and secondary progressive 
disease the same or are there important differences that are not revealed by 
cumulative disability scores? What effect does the patient's age and sex have on the 
appearance of clinical signs? Do all clinical signs obey the same rules or are they 
responding to different pathophysiological cues? 
The answers to these questions are critical to further our understanding of the manner 
in which impairment, the substrate of disability, accumulates in patients with 
multiple sclerosis. If individual clinical signs all appear in response to the same 
constitutional factor then there is likely to be a common disabling pathogenetic 
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process, possibly susceptible to a single therapeutic agent, as the basis for all 
disability. The obverse is also likely to be true. 
Methods 
Between 2002 and 2004 151 patients with multiple sclerosis were referred to 
Frenchay hospital neurology department to be assessed as to their suitability for 
disease modifying drugs in multiple sclerosis as part of the United Kingdom 
Governments Risk Sharing scheme31 ;32;123. Referrals were accepted from consultant 
neurologists and were limited to patients with definite multiple sclerosis according to 
the McDonald criteria15, aged 18 years and over but were otherwise unselected. In 
particular, patients in whom it was immediately evident that they were not serious 
candidates for disease modifying drugs, such as those without any relapses or with 
advanced disability, were not excluded from assessment. Any patient considered to 
be in relapse at the time of initial assessment was re-assessed at a later date when 
relapse recovery was considered complete. One patient was excluded from the 
analysis as they declined physical examination. The demographic data, including sex, 
age and disease duration at the time of assessment of these patients was evaluated by 
interview and examination of their case records. A full neurological examination as 
part of an assessment of Expanded Disability Status Score (EDSS)19 was also 
recorded. All details of the patients demographic and EDSS examination, ranging 
from detailed modality and site-specific findings through the individual Functional 
Score Systems (FSS) to the overall EDSS score were entered into a password secured 
computer database (Microsoft Access). The forms used for data recording can be 
seen in Appendix l. 
The computer database was discussed with and kept in accordance with l"orth Bristol 
NHS Trust Data Protection regulations. Ethical approval for this study was obtained 
fi'om Frenchay Hospitals Local Research and Ethics committee (Frenchay 
LREC/2003!31). All patients gave their written consent for their clinical data to he 
used in this study. 
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All assessments were performed by either the author or Dr Janice Burrow. both of 
whom have several years of experience in taking a history and performing 
neurological examination. 
Statistical analysis 
Statistical analysis in this study include standard methods of descriptiye statistics, as 
well as binary logistic regression to analyse the effects of sex, age, disease duration 
and disease subtype on the presence of various clinical signs. Data analysis was 
performed using SPSS version 12 (SPSS inc., Chicago, IL) statistical package. Based 
on the non-parametric distribution of scores in ordinal ranks within many Kurtzke 
Functional Score System sub-categories including a frequent large proportion of 
zeros it was decided that linear regression was inappropriate. The need for 
multivariate analysis necessitated against the Kruskall-Wallis test. Binary logistic 
regression was preferred to ordinal logistic regression based on the size of the study 
population. For purposes of binary logistic regression the absence of a clinical sign 
was scored as 0 whilst the presence of a clinical sign was scored as 1. The 
comparator groups for the binary logistic regression included female sex and 
secondary progressive disease. We considered the role of multiple observations 
increasing chances of type 1 errors but decided against making correction for this as 
observations are being made on different impairment types, and although we accept 
there may be some associations between individual clinical signs these are partially 
compensated for by the inclusion of the qualitative predictors (sex, age, disease 
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(1) Demographic and disability data 
Table 2-1: Gender, disease sub-type, age and disease duration of the 150 study 
patients with multiple sclerosis 
Demographic feature Male Female RRMS S PMS PPMS J\ 
Sex Female 78 31 7 116 
Male 25 7 2 34 
Disease Duration at Mean 7.2 9.7 8.2 12. 1 7.9 9.2 
assessment (years) Range l.33- 0.58- 0.58- 1.33- 2.9 1- 0.58-
23.17 39.67 33 .92 39.67 16.5 39.67 
Age (years) Mean at 38.8 40.1 37.9 42.9 48.6 39.8 
assessment 
Mean at onset 31.6 30.4 29.7 30.8 40.7 30.6 
Range at 18-56 19-72 19-64 18-63 36-72 18-72 
assessment 
Figure 2-1: The distribution of sex and disease subtype amongst study cohort 
(n=150) 
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Figure 2-2: Mean age of patient sub-groups at d isease onset and as es ment 
(n=150) 
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Table 2-2: Mean EDSS and FSS amongst 150 patients with multiple sclerosis 
Male Female RRMS SPMS PPMS All 
Visual 1.47 l.0 1 l.09 1.53 0.89 1.11 
Pyramidal l.68 1.83 1.34 2.68 3.11 1.79 
Cerebellar l.94 l.81 1.52 2. 53 2.55 1. 4 
Brainstem 1.06 1.09 0.9 l.5 3 1.33 1.09 
Sensory 2.38 2.54 2.31 3.02 2.56 2.50 
Sphincter l.29 l.43 l.24 1.71 1.89 1.4 
Mental 0.56 0.46 0.42 0.63 0.55 0.48 
EDSS 3.86 4.44 3.71 5.58 5.83 4.31 
Figure 2-4: Selected Mean Functional Systems Scores across the disease sub-
types (n=150) 
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Table 2-3: Comparative frequency of clinical signs in multiple sclerosis from 2 
previous studies 
Clinical signs in 301 prevalent 0/0 Clinical SIgns III 557 % 
patients in South Glamorgan by frequency patients III North-East frequency 
examination 113 1"'1") Scotland --
Visual Function: 
Impaired acuity 72.4 Not reported 
Impaired colour vision 59.8 
Field defect 25.9 
Disc pallor 4l.5 
Normal 08.0 
Brainstem function: 
Nystagmus 48.2 Nystagmus, horizontal 40.6 
Eye movement disorder 23.9 Nystagmus, ataxic 19.0 
Facial weakness 09.0 
Dysarthria 2l.3 Dysarthria 21.2 
Dysphagia 05.6 
Other 13.0 
Normal 44.9 Normal 19.4 
Tone and Power: 
Increased tone 56.5 
Monoparesis 06.6 Monoparesis 21.2 
Hemiparesis 04.3 Hemiparesis 12.4 
Paraparesis 27.3 
Para- and mono-paresis 14.9 Para- and mono-paresis 15.3 
Quadriparesis 25.9 Quadriparesis 7.5 
Normal power 25.9 Normal power 16.3 
Sensation: 
Impaired spinothalamic 49.2 Impaired spinothalamic 32.0 
Impaired vibration 6l.5 Impaired vibration 62.5 
Impaired proprioception 38.5 Impaired proprioception 33.1 
Impaired two point 42.2 Normal 
Normal 2l.6 19.4 
Cerebellar function: 
Upper limb ataxia 46.8 Upper limb ataxia 58.2 
Lower limb ataxia 25.2 Lower limb ataxia 39.0 
Combined ataxia 17.3 Combined ataxia 29.6 
Normal 36.2 Normal 32.4 
Tendon reflexes: 
Clonus 16.0 Clonus ~7.6 






Relapse and Disability in Multiple Sclerosis 
Table 2-3 (cont): Comparative frequency of clinical signs in multiple sclerosis 
from 2 previous studies 
Clinical signs in 301 prevalent 0/0 
patients in South Glamorgan by frequency 
examination 113 
Sphincteric function: 
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(2) Incidence of clinical signs in this study cohort (n=150) 
Table 2-4: Incidence of specific clinical signs amongst the study cohort (%) 
System Sign Site Male Female RRMS SPMS PPMS All 
Increased tone Ann 13.2 4.3 1.5 17.1 16.7 6.3 
Leg 27.9 27.6 17.0 47.4 66.6 27.7 
Weakness SA 7.4 4.7 2.91 10.5 11.1 5.3 
EF 10.3 3.0 3.4 7.9 5.6 4.7 
EE 8.8 3.0 1.9 7.9 16.7 4.3 
WF 8.8 4.3 3.9 9.2 5.6 5.3 
WE 8.8 6.9 5.8 11.8 5.6 7.3 
HF 30.9 32.8 21.4 54.0 66.7 32.3 
Pyramidal KF 29.4 28.0 18.9 44.7 66.7 28.3 
KE 19.1 10.3 6.3 21.1 44.4 12.3 
ADF 20.6 16.4 8.3 32.9 55.6 17.3 
APF 14.7 11.2 4.9 25.0 38.9 12.0 
Bicep 13.2 11.6 10.2 14.5 22.2 12.0 
Supin. 16.2 10.3 8.7 17.1 22.2 11.7 
Brisk Reflexes Tricep 8.8 9.5 6.8 13.2 22.2 9.3 
Knee 26.5 20.7 17.0 31.6 38.9 22.0 
Ankle 20.6 9.1 11.2 11.8 16.7 11.7 
Extensor Plantar response 44.2 40.1 24.3 75 88.9 41 
Superficial Ann 44.1 34.1 28.6 56.6 38.9 36.3 
Leg 42.6 38.4 34.4 57.9 16.7 39.3 
Vibration Ann 63.2 75.9 66.5 88.2 83.3 73.0 Sensation Leg 76.5 90.5 81.6 100 100 87.3 
Proprioception Ann 4.4 4.3 1.9 11.8 0 4.3 
Leg 11.8 7.3 4.4 27.6 5.6 10.3 
Rhomberg's test +ve 17.6 20.7 6.8 50 33.3 19.3 
Dysmetria Ann 27.9 18.1 16 26.3 44.4 10.3 
Leg 35.3 30.6 21.8 50 66.7 31.7 
Dysdiadochokinesis Ann 26.5 15.9 13.1 25 50 18.3 
Leg 42.6 28.9 21.3 50 77.7 32 Cerebellar 
Arm 2.9 3.4 2.9 5.2 0 3.0 Resting Tremor 
Leg 2.9 0 0 2.6 0 0.7 
Gait Abnormality Eyes open 55.9 60.3 42.7 94.7 100 59.3 
Eyes closed 79.4 78.4 70.9 94.7 100 78.7 
Acuity (~/9) 30.9 24.1 18.9 39.5 44.4 25.7 
Visual Field Defect 10.3 1.3 2.9 5.3 0 3.3 
Scotoma 5.9 12.1 10.7 13.4 5.6 10.7 
Optic Atrophy 32.4 31.9 28.2 47.4 11.1 32.0 
Eye movements 17.6 8.6 7.8 18.4 11.1 10.7 
Nystagmus 29.4 12.9 13.6 21.1 33.3 16.7 
Trigeminal sensory deficit 29.4 28.4 25.2 42.1 11.1 28.7 
Facial weakness 5.9 2.6 2.9 5.2 0 3.3 Brainstem 
Hearing loss 11.8 5.2 4.9 10.5 11.1 6.7 
Dysarthria 14.7 18.1 11.7 28.9 33.3 17.3 
Dysphagia 5.9 12.1 4.9 23.7 22.2 10.7 
Tongue RAM 8.8 6.9 2.9 15.8 22.2 7.3 
Urinary Urgency 55.9 57.7 50.5 65.8 100 57.3 
Urinary Hesitancy 52.9 43.1 37.9 60.5 66.7 45.3 
Sphincter Urinary Retention 5.9 24.1 12.6 36.8 33.3 20.0 
Urinary Incontinence 17.6 31.0 18.4 44.7 66.7 28.0 
Bowel Dysfunction 29.4 39.7 32.0 50.0 44.4 37.3 
Depression 17.6 12.9 11.7 26.7 11.1 14.0 
Cognitive Euohoria 2.9 3.6 1.9 5.3 11.1 3.33 
Decreased mentation 17.6 17.2 15.5 21.1 22.2 17.3 
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Table 2-5: Factors affecting presence of clinical signs in study cohort 
E 
Clinical sign Site Clinical factor 
~ Male sex Age ( ear ) Di ease duration RRMS PP~IS v; 
>. (m) 
V'J 
p-value OR p-value OR p-value OR p-\alue OR p-\ alue OR 
Increased Arm 0.001 8.54 0.116 0.274 <0.001 0.068 0.818 
tone Leg 0.435 0.470 0.309 <0.001 0.273 o.n:! 
SA 0.205 0.485 0.519 0.034 0.293 0.969 
EF 0.018 3.87 0.297 0.988 0.053 0 . 8 ~-l 
EE 0.017 4.57 0.482 0.572 0.039 0.240 0.3-l6 
Weakness HF 0.518 0.049 1.036 0.013 1.005 <0.001 0.292 0 .33~ 
KF 0.463 0.776 0.166 <0.001 0.309 0.069 
Ci3 KE 0.015 2.77 0.159 0.961 0.001 0.262 0.123 
:g 
... ADF 0.151 0.317 0.546 <0.001 0.170 0 .33~ ~ APF 0.223 0.325 0.503 <0.00 I 0.169 0.053 >-. 
0.. Bicep 0.3 19 0.215 0.045 1.004 0.924 0.333 
Sup ina- 0.048 2.29 0.459 0.043 1.005 0.209 0.458 
Brisk tor 
Refl exes Tricep 0.488 0.105 0.032 1.005 0.569 0 . ~6~ 
Knee 0.2 15 0.112 0.633 0.019 0.472 0.8§9 
An kle 0.008 2.79 0.062 0.163 0.678 0.311 
Extensor Plantar 0.127 0.41 3 0.112 <0.001 0.117 0.116 
plantar 
Reduced Arm 0.047 1.80 0.360 0.515 <0.001 0.327 0.166 
superficia l Leg 0.292 0.798 0.195 0.001 0.403 0.009 0.16 
sensation 2 
C Reduced Arm 0. 173 0.157 <0.001 1.008 0.002 0.297 
0.996 
0 vibrati on Leg 0.190 0.296 <0.001 1.022 0.996 1.000 (/) 
c Reduced Arm 0.526 0.122 0.008 1.01 0.008 0.177 0.998 t!) 
V'J proprioceptio Leg 0.282 0.346 0.640 <0.001 0.133 0.071 
n 
Rhomberg 0.765 0.3 19 0.650 <0.001 0.085 0.33 1 
+ 
Dysmetri a Arm 0.252 0.500 
0.028 1.005 0.302 0.305 
Leg 0.808 0.832 0.067 <0.001 0.218 0.545 
~ Dysdi adocho Arm 0.153 0.572 0.007 1.006 0.011 0.338 0.127 
'0 k. Leg 0.302 0.287 0.155 <0.001 0.210 0.216 
.D 
t!) Gait Eye 0.529 0.409 0.074 <0.001 0.043 0.999 .... 
t!) 
U open 
Eye 0.752 0.419 0.073 0.006 0.120 0.999 
close 
Opt ic 0.354 0.360 <0.001 1.007 0.022 0.507 0.050 0.20 
C;; Atrophy Eye 5 :::l 
0.387 (/) Acuity >6/6 0.056 0.877 0.003 1.005 0.005 0.257 :> 
Scotoma 0.004 0.33 0.431 0.008 1.006 0.021 0.419 0.237 
Nystagm us 0.020 3.11 0.593 0.113 0.096 0.374 
E Dysarthri a 0.782 0.23 1 0.683 0.036 0.361 0.963 




Urinary Hes itancy 0.120 0.971 0.025 1.006 0.060 0.557 
.... Urinary Incontinence 0.296 0.151 0.121 0.028 0.376 0.230 
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(3) Results summary 
Table 2-6: Summary of clinical signs found to be significantly affected by 
patients sex (statistically significant at 0.05 level and corrected for age, disease 
duration and disease sub-type). 
Clinical sign p-value OR for male sex (95% CI) 
Arm Tone Raised 0.001 8.543 (2.547 - 28.650) 
Weakness Elbow Flexion 0.018 3.868 (1.267 - 11.810) 
Weakness Elbow Extension 0.017 4.571 (1.313 - 15.915) 
Weakness Knee Extension 0.015 2.77 (1.217 - 6.305) 
Brisk Supinator Reflex 0.048 2.293 (1.008 - 5.217) 
Brisk Ankle Reflex 0.008 2.7890.306 - 5.955) 
Presence of Nystagmus 0.020 3.111 0.200 - 8.064) 
Impaired L T /PP sensation in upper limbs 0.047 1.800 (1.009 - 3.210) 
Presence of Visual Scotoma 0.004 0.329 (0.154 - 0.700) 
Presence of Urinary Retention 0.047 0.213 (0.046 - 0.982) 
Table 2-7: Summary of signs more likely to be found with increasing disease 
duration (statistically significant at 0.05 level and corrected for age, sex, and 
disease subtype). 
Sign p- Odds Ratio (95%CI) Years to 
value (monthly) double 
odds 
Weakness of hip flexion 0.013 1.005 0.001 -1.008) 12 
Brisk Bicep Reflex 0.045 1.004 0.000 - 1.009) 15 
Brisk Supinator Reflex 0.043 1.005 (1.000 - 1.009) 12 
Brisk Tricep Reflex 0.032 1.005 (1.000 - 1.010) 12 
Finger Nose ataxia 0.028 1.005 0.001 - 1.009) 12 
Dysdiadochokinesis (upper limbs) 0.007 1.006 0.002 - 1.011) 10 
Decreased Vibratory Sensation <0.001 1.008 (1.004 - 1.013) 8 
(upper limbs) 
Decreased Vibratory Sensation <0.001 1.022 (1.011 - 1.033) 3 
(lower limbs) 
Decreased Proprioception (upper 0.008 1. 01 0 (1. 003 - 1. 1 1 7) 6 
limbs) 
Urinary Hesitancy 0.025 1. 006 (1.00 1 - 1. 0 1 1 ) 10 
Impaired Visual Acuity 0.003 1.005 (1.002 - 1.009) 12 
Optic Atrophy <0.001 1.007 (1.004 - 1.011 ) 9 
Visual Scotoma 0.008 1. 006 ( 1. 00 1 - 1. 0 1 0 ) 10 
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Table 2-8: Summary of signs less likely to be found in relapsing remitting 
disease compared with secondary progressive disease (statistically significant at 
0.05 level and corrected for age, sex, and disease duration). 
Sign p-value Odds Ratio (95 0 oel) 
Arm Tone Raised <0.001 0.068 (0.017 - 0.268) 
Leg Tone Raised <0.001 0.273 (0.150 - 0.499) 
Weakness of Shoulder Abduction 0.034 0.293 (0.094 - 0.912) 
Weakness of Elbow Extension 0.039 0.240 (0.062 - 0.928) 
Weakness of Hip Flexion <0.001 0.292(0.161 - 0.530) 
Weakness of Knee Flexion <0.001 0.309 (0.171 - 0.557) 
Weakness of Knee Extension 0.001 0.262 (0.115 - 0.598) 
Weakness of Ankle Dorsi-Flexion <0.001 0.170 (0.073 - 0.397) 
Weakness of Ankle Plantar-Flexion <0.001 0.169 (0.082 - 0.349) 
Brisk Knee Reflex 0.019 0.4 71 (0.251 - 0.882) 
Extensor Plantar Reflex <0.001 0.117 (0.63 - 0.219) 
Heel-Shin Ataxia <0.001 0.218 (0.76 - 0.631) 
Dysdiadochokinesis (upper limbs) 0.011 0.338 (0.146 - 0.781) 
Abnormal RAM (lower limbs) <0.001 0.210 (0.114 - 0.387) 
Gait Ataxia (Eyes open) <0.001 0.043 (0.010 - 0.193) 
Gait Ataxia (Eyes closed) 0.006 0.120 (0.27 - 0.541) 
Dysarthria 0.036 0.361 (0.139 - 0.937) 
Dysphagia 0.009 0.201 (0.060 - 0.672) 
Decreased L T IPP Sensation (upper limbs) <0.001 0.327 (0.186 - 0.576) 
Decreased L T IPP Sensation (lower limbs) 0.001 0.403 (0.231 - 0.703) 
Decreased Vibratory Sensation (upper limbs) 0.002 0.297 (0.136 - 0.650) 
Decreased Proprioception (upper limbs) 0.008 0.177 (0.049 - 0.642) 
Decreased Proprioception (lower limbs) <0.001 0.133 (0.056 - 0.315) 
Positive Rhombergs test <0.001 0.085 (0.031 - 0.235) 
Urinary Incontinence 0.028 0.376 (0.158 - 0.897) 
Urinary Retention 0.012 0.303 (0.119-0.771) 
Impaired Visual Acuity 0.005 0.257 (0.088 - 0.752) 
Optic Atrophy 0.022 0.507 (0.283 - 0.907) 
Visual Scotoma 0.021 0.419 (0.200 - 0.879) 
Table 2-9: Summary of signs less frequently found in primary progressive 
disease compared with secondary progressive disease (statistically significant at 
0.05 level and corrected for age, sex, and disease duration). 
Sign p-value Odds Ratio (950/0C1) 
Decreased L T IPP Sensation (lower limbs) 0.009 0.162 (0.042 - 0.629) 
Optic Atrophy 0.050 0.205 (0.042 - 0.9971 
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Discussion 
We have reported the incidence of a comprehensive set of varying clinical signs in 
150 patients with multiple sclerosis and shown how they vary within the group 
according to patient sex, age, disease duration and disease subtype. We have 
statistically analysed this data and shown that whilst the majority of clinical signs are 
more likely to be evident in patients with secondary progressive disease. there are 
also clinical signs that seem more likely to appear in relation to overall disease 
duration. We have also revealed that certain clinical signs are more frequently found 
in relation to the patient's sex but rarely is age at assessment independently 
associated with the presence of clinical signs. 
Our cohort is unlikely to be truly representative of our geographical multiple 
sclerosis population. Our data has been collected from a clinic designed to assess the 
suitability of multiple sclerosis patients for disease modifying drugs3 U:!: 123; 124 and 
whilst the only referral criteria was a secure diagnosis of multiple sclerosis according 
to the McDonald criteria15, most referrers were aware that patients with relapses and 
without marked disability were more likely to be suitable. Hence our cohort probably 
shows more relapsing disease and less severe disability than would be expected by 
chance in a truly unselected prevalent population. 
Previous studies17;I2:!J25;1:!6 of clinical multiple sclerosis are rarely unaffected by 
inherent selection bias, usually due to the hospital based nature of recruitment. Other 
differences between studies include the diagnostic criteria used13:15 ; varying 
geographical and racial distributions l25 ; and the obvious but salient fact that clinical 
signs are observer dependent. Therefore comparison with previous studies is 
therefore only partial instructive. We have however provided the details of 2 
prevIous studies, both performed within mainland Britain in table format for 
comparison7:1:!:! (see table 2-3). It should be borne in mind that our reported 
frequencies pertain to individual clinical signs rather than a cumulative chance within 
a patient. thus a figure of 54° 0 for weak hip flexion in secondary progressive patients 
(see table 2-4) indicates that 540/0 of all hips were weak in this sub-group and as each 
patient has 2 hips the chances of any hip weakness within an individual will be 
somewhat higher. 
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Initial analysis of our cohort's demographic data reveals a higher proportion of 
females as widely reported in other series (see table 2-1 and figure 2-1). \\'hilst we 
did observe an unexpected preponderance of females in our primary progressiye 
group, our group size is clearly not sufficient to challenge the conventional belief 
that there is probably sexual equality amongst primary progressiYe patients. 
Our cohort's age of onset is comparable with previous studies (see table 2-1 and 
figure 2-2). Our combined cohorts mean age of onset of 30.6 years is very similar to 
previous larger studies which have reported figures of 3l.3 years121 and 30.5 years 17. 
Our average age of onset of relapsing remitting disease and secondary progressiYe 
disease are similar as one would expect of disease subtypes that are largely the same 
disease at different stages of evolution. The important caveat to this is that there is a 
small group of relapsing-remitting patients who will never enter the secondary 
progressive phase and so it is not unreasonable that there is a small difference 
between these groups. The age of onset (40.67 years) in our primary progressive 
patients was substantially later than in relapsing onset disease and was comparable 
. h . d· 127-129 WIt preVIOUS stu Ies . 
We did not record the date of onset of progressive symptoms. Previous 
observations129 indicate that the progressive phase starts at a remarkably similar age 
in both secondary and primary progressive patients. 
Our disease duration statistics (see table 2-1) show that on the whole our patients are 
at a relatively early stage of their disease. This is in keeping with the nature of the 
disease-modifying clinic to which they were referred. This would also explain the 
relatively low proportions of patients from a prevalence perspectiYe of progressiYe 
disease sub types. 
Our disability data, as measured by the EOSS 19 (see figure 2-3 and table 2-2) varies 
from previous cross sectional analyses as we have relatiyely fewer patients with 
advanced EOSS scores 17. This is again presumably a rcsult of the prcyiously notcd 
referral bias towards less disabled patients. 
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Notably we had no patients at EOSS zero. This was consistent with the cross-
sectional disabilities reported in a much larger previous studi7 of 1099 patients. It 
does seem difficult to reconcile the traditional view of relapsing-remitting disease 
where clinical signs are 'not infrequently absent'! 17, with the notion that not one of 
the 1249 patients in either of our studies was normal to neurological examination. 
Therefore one of the following is probably true: remission after 2 disease-defining 
relapses is virtually never complete or there is a parallel insidious progression qj" 
neurological deterioration (albeit less disabling than in classical progress in.! 
disease) that commences following, or even preceding the first or second relapse23. 
Recent studies suggest atrophy and axonal loss are present very early in the course of 
I · 1 1 ' 38'130-132 Th . d f h' h' h h' h mu tIp e sc erOSIS' . e magmtu e 0 t IS atrop y IS SUC t at It may ave 
been evident, if looked for, before the first clinical episode of acute neurological 
deterioration51 . There is also neuro-physiological evidence of early asymptomatic 
visual disturbance that supports this hypothesis 133. Indeed a recent therapeutic 
study l34 of clinically isolated demyelination found their 91 patients to have a mean 
EOSS of 2.2 at entry to their study. It may therefore be the case that a proportion of 
patients are already at EOSS 1.0 or higher in advance of developing symptoms. 
Our primary progressIve group has a very similar temporal disability course to 
previous studies. The London, Ontario cohort and Lyon cohort of primary 
progressive patients were found to take 8 years23 and 7.1 years 10 respectively to reach 
an EOSS of 6. Our primary progressive group, albeit much smaller, had a median 
EOSS of 6 (mean 5.83) at a disease duration of 7.89 years. 
Our findings that primary progressive patients had a similar EOSS distribution to 
secondary progressive patients despite a much shorter disease duration parallels 
previous observations 10 that disability evolves substantially more rapidly in 
progressive rather than relapsing onset disease. 
Therefore whilst our group demonstrates a modest bias towards earlier relapsing 
disease than would be expected from a truly un selected multiple sclerosis population 
we believe that the differences between our sub-groups in tenns of sex. age, disease 
duration and disease subtype are not incomparable with previous studies. 
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(i) Visual Signs 
We found corrected visual acuity to be worse than 6/6 on Snellen chart testing in 
25.70/0 of all our patient's eyes (see Table 2-4). This is lower than a previous series of 
301 patients studied by Dr Swingler7 (see Table 2-3) in a similar geographical 
location, who reported impaired visual acuity in 72.40/0 of these patients. This is 
probably due to the differences in reporting the proportion of eyes versus patients 
and also as previously mentioned the bias in our population towards earlier disease 
states. This is given further credence by our finding that impaired visual acuity was 
statistically significantly (p=0.003) more likely with increasing disease duration. 
Assuming our Odds Ratio correct this would equate to a doubling of risk of impaired 
visual acuity every 12 years of disease duration (see table 2-7). 
Optic atrophy as defined by optic disc pallor was found in 320/0 of eyes in our cohort. 
This is probably comparable to the 41 % of patients with optic atrophy reported by Dr 
Swingler (see Table 2-3). Factors that appeared to affect the presence of optic 
atrophy (see Table 2-5) were increasing disease duration (p<O.OOI) and both 
relapsing remitting (p=0.022) and primary progressive disease (p=0.05) appeared to 
have significantly lower incidences of optic atrophy compared with secondary 
progressive disease. Visual field abnormalities to confrontational testing were 
uncommon III our group. 
Visual scotoma was found in 10.7% of our patients eyes over all. It appeared more 
likely to be found with increasing disease duration (p=0.008) and less likely to be 
found in relapsing remitting disease (p=0.021) and, inexplicably, men (p=0.004). 
Previous work 13) has suggested that episodes of optic neuritis per se infrequently 
result in impaired visual acuity in the long term, this study also found that visual 
acuity was more likely to be impaired in optic neuritis patients with multiple 
sclerosis than those without MS. This suggests that visual impairment in multiple 
sclerosis is not dependent upon episodes of optic neuritis. A supporting observation 
from our group was that primary progressive patients. who had no episod~s of optic 
neuritis. were found to han? the highest incidence of impaired visual acuity but the 
lowcst incidence of obs~rved optic atrophy. The lowcr incidence of optic atrophy in 
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pnmary progressIve patients was statistically significant compared to secondary 
progressive patients (p=0.05). Impaired visual acuity was more common in primary 
progressive patients than relapsing onset disease, although this did not reach 
statistical significance. However the casual observation of impaired visual acuity in a 
group with paradoxically low levels of optic atrophy is interesting. It possibly 
suggests that dysfunctional axons and myelin are relatively preserved in primary 
progressive disease compared with secondary progressiYe disease, preventing optic 
atrophy. However the functional paradigm is that visual acuity in primary 
progressive patients may be worse. Inflammatory or apoptotic 'pruning' of 
dysfunctional neurological tissue may lead to a paradoxically better functional 
outcome. 
(ii) Pyramidal signs 
Our study (see table 2-4) confirmed the received wisdom that increased tone in 
multiple sclerosis is more frequent in lower than upper limbs and is more likely in 
progressive disease than relapsing remitting disease. We also found that raised arm 
tone appeared to be significantly (p=0.00 1) more likely in males (see table 2-5). This 
trend towards more marked pyramidal signs of disease in males, is not produced 
from a skew towards primary progressive disease or late onset disease as this was not 
found in our cohort. Neither could disease duration explain this as our male patients 
had a shorter disease duration (table 2-1). 
Interestingly disease duration was not independently associated with raised limb 
tone. Our models indicate that the presence of progressive disease was the major 
determinant in the presence of raised limb tone. 
Clinically detectable limb weakness is more common in legs than arms in our study 
(see table 2-4). Hip flexion was the movement most commonly weak. A 'pyramidal' 
pattern of leg weakness was observed with weakness of knee tlexion substantially 
more common than weakness of knee extension (28.3% vs. 12.3° 0). A pattern of 
'pyramidal' arm weakness (elbow flexion stronger than elbow extension) was not 
observed except in our primary progressive group. 
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Men were significantly more likely to have weakness of elbow flexion, dbow 
extension and knee extension (see table 2-5) than females. This in combination with 
the above observations of significantly increased frequency of raised arm tone in 
males has supporting evidence from a pathological study136 that found that ner\"l? 
fibre density in the crossed pyramidal tracts at the C3 spinal levd was significantly 
reduced in males compared with females (41 % male vs 190/0 female reduction, 
P<O.003). This reduction in nerve fibre density was unrelated to local plaque 
formation. There was no difference between the sexes in healthy controls in this 
study. Whilst weak hip flexion alone was significantly more common with increasing 
disease duration the notable trend was towards limb weakness being significantly 
more likely in progressive rather than relapsing remitting disease, and being 
otherwise independent of disease duration. 
We were surprised initially to find such a low incidence of brisk reflexes in our 
cohort (see table 2-4) compared to previous studies which quote figures of 92.XO () 122 
and 59.1 % (see table 2-3) for hyper-reflexia. This is probably due to a combination 
of factors. We are examining and reporting individual reflexes as opposed to noting 
the presence of any hyper-reflexia as well as our cohort's tendency towards earlier 
relapsing disease. However the persistent variance between these three reported 
incidences of hyper-reflexia may also emphasise the limitations of subjective 
examinations and highlight that comparing between centres and observers is of 
limited value. 
In contrast, relative observations made by the same observers at the same centre are. 
we believe, perhaps more instructive. Brisk ankle and radial reflexes were more 
common in men. Arm reflexes showed a statistical trend towards being brisk with 
increasing disease duration whereas knee reflexes were more likely to be brisk in 
progressive rather than relapsing remitting disease without an independent effect of 
disease duration. We also found that retlexes were not infrequently absent. Reflexes 
wen: not found in 6.70/0 of knee reflexes and 12.30/0 of ankle reflexes. This parallels 
earlier findings of reflex absence in 130/0 ofMS patients l37 . 
Overall .f 1 010 of plantar reflexcs wcre extensor on examination although there were 
marked variations depending on whether the patient was in the relapsing remitting 
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(24.30/0), secondary progressive (75%) or primary progressive (88.9%) disease phase. 
This provides partial support for the hypothesis that an extensor plantar may be a 
useful sign of impending secondary progression 138. There was no independent effect 
of disease duration on presence of extensor plantar reflexes. 
(iii) Cerebellar signs 
Ataxia refers to disturbance in the smooth perfonnance of voluntary motor acts 139. It 
encompasses dysmetria, dysdiadochokinesis and past pointing. The tremor found in 
multiple sclerosis, although complex, is considered to be largely cerebellar in 
origin14o. Our analysis of cerebellar signs reveals a higher incidence of ataxia in legs 
than anns (see table 2-4). This contrasts with previous studies 113;122, however at least 
one of these studies122 notes that their excess of cerebellar signs in the upper limbs 'is 
explained by the frequent presence of a marked spastic paraparesis precluding the 
testing of cerebellar function in the lower limbs. When it can be tested, cerebellar 
dysfunction is more common in the lower limbs'141. The trend towards less severe 
disability levels in this study may again offer partial explanation for this but it is 
accepted that despite best efforts confidently distinguishing cerebellar ataxia from a 
pseudo-pyramidal ataxia is rarely easy. Our two measures of ataxia - essentially 
dysmetria and dysdiadochokinesis - disclosed very similar infonnation. Dysmetria 
and past pointing in the anns was significantly (p=0.028) more likely with increasing 
disease duration (see table 2-5) but we did not find an independent correlation with 
disease subtype. Dysdiadochokinesis in the anns was independently correlated with 
disease duration (p=0.007) and secondary progressive disease (p=O.Oll). In the legs 
both dysmetria and dydiadochokinesis were significantly (p<O.OO 1) less likely in 
relapsing remitting disease. We did not find a statistically significant independent 
effect of disease duration on leg ataxia. 
We found resting tremor in only 3% of anns and 0.70/0 of legs. This is similar to the 
findings of a study of tremor in 100 patients with multiple sclerosis 140 (mean diseasc 
duration 18.8 years) which found no examples of rest tremor. They did. howen~r. 
find postural or kinetic tremor in 58 of their patients. Our Ycry low incidence of rest 
tremor further highlights the fact that basal gangl ia function is usually prcscrn:d in 
multiple sclerosis. 
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Gait, although reported as part of the cerebellar examination is clearly reliant on 
several neurological systems including pyramidal, visuaL brainstem and sensory. 
This is highlighted by the worsening of gait with eye closure. However abnormalities 
of gait with the eyes open better distinguished relapsing from progressi\'e disease 
(p<O.OO 1) whilst gait abnormalities with eyes closed are frequent even in relapsing 
remitting disease and may be a sensitive early marker for multiple sclerosis, possibly 
of use in stratifying risk of developing multiple sclerosis from clinically isolated 
syndromes. Longer disease duration was not found to be an independently significant 
(p=O.074) cause of gait impairment. 
(iv) Brainstem signs 
The analysis of brainstem signs, principally inferred through the examination of 
cranial nerves, is shown in table 2-4. Our overall figure of 10.70/0 of patients with eye 
movement abnormalities is comparable with the 13 % of patients found to have 
diplopia on examination in a previous stud/ 26 of 991 patients. Our figures for 
individual signs are generally less than in previous studies (see table 2-3) although 
similar ratios between the various signs are observed. As previously mentioned this 
is likely to be a reflection on our group's bias towards earlier disease. 
We found nystagmus appeared to be more common in men (p=O.020), whilst 
dysarthria (p=O.036) and dysphagia (p=O.009) appeared to be significantly more 
common in secondary progressive rather than relapsing remitting disease. Disease 
duration did not independently appear to affect the likelihood of finding these signs. 
(v) Sensory signs 
We found that vibratory sensation was most frequently abnormal whereas 
proprioception was most likely to be preser\'ed. Sensation to touch and pain was 
somewhere between these two extremes (see table 2-4). 
In considering our findings for touch and pain sensation it is important to consider 
the protocol by which our examinations and assessments were perfomled (see 
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Appendix X). Superficial sensation is assessed by both light touch and pin prick 
sensation. Whilst with hindsight it would have been useful to discriminate between 
light touch and pinprick sensation as they are generally carried in different pathways 
it is our recollection that a large majority of abnormal results were associated with 
abnormal pinprick sensation whereas an isolated abnormality of light touch sensation 
was very unusual. For this reason we believe that our findings in this category of 
superficial sensation principally reflect dysfunction in the spino-thalamic tracts of the 
spinal cord. 
Of note we did not find a dramatic difference in the loss of normal superficial 
sensation between arms and legs. If sensory loss occurs secondary to focal 
demyelination and chronic plaque formation one would expect leg sensation to be 
significantly worse than arm sensation due to the greater length of central nervous 
system white matter that the leg sensory neurons have to traverse compared with the 
arms. This was not the case, and seems to be counter-intuitive at first site. A pr~vious 
study142 of pain evoked sensory potentials found that of twelve patients, three had 
delayed sensory evoked potentials in the hands, whilst seven had delays in the feet. 
In our experience clear sensory levels are difficult to find in patients with multiple 
sclerosis. We found this to be the case even when we were forearmed with 
knowledge of clear and focal abnormalities of spinal MRI in 10 of our patients. This 
would concur with a recent study that found axonal injury in the spinal cord occurs 
largely independently of T2 lesions 143. Another study of axonal loss in multiple 
sclerosis found a statistically significant loss ofaxons in the sensory tracts of the 
spinal cord only in the upper and lower segments of the cervical cord. The axonal 
loss was most marked in the upper cervical cord. These findings would tend to 
suggest that there is likely to be little difference in sensation between upper and 
lower limbs. At the point where the sensory tracts reach the lower cervical cord the 
majority of the damage has been done. Even axons lost in the lower cervical cord 
(C5-8) will probably affect sensory disturbance in the arms, to a degree, in addition 
to the legs. Th~re may in fact be a sensory level between occiput (C~) and vertex of 
the skull but this is not routinely examined for. This similarity between sensory 
disturbance in arms and legs is despite data in the next chapter that re\'~als relapses 
affecting sensation in the legs are more commonly reported than in the arms. 
('ertainly acute relapses do s~em to more commonly affect sensation in the legs. 
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possibly with a clear sensory level at the time of the relapse. However this, in our 
experience, does not frequently translate into a chronic sensory level. 
F actors that appeared to increase the presence of abnormal superficial sensation were 
being in a secondary progressive stage of the disease compared to relapsing remitting 
for both arms (p<O.OOI) and legs (p=O.OOI). Also we noted a tentative relationship 
between male sex (p=0.047) and increased incidence of superficial sensory 
abnormalities in the arms. 
Perhaps most strikingly pnmary progressIve patients were found to have a 
significantly (p=0.009) lower incidence of superficial sensory abnormalities in their 
legs compared to secondary progressive patients. In our cohort the incidence of 
superficial sensory abnormalities in the legs of primary progressive patients was 
lower than in their arms or in the legs of even relapsing remitting patients. Despite 
being statistically significant at 0.01 level we were concerned that this may be a false 
positive result and so again checked our original forms to ensure correct data entry 
and examined our qualitative data. This showed the same trend. It does however 
seem unlikely that such a finding would have evaded prior detection by other 
investigators and a rational explanation is not obvious, raising the possibility that this 
is a false-positive result but for two reasons we believe this finding at least merits 
further investigation. Firstly it is of note that this quite marked finding was not 
suspected by ourselves even after the data collection phase, only upon systematic 
analysis of our data did it become obvious that there was a marked difference 
between two groups in whom we had not anticipated a significant difference. This 
raises the possibility that significant differences and intricacies in multiple sclerosis 
may be beyond experiential detection. We also checked our qualitative data, which 
showed the same trend. If we compare only the legs of the two progressive groups 
who have an abnormality of superficial sensation then we see that of the 3 affected 
legs in the primary progressive group all have only a mild abnormality. This 
compares with 13 mild, 20 moderate and 11 marked abnormalities in the secondary 
progressive group. Clearly this result could still be obtained by chance, especially 
when so many observations have been made and a rationale explanation for this 
finding is not obvious. If this finding were prospectively validated in a new cohort 
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then it may help further our understanding of the differences between the progressive 
disease forms. 
Vibratory sensation was found to be abnormal in 87.3% of all legs. This corresponds 
with anecdotal observationsl44 but is somewhat greater than previous studies which 
have reported impaired vibratory sensation in 61.5% (see Table 2-3) and 62.5° 0 122 of 
patients. Impaired vibratory sensation seemed to be most affected by disease duration 
(p<O.OOI) rather than whether the patient was in a progressive disease phase. ~one of 
four patients with a disease duration of 12 months or less had any impaired vibratory 
sensation whilst only one of sixty six patients with a disease duration over 92 months 
was similarly unaffected. Vibratory sensation may have some potential as an early 
surrogate marker for disease progression in therapeutic trials aiming to show early 
preservation of neurological function. 
We found proprioceptive abnormalities to be uncommon in our cohort and 
principally worse in legs than arms (see table 2-4). In upper limbs proprioceptive 
abnormalities became more likely (see table 2-5) with increasing disease duration 
(p=0.008) and in secondary progressive disease (p=0.008) rather then relapsing 
remitting disease whereas in lower limbs only the presence of secondary progressive 
disease was independently associated with an increased incidence of proprioceptive 
abnormalities. 
Romberg's test, although principally a test of proprioception clearly relies on other 
sensory and motor modalities. This is highlighted by the fact that many more of our 
patients had a positive Rombergs (would have fallen if not caught) than individual 
abnormalities of proprioception. Rombergs was more likely to be positive if the 
patient was in a progressive disease stage «0.001) but disease duration was not 
found to be independently significant to Romberg's test. 
(vi) Bladder and bowel symptoms 
Sphincter dysfunction was assessed from the patient's history rather than 
~xamination. In our group (see table 2-4) we found urinary urgency (57.3%) to he the 
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most common symptom followed by urinary hesitancy (45.3%). bowel dysfunction 
(37.3%), urinary incontinence (28.0%) and urinary retention (20%). These figures 
are somewhat higher than previous studies who have similarly reported these as 
separate entities122 (see Table 2-3), but overall likely similar to previous studies who 
have reported sphincter disturbance as a single entity. One study 125 found sphincter 
disturbance in 740/0 of patients with multiple sclerosis in a similar geographical 
location. 
Analysing factors that possibly affect the onset of sphincter disturbance we found 
that urinary hesitancy was more often found with advancing disease duration 
(p=0.025), but not independently associated with disease sub-type (see table 2-5). 
Urinary incontinence and urinary retention were both more commonly found in 
secondary progressive disease rather relapsing remitting disease but neither symptom 
was found to be independently affected by disease duration. 
(vii) Mood and cognitive symptoms 
Analysis of mood and intellectual function (see table 2-4) revealed that our patients 
were more likely to be depressed (140/0) than euphoric (3.3 0/0), in contrast to a 
Scottish series l22 which reported euphoria in 17.4% and depression in only 7.5%. 
Our patients more frequently reported new cognitive and memory problems (17.3%) 
compared with their Scottish counterparts l22 (6.1 %), but about as frequently as 
patients from Wales l13 (13.3%). 
We found no statistically significant effects of patient sex, age, disease duration or 
disease subtype on the development of these symptoms. 
Factors affecting the neurological examination: 
(i) Age 
The age of the patients at the time of clinical examination did not appear to 
independently affect the clinical examination. Only weakness of hip flexion achieved 
an independent 'statistical' trend (p=O.049), with increased incidence of weakness 
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with increasing age. However the marginal nature of this result in the context of the 
number of possible associations examined should limit the conclusions drawn from 
this result. Although ours, and previous studies 122 have found progressive onset 
disease more likely to have a later age of onset, we did not find that agc 
independently affected the presence or absence of signs except for hip flexion 
mentioned above. This indicates that advancing age is probably not a significant 
independent determinant of the presence of clinical signs, and ultimately disabi lity in 
multiple sclerosis. Any observation of more advanced disability in the aged patients 
of a cross sectional population is probably due to a combination of longer disease 
duration and higher probability that the disease was progressive from onset rather 
than aging per se. In conclusion the neurodegenerative abilities of natural aging is 
trivial compared to the effects of multiple sclerosis. Our findings are somewhat 
different to those of Confavreux who found in the large Lyon cohort that the age at 
which certain stages of disability were achieved was very similar whether the disease 
onset was relapsing or progressive, thus making age a key determinant in disability120 
and further suggesting that relapses are largely inconsequential in the long term 
formation of disability. It may be that within our cohort the relatively small number 
of primary progressive patients, consequent upon the clinic setting, and the co-
analysis of disease duration, has down played the role of ageing. 
(ii) Sex 
Male sex was associated with an increasing incidence of several signs (see table 2-6). 
Increased arm tone; weakness of biceps, triceps and quadriceps; brisk ankle and 
radial reflexes; impaired superficial sensation in the arms and nystagmus wcre all 
significantly more common in men in our study. When the various signs are 
considered together, there does appear to be a trend towards pyramidal tract signs in 
men. This is independent of age, disease duration and presence of primary 
progressive disease. 
Gender is undoubtedly important in multiple sclerosis 145. Multiple sclerosis is less 
common in males. It is known that males with multiple sclerosis generally havc a 
more progressi\'c and sc\'cre outcome than females 6;22. Gender may affect not only 
alter the susceptibility of the central nervous system to damage but also its intrinsic 
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repair mechanisms146-148. MRI studies in multiple sclerosis have found that whilst 
males have relatively fewer inflammatory central nervous system lesions. 
paradoxically they tend to have more destructive lesions than females149.150. 
The pathophysiological basis for this effect of gender on phenotype is not entirely 
clear. It is certainly not a phenomenon limited to multiple sclerosis but is e\'ident in 
many inflammatory diseases including systemic lupus erythematosis and rheumatoid 
arthritis151 . Gender differences in multiple sclerosis could be a direct effect of the Y 
chromosome (or lack of the second X chromosome), an indirect effect mediated by 
sex hormones or a gender specific environmental effect. Several observations suggest 
that of these different factors sex hormones are most likely to be relevant to multiple 
sclerosis. 
Clinical observations of multiple sclerosis suggest clear changes in disease activity 
with alterations in sex hormone production in females. Pregnancy has long been 
associated with a reduction in relapse rates and first ever episode of multiple 
sclerosis, especially during the third trimester145when compared with non-pregnant 
states. The post partum period seems to be associated with a compensatory increase 
in disease activity. Pregnancy is also associated with an improvement in other auto-
immune diseases such as rheumatoid arthritis152. The reasons for this are thought to 
be an evolutionary suppression of Th I-type immune responses that can cause fetal 
rejection. Both oestrogen and progesterone levels gradually increase during 
pregnancy. Treatment of animal models of multiple sclerosis and rheumatoid arthritis 
suggest that oestrogen rather than progesterone is responsible for the beneficial 
immunomodulation 145. 
Testosterone appears to be protective in a variety of auto-immune diseases153 perhaps 
explaining the lower incidence of multiple sclerosis in men. The later onset of 
multiple sclerosis in men may be explained by the decline in bio-available 
testosterone observed in middle aged men154. It is suggested therefore that young 
men may be protected from multiple sclerosis by high testosterone levels. 
One studyl:'5 of 60 patients with relapsing-remitting multiple sclerosis investigated 
the relationship between serum sex honnone concentrations and characteristics of 
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tissue damage on conventional MRI brain scans in men and women suffering from 
relapsing-remitting MS. In women it was found that serum testosterone was 
significantly lower in MS patients than controls (p=O.OOO 1) and that the lowest leyels 
of testosterone were found in females with the greatest number of gadolinium 
enhancing lesions (p=O.02). Higher serum testosterone levels in females were 
associated with a significantly greater TI lesion load (p=O.006). Oestradiol 
concentrations did not significantly affect the MRI appearances in women. However, 
in males it appeared that oestradiol and not testosterone was affecting MRI brain 
appearances. In males a positive correlation was found between oestradiol 
concentrations and both T2 (p=O.02) and Tl (p=O.04) lesion load whereas 
testosterone levels were not associated with MRI parameters. The above study 
indicates that sex hormones playa role in the development of MRI lesions, although 
further work is required to examine this phenomenon in more detaL particularly 
whether spinal cord lesions are similarly affected. 
Whilst several previous studiesl56-159 have found male sex is associated with a more 
rapid accumulation of composite disability the nature of this disability is not made 
clear. A large study of primary progressive patients found that there was similar 
disability progression between the sexes in the early stages of the disease but that 
survival in males was significantly shorter than in females5. Our data shows a trend 
towards spasticity, weakness and hyper-reflexia particularly in the upper limbs of 
men. The relatively poor outcome for cortico-spinal tracts in males has previously 
been noted in pathological studies l36. That this finding in our study is independent of 
the presence of primary progressive disease suggests that men are generally more 
susceptible to a cortico-spinal pattern of disease that is not dependent upon their 
propensity for primary progressive disease. It has previously been obseryed7 that the 
gender differences in multiple sclerosis is likely due to females haying a relati\dy 
pro-inflammatory phenotype compared with males. Howe\'t~r this does not 
immediately explain why men are not found at the less severe end of the disease 
spectrum. In spite of their inherently 'anti-intlammatory' sex, men appear to 
selectively suffer more scyere damage to some of the most functionally uscful 
neurological pathways. This may be because some intlammation in a multiple 
sclerosis population is beneficiaf6;l60-16~ and a males relatiyc lack of intlammation 
can thus be plausibly associated with a more disabling disease phenotype. 
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(iii) Disease duration and disease sub-type 
Intuitively multiple sclerosis should get worse the longer you ha\'e it and we already 
know that primary and secondary progressive disease are associated with more 
advanced disability when compared to relapsing remitting diseaseIO. Howe\,er the 
disease duration and disease sub-type are partially correlated. The longer the disease 
duration the more likely secondary progressive disease is to ha\'e commenced. But 
which is the more important factor with regard to the development of clinical signs? 
Our results indicate that many clinical signs within a population of multiple sclerosis 
become apparent depending on whether secondary progression has occurred, without 
independent regard for the disease duration (see table 2-8). Less frequently signs (eg 
leg vibratory sensation, brisk ann reflexes) appear more commonly with advancing 
disease duration (see table 2-7), without apparent independent regard for secondary 
progression. Vibration sensation, particularly in the legs seems to become unifonnly 
impaired at a stage well in advance of recognised secondary progression - raising the 
possibility that the secondary progressive stage may be dispersed in time and 
consequent upon properties of the underlying pathway: degree of myelination, axonal 
size, proximity to cerebrospinal fluid, functional reserve and plastic capabilities. 
Fonnal diagnosis of secondary progression may only occur at the stage at which the 
corti co-spinal tracts enter this phase. 
Often both disease duration and secondary progression were risk factors for presence 
of clinical signs independent of each other. Overall a clear majority of signs that 
might be expected to have a greater impact on mobility and thus disability scales (i.e. 
EDSS) such as leg weakness, were found to be independently associated with 
presence of disease progression rather than disease duration. This echoes the findings 
of previous longitudinal natural history studies that report the presence of progressi \'l~ 
disease to be the most ominous prognostic feature JO;ll. 
Whilst a highly \'ariable clinical phenotype between indi\'iduals with multiple 
sclerosis is self c\'ident. our findings suggest that not all neurological pathways 
within a population of paticnts with multiple sclerosis degeneratc in idcntical ways. 
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Some clinical signs seem to appear in a constant time dependent manner whilst the 
majority seem more prone to a step-wise deterioration heralded by the onset of 
secondary progression. Due to plasticity and lUxury function it may be that constant 
rates of axon loss result in apparent stepwise neurological dysfunction at a time 
remote from the onset of pathology. Our findings that leg weakness is highly 
correlated with the secondary progressive phase may indicate that axonal loss is 
relatively constant with the cortico-spinal tracts reaching the limit of their functional 
reserve and thus defining the point at which clear progression of disability is 
observed. Alternatively there may be a distinct pathological process that occurs at the 
time of disease progression that is independent, although possibly co-incidentally 
related, to the onset of relapsing disease 
The recent work of DeLuca et al l19 examining axonal loss in the spinal cord found 
axonal loss varied dependent upon tract type and segment of the cord. Sensory tract 
axonal loss was only statistically significant compared with controls in the upper 
cord, whilst corticospinal tract loss was significant at all levels. Further examination 
of the corticospinal tracts and the upper cervical sensory tracts revealed that there 
was selective preservation of large (>3flm) diameter fibres. This provides 
histopathological evidence that axonal loss is site and size dependent. Although the 
precise function of small and large fibres are yet to be fully elucidated it may be that 
the variance in clinical signs according to disease duration and disease sub-type that 
we have observed are also as a result of varying site and size specific axonal loss. 
Whilst in mild contrast to our study DeLuca et al l19 found few correlations with 
disease duration and histopathology it should be remembered that post-mortem 
studies may not pick up dynamic changes occurring at lower disability levels. 
(iv) Differences between primary and secondary progressive multiple sclerosis'! 
Of further interest was our comparison of clinical signs in secondary progressive and 
primary progressi\'e disease. Although neglected for some time there is renewed 
interest in primary progressin? disease l63 . O\'erall clinical examination ren?als many 
more similarities than differences between primary and secondary progressin? \ lS 
(sec table 2-5 and 2-9). Howc\,er our finding of preser\'ation of superficial sensation 
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III the lower limbs of pnmary progressIve patients (p=O.009) compared with 
secondary progressive patients was striking and merits further study. The finding of 
relatively low levels of optic atrophy in primary progressive patients in the face of 
relatively poor visual function as previously mentioned may further hint at the 
dissociation between inflammation and dysfunction. If primary progressi\·e disease is 
essentially prototypical multiple sclerosis, with secondary progressive disease being 
identical save for an ultimately inconsequential pro-dromal relapsing phase. then it is 
reasonable to suppose that the clinical difference between them represents the legacy 
of the relapsing remitting phase. Our study suggests this amounts to decreased 
superficial sensation in the lower limbs and a higher incidence of asymptomatic optic 
atrophy. Neither of these findings is likely to significantly affect the EDSS, 
especially at higher disability levels and thus our findings are consistent with large 
natural history studies10;11 that indicate that acute relapses have little or no effect on 
long term disability. 
In summary, the majority of central nervous system pathways display clinical signs 
of damage dependent upon the development of either primary or secondary 
progression. However, some central nervous system pathways appear to be more 
sensitive to the overall disease duration. Males appear to develop signs of 
corticospinal dysfunction more frequently and rapidly than women. The disability in 
primary and secondary progressive disease appears to be qualitatively similar apart 
from more frequent abnormalities of lower limb sensation and optic atrophy in 
secondary progressive disease. 
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Conclusions 
(l) The majority of clinical sIgns III multiple sclerosis become evident In 
progressive disease. 
(2) A few clinical signs become consistently evident before the onset of classical 
progressive disease, suggesting that secondary progression may be temporally 
dispersed and only frequently diagnosed when cortico-spinal tracts become 
involved. 
(3) None of our patients had an EDSS of zero. Either remission is virtually never 
complete or insidious disease progression starts at the time of, or preceding 
the diagnosis. 
(4) The finding of relatively infrequent optic atrophy in conjunction with 
relatively poor visual acuity in primary progressive patients suggests that 
optic neuritis may not be the dominant cause of poor visual acuity in multiple 
sclerosis. 
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Chapter 3: An analysis of relapse rate and quality in multiple 
sclerosis 
Introduction 
The presence of a sub-acute neurological deficit with subsequent remISSIOn 111 a 
young adult is highly suggestive of idiopathic demyelination7. A subsequent relapse 
disseminated in space is diagnostic of multiple sclerosis 1 5 where there is no 
reasonable alternative explanation. Approximately10 85% of multiple sclerosis cases 
begin in this relapsing-remitting fashion. Hence the relapse is usually the disease-
defining event. 
The English word 'relapse' derives from the latin word 'relaps' (slip again) which is 
the past participle of the verb 'relabi' ('to slip'). In relation to multiple sclerosis the 
relapse is defined in the McDonald criteria as an 'episode of neurological 
disturbance of the kind seen in MS, when clinicopathological studies han! 
established that the causative lesions are inflammatory and demyelinating in nature. 
Although there was some divergence of opinion. the group agreed that. for general 
diagnostic purposes, an attack, defined either by subjective report or by objective 
observation, should last for at least 24 hours 13. This assumes that there is expert 
clinical assessment that the event is not a pseudo attack, such as might be caused by a 
change in core body temperature14 or infection. Whereas suspicion of an attack may 
be provided by subjective historical reports from the patient, objective clinical 
findings of a lesion are required to make a diagnosis of MS. Single paroxysmal 
episodes (eg, a tonic spasm) do not constitute a relapse, but multiple episodes 
occurring over not less than ]4 hours do.' 15 The requirement for symptoms to last 
for greater than 24 hours is an attempt to discount 'pseudo-relapses' which may be 
caused by a transient rise in body temperature 14 associated with hot weather. exercise 
or fever. 
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(i) The pathology of relapse 
The relapse is the clinical embodiment of an acute pathological event: plaque 
.c: • SO-S9 Th h' I . I h . 10rmatlOn '. e IStO oglca c anges assocIated with the hyper-acute stages of 
plaque formation remain the subject of much interese. However the principle that 
acute plaque formation is more common in peri-venular distributions and invohes 
local breakdown of the blood-brain barrier with ensuing infiltration of lymphocytes, 
macrophages and microglia leading to comprehensive demyelination and a lesser 
degree of axonal transection is generally accepted 7. The mechanisms relating to 
clinical remission variably involve remyelination, neuronal plasticity and resolution 
of inflammatory conduction block with dispersion of voltage gated sodium channels 
along demyelinated axons to restore salutatory conduction. 
MRI studies reveal that the rate of new plaque formation in multiple sclerosis is ten 
to fifteen times higher than observed clinical relapses 7;63 and explanations for this 
would include plaques affecting clinically non-eloquent pathways, luxury 
neurological functionS8 and incomplete ascertainment of minor relapses. An 
increased rate of new plaque formation at the time of clinical relapse has also been 
described l64 and whilst occasionally the relapse is poly-symptomatic and all 
identified new plaques are clinically apparent, often the relapse causing plaque is 
identified in association with new asymptomatic plaques. This suggests a systemic 
change at the time of relapse. 
(ii) Relapse rates 
The frequency with which relapses occur has been the subject of several natural 
history studies lO;ls7;16s-168. Despite broad agreement on the definition of a relapse l6 
there is considerable variation in reported relapse rates. The range of reported relapse 
166 . 90 . rates extends from the 0.14 relapses per year found by Gudmunsson In patIents 
to the 1.1 relapses per year found by Patzold 168 in 102 patients with multiple 
sclerosis. Other relapse rate estimates include 0.86 relapses per year in relapsing-
remitting disease and 0.31 relapses per year including all progressive disease 
types I~ I. These dramatic variations are likely to be due to a synergistic combination 
of real phenomenon and systematic inequalities. 
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Natural history studies indicate that relapse frequency is highe t earl y in th di a 
d d t · 167'168 P . d" . bl . an ecreases over lme ' . rospect! e stu les In ana y report a hIgher r lap 
165-168 h h' . h' 
rate ' t an t elr retrospectIve counterparts, owe er It seem that th relap rat 
in the first few years after diagnosis is similar whether asses ed retro pecti r 
prospectivel/ 68. In Patzold 's study of 102 patients with MS the relapse rat 
first year after diagnosis were 1.8 for both prospectively and retrospecti el a d 
patients. In the second year the relapse rates were 1.3 in the prospecti el a d 
group against 1.2 in the retrospectively assessed group howe er, by the t nth ar 
the prospective relapse rate was 0.9 against a retrospecti e relapse rate of 0.5 ( 
figure 3-1). Thus retrospective assessment of relapses seem to undere timat th 
relapse frequency at later disease stages only. This may be related to th high r 
attention to detail in documentation around the time of diagno i wh re follow up 
may be more frequent: indeed relapse rate has been po iti ely corr lat d with 
frequency of follow Up1 65. In addition patients may paradoxically ha a m r 
detailed memory for their chronologically more remote early disea e cour 
Figure 3-1: Annua lised r elapse r ate in 102 multiple sclerosis cases depending on 
time from d iagnosis a nd assessment method (adapted from Patzold et al 1982168) 
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Accepting the heterogeneity in the results of natural history studies, the general 
consensus is that, in a geographically based population of multiple sclerosis patients 
the annualised relapse rate would tend towards 0.5 169. 
Relapse rate has proven to be a popular and intuitively logical primary outcome 
measure in therapeutic trials for multiple sclerosis. Indeed relapse rates are one 
aspect of the clinical natural history of multiple sclerosis that current 'disease 
modifying drugs' have an unequivocal effect on, at least for the first year108 . The 
placebo arms of treatment trials have also yielded significant data \\'ith regard to 
relapse rates (see Table 3-1). It must be remembered however that these patients 
have frequently been selected for a high pre-trial relapse rate and so are not 
representative of an ideal natural history cohort. Table 3-1 shows a higher relapse 
rate in the placebo groups than would be expected in an un selected multiple sclerosis 
population and this is likely the result of systematically selecting patients with a high 
pre trial relapse rate. 
Table 3-1: The annualised relapse rates from MS treatment trials 
Study Drug Annualised relapse rate p-value 
Active drug Placebo 
Johnson et alTm1 Glatiramer acetate 0.59 0.84 0.007 
BDMSAT-wl Azathioprine 0.73 0.83 >0.05 
Jacobs et al8 Interferon-~-la (im) 0.67 0.82 0.04 
IFNB study group 170 Interferon-~-l b 0.84 1.27 0.0001 
PRlSMS 171 Interferon-~-1 a (sc) 0.86 1.28 <0.005 
AFFIRM I7- Natalizumab 0.22 0.67 <0.001 
(iii) Relapse quality 
Does the quality or character of the relapse really matter? After all several studies 
suggest that overall relapse frequency and degree of recovery from relapse appears to 
be insignificant with regard to future prognosist>·1 n. HO\\'ever certain relapse types 
such as sensory relapse 158 and optic neuritis 174 are generally associated with a better 
prognosis whilst others provide data30 supporting a role for relapses in permanent 
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disability fonnation. Furthennore with regards to large, partially prospective natural 
h· d· 17'120 d . 8'106'170'171 Istory stu les' an treatment trIals' , , the relapse is generally considered 
to be a binary all or nothing phenomenon. To individual patients the quality of a 
relapse does matter: optic neuritis is an entirely different experience than a 
paraparesis. The grouping of pathologically similar but clinically dissimilar 
phenomenon is only partially sensible. Myocardial infarction, stroke and peripheral 
vascular disease share pathogenesis but may result in markedly different clinical 
phenomenon and their combined assessment would usually be inappropriate _ 
particularly where one was looking to examine the chronic disability produced by 
these diseases. Similarly one would not expect optic neuritis to lead to a chronic 
paraparesis or an acute cord lesion to result in chronic visual failure. Crude relapse 
counts ignore this critical nuance. 
Several studies have detailed the quality or character of relapse in multiple 
sclerosis I7;121;159;175;176. Comparison between different studies is hampered by a 
heterogeneous approach to assessment of relapse quality despite good agreement on 
the definition of a relapse I6;177. Most studies have recorded details of the first 
relapse I21 ;159;176 or clinical presentation17, which often inspires more detailed and 
precise record keeping as the clinician considers the differential diagnosis. Some 
studies have in addition recorded the quality of the subsequent relapses I21 ;159. 
The literature pertaining to relapse quality provides highly heterogeneous results that 
are likely the result of variable methodology (see figure 3-3). The only area where a 
degree of homogeneity is achieved is in sensory symptoms and optic neuritis, which 
may be less ambiguous than other categories such as ataxia and motor dysfunction 
that can be partially interdependent. Another problem with these comparisons is the 
different methods of lumping and splitting employed by various researchers. Most 
. IH-I21'159 d . I 176. researchers deal wIth symptoms -. . ; or both symptoms an sIgns seperate y , 
d . h 17 whilst others group symptoms an sIgns toget er . 
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Figure 3-3: Initial presentation of relapse onset MS patients from 6 natural 
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To produce figure 3-3 it has been necessary to re-interpret result categorie for th 
sake of comparison: for instance Muller l59 recorded cranial nerve symptom whil t 
Swingler 1 13 reported several distinct symptoms referable to the brain tern (of which 
oculomotor disturbance (8%) was by far the most common) and not brain tern ign . 
In several areas figures have not been obtainable by reasonable re-interpretation of 
categories. In no cases is there an incidence of zero therefore where a study ha n 
representative bar this is merely an indication we found their data to b 
incomparable. Attempting to obtain figures from these particular tudi fI r all 
prevalent relapses is even more challenging (see figure 3-4) a thi a p ct ha n t 
d · h f h d' 22 ' 1 13 ' 176 Of h . . been reporte In tree 0 t e stu les ' ' . t e remaInIng tw tudie 
categorie have been recorded in a manner that bear r a nabl 
en ory brain t m and phincter ymptom . 
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Confavreux 121 has divided motor symptoms at onset into tho e affecting upp rand 
lower extremities and so cannot be directly compared with other tudie which d n t 
make this distinction. Also this study does not attempt (perhap wi ely) to di tingui h 
motor and ataxic dysfunction. 
The London, Ontario natural history study of 1099 multiple sclero i patient 17 ha 
recorded data on the initial clinical presentation of their patients These data d 
however include 205 patients (18.70/0) who were progressive from on et and whil t 
they do record the distinction between acute motor onset and insidious motor on et it 
does not distinguish acute and insidious onset for sensory, brainstem ataxic or i ual 
ymptoms. The case assessment of the London Ontario cohort, although n t ntir I 
pro pecti e has been validated by means of a ri gourous geographical ub t (th 
Middl ex County) and a seen from on et ubgroup. With regard t th initi I 
pr entation the author re al ery imilar data from th e ntr u gr u 
which ugg t th ir data i practicall y pro p cti H w fi ur r 
n rally ub tanti lly I w r than th trul pro p ti wh h 
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out on a working holiday on Omaha beach there may have been a tendency for e\en 
genuine MS sufferers to over report symptoms and exaggerate signs. 
In addition to revealing information on relapse quality Figures 3-3 & 3--t also 
disclose the very substantial complexity and discordance within the literature with 
regard to relapse quality. 
The discrepancy between the clear effect of current disease modifying therapies on 
relapse but lack of effect on chronic disability progression may be related to an over-
simplistic but ubiquitous practice of recording only the quantity and not quality of 
relapses, in tum explaining our lack of understanding of the relationship between the 
neurological character of each relapse and later chronic disability. Our first step in 
attempting to explore this relationship was to define and analyse the clinical features 
of disability in our cohort of patients and this is presented in Chapter 2. OUf next step 
is to define and analyse the clinical features of each relapse in OUf cohort of patients 
and this is presented here. 
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Methods 
The database of 150 patients with multiple sclerosis described in Chapter 2 wa 
analysed. The nine patients with primary progressi e disea e had uf£ r d n 
relapses and were excluded from this analysis. Relapse details ere obtain d b 
interview with the patient and detailed examination of the case record . For ach 
relapse the date of onset was recorded. An attempt was made to characterl th 
quality of each relapse. For each relapse the following laterali ing charact ri tic 
were recorded if present: 
Deficit Eye Face Arm Leg 
Right Left Right Left Right Left Right Left 




Additionally the following non-Iateralising relapse qualities were also recorded: 
• Sphincter symptoms (bladder or bowel) 
• Oculomotor symptoms 
• Vestibular symptoms 
• Bulbar symptoms 
These categories are similar to those employed by the European Databa D r 
Multiple Sclerosis29 but we have also recorded the specific limb in 01 ement wh r 
applicable. Obviou ly an individual relapse could ha e more than one of th abo 
qualitie . 
All a m nt w r arn d by out by ith r Dr Luk B nn tt r Dr J nI 
B W b th f whom ha lilT , eral ar of p n nc in taking a hi t ry n 
p rD lming n ur 1 gi 1 amlll ti n . 
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Comparison of frequency of relapse qualities between sexes and di ea 
was assessed using Fisher' s exact test. 
Results 
ub group 
Of the 150 patients on the database 9 were excluded as they had primary progr IV 
multiple sclerosis and no relapses. 141 patients were analysed of whom 103 w re in 
the relapsing remitting stage whilst 38 were in the secondary progres i e pha . 10 
of these patients were female whilst 32 were male. See Chapter 2 for ba i 
demographic details. 
(i) Relapse rates 
Figure 3-5: Mean total relapse counts and disease duration (n=141) 
13 
12.1 
12 Mean relapse count 

















Male Female RRM PM Total 
4 
Relapse and Disability in Multiple Sclera i 







~ 0.75 ;.. 
~ 
rI'J 
c. 0.7 ~ 












Male Female RRMS SPMS Total 
(ii) Relapse quality 
Figure 3-7a: % incidence of motor, sensory and ataxic symptoms per relapse 
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Figure 3-8: An approximate comparison of relapse quality between our cohort 
and other studies 
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weakness is recorded as 2 episodes of unilateral leg weakness and it is therefore 
worth noting that figures of up to 200% are technically possible in these figures. 
Discussion 
We have obtained retrospective quantitative and qualitative relapse data from 141 
patients with McDonald criteria relapse onset multiple sclerosis. We will discuss our 
findings for relapse rate and relapse quality separately. 
(i) Relapse rate 
The annualised relapse rate of 0.67 (see figure 3-6) compares reasonably well with 
other studies. As previously mentioned published figures for annualised relapse rate 
range from 0.14166 to 1.1 168 in natural history studies and from 0.6i 72 to 1.28 171 in 
the placebo arms of treatment trials. Two factors likely explain our figures being 
slightly lower than the average placebo arm. 
Firstly all of the patients in the placebo arms of treatment trials had been selected by 
virtue of a high pre-trial relapse rate (usually 2 in preceding 2 years)8;170;l71 which 
has been shown to correlate with a high subsequent relapse rate l78 . Our patients, 
however, were recruited at the assessment stage for which there was no minimum 
relapse rate although it is likely there was a referral bias towards higher relapse rates. 
Secondly our study was retrospective as opposed to the prospective treatment trials. 
However, accepting that prospective studies will always be preferable to their 
retrospective counterparts we are reassured by the proximity of our annualised 
relapse rate to those reported in the prospectively assessed treatment trials. \\' e 
believe this provides notional validation of our data collection techniques. 
Anecdotally record keeping was generally of a high standard and patient history 
often supported by meticulously kept, if slightly dated diaries. 
The lower annualised relapse rate of secondary progressi\"\~ patients (0.52) compared 
with their relapsing-remitting counterparts (0.75) is mainly a result of a longer follow 
up period extending into the secondary phase of disease where relapses are much less 
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fi t7;179 Th 1 d' d" requen . e onger Isease urahon III secondary progressiye patients also 
increases the amount of retrospection required with an ineyitab]e, albeit hopefully 
small, loss of data integrity168 (see figure 3-1). 
The slightly higher annualised relapse rate in males (0.85 ys 0.63) is partially 
explained by their having been assessed comparatively early in the disease course 
(see figure 3-5). In contrast to our findings research on the placebo arm patients from 
treatment trials suggest that the relapse rate is higher in females 1-9. Certainly whi ]st 
men are widely reported as having a worse prognosis156;157;157J74 it is not clear that 
this is a result of more frequent relapses. It is possible that our findings may have 
their roots in the lower than expected number of men in our cohort. According to 
natural history data17;25;121;180 we should have approximately 50 men in a sample of 
150 patients. The fact that we had only 34 may haye been a result of a re]ati\'l~ 
reluctance of men to be assessed for treatment in turn meaning that there was a 
relative referral bias towards males with particularly high relapse rates. 
(ii) Relapse quality 
Our results (see figure 3-7a) indicate that relapse quality in the face and limbs 
frequently involves sensory disturbance over motor dysfunction. Limb ataxia in 
relapse seems to be a relatively infrequent phenomenon in this retrospective 
assessment. An approximate ratio of frequency of ataxic:motor:sensory relapse 
would be 1 :3:5. Similarly episodes of sensory and motor relapse become 
progressively more frequent in more distal body structures with a topographical ratio 
for face:arm:leg of about 1:5:10. 
We believe it is reasonable to assume that relapses have no inherent tendency to 
lateralise to one particular side of the body or nervous system except by chance. We 
present our lateralised data in figure 3-7a. This may act as partial validation for our 
data ascertainment by re\'l~aling very similar figures for left and right sided relapse. If 
the study were too small then clear differences in laterality may be evident by 
chance. 
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Figure 3-7b shows the frequency of visual, brainstem and sphincter symptoms per 
relapse. As has already been discussed comparison between existing studie~ is 
difficult due to variable methodology and results therefore can seem to be disparate 
(see figure 3-3). In figure 3-8 we attempt to compare our results with others. It 
should be noted that like is not strictly being compared with like as several 
approximations have been required to enable a visual comparison of the data. As 
previously described some studies were prospectivel 76 while most were largely 
retrospective. The majority of the data presented pertains only to the initial relapse or 
. h d 121-159 presentatIOn were our stu y and two others ' pertain to all relapses. Our own 
data has had to be recalculated in a lower resolution fonnat that bears comparison. 
Therefore it would be wrong to draw strong conclusions from figure 3-8. However 
despite the inherent heterogeneity of this data we believe our own figures compare 
reasonably well: all of our data is bounded both above and below by other study 
results and we have no outliers. 
(iii) The effects of gender and disease subtype on relapse quality 
Next we have sought to examine whether gender and disease sub-type have any 
effect on relapse quality. For this purpose we have not analysed uncommon 
symptoms to reduce the possibility of false positive errors. 
Figure 3-9a compares the frequency of these symptoms per relapse between males 
and females. Results are generally comparable except leg weakness which is much 
more frequent in female relapses (53.30/0 \'S 24.7%, p=0.005 using Fisher's exact 
test). This result was not expected from the literature although we could find no 
previous work that had addressed the issue of relapse quality according to gender. 
Quite why leg weakness should be more common in female relapses whilst the other 
relapse qualities are comparable is unclear. It is possible that these findings are 
related to systematic differences between the sexes in the way they interact with 
healthcare provision and report relapses - although if this were the case perhaps one 
would expect to see significant differences across all the relapse qualities examined. 
In addition from previous work we know that gender clearly does modulate the 
phenotype of multiple sclerosis. Mutliple sclerosis is approximately twice as 
common in females 17,121 and tends to have a worse prognosis and start later in 
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men
I7
;181, also primary progressive disease is relatively more common in men5. As 
th d'f~ . I' I I . l-i~"150 o er sex I lerences III mu tIp e sc erosls -, are probably attributable to sex 
honnones such as testosterone and oestrogen we assume this may underlie this 
observation also although less likely possibilities could include factors associated 
with pregnancy and parturition including epidural anaesthesia. Further research. with 
an a priori hypothesis would be required to validate this observation. 
Figure 3-9b compares relapse quality between secondary progressive and relapsing 
remitting patients. This shows that relapses involving sensory disturbance in the arms 
are more frequently recorded in relapsing remitting patients than in secondary 
progressive patients. This is of some interest as even in the secondary progressive 
patients the vast majority of the relapses recorded had occurred during the relapsing-
remitting phase of the disease. 
There are two possible explanations for this observation. Firstly it may, partially at 
least, be an artefact of the longer disease duration and cogniti\"e decline occasionally 
found in secondary progressive patients with relatively poor recall of early disease 
events. This problem is certainly not new in natural history studies of MS. The 
London, Ontario stud/ 7 found that 30% of patients who were assessed 
retrospectively reported progressive disease from onset whereas 15% of patients who 
were seen by a neurologist from disease onset reported that their disease was 
primarily progressive. The authors believe this "disparity possibly reflects a tendency 
for patients who are seen for the first time at a later point in their illness to discount 
or forget earlier remitting symptoms when progressive disease intervenes 
subsequently"I7. We accept this is possible within our own cohort but believe it 
unlikely to be a significant factor as a large majority of the patients had been seen 
from onset by the local clinical institutions and early relapses were frequently 
confinned by examination of the case records. 
Another possibility is that sensory relapses may be neutral or even in effect 
protective against the onset of secondary progression. Sensory relapses ha\e he en 
shown to be a favourable prognostic factor in many studies but so has optic neuritis 
182;183 which in our study was found more frequently in secondary progressive 
patients. The mechanisms by which sensory relapses and optic neuritis might 
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predispose to a favourable course are unclear and may partially relate to the frequent 
use of the EDSS and DSS 18;19 that places a heavy emphasis on mobility which is less 
likely to be affected by sensory or visual disturbance. 
Alternative explanations would include an MS phenotype that largely spares motor, 
but not sensory or optic, nerve fibres. Certainly there is a precedent for ~ t S 
phenotypes with anatomical bias: oriental MS 125 is typically optico-spinal in 
distribution. The possibility that the clinical quality of relapses represents more than 
just a random occurrence of symptomatic demyelination exists. We know that plaque 
distribution generally observes certain macroscopic patterns: peri-venous, peri-
ventricular, cortical u-fibres, brainstem, optic nerves and spinal cord". Might more 
subtle MS phenotypic variation also have a preference for individual fibre types and 
in tum relapse quality? 
Conclusions 
• The annualized relapse rate of 0.67 ill our cohort suggests good relapse 
ascertainment. 
• In our cohort sensory symptoms are more frequent than motor symptoms. 
• Comparison with previous studies is difficult but suggests our relapse quality 
data is both reasonable and broadly comparable. 
• Leg weakness is a more frequent relapse quality in females. 
Whilst these are interesting observations the main purpose for presenting this data is 
to allow the reader to make their own assessment of the validity of our retrospectiYe 
relapse data. The quality of this data is critical for our attempt to correlate relapse 
quality with the findings of a subsequent prospective neurological examination. 
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Chapter 4: The relationship between relapse and disabilit)· in 
multiple sclerosis 
Hypothesis: That in patients with multiple sclerosis, chronic disability correlates 
poorly with individual acute relapses. 
Introduction 
The precise relationship between acute clinical relapse and subsequent 
disability in multiple sclerosis is unknown. It is widely believed that relapses 
confer a poor prognosis and shape future disability'. Recent evidence suggests 
this may not be the case. Patients who have primary progressive disease and 
therefore little or no relapse activity accumulate disabilit~, more rapidly than 
patients with relapsing onset disease10;129. Relapses during the secondary 
progressive phase do not appear to be detrimental10 to prognosis. The acute 
central nervous system inflammation associated with clinical relapse in multiple 
sclerosis is known to have both harmful and beneficial sequelae26:28• If clinical 
relapse is not the determining pathological process in multiple sclerosis then one 
might expect to see qualitative discordance between relapse and subsequent 
disability in the same individual over time. 
The later stages of multiple sclerosis are frequently characterised by marked 
disability. After 30 years disease duration most patients have been found to be 
wheelchair dependent lO. The majority of the morbidity associated with multiple 
sclerosis is likely to come from these latter stages of fixed disability as compared to 
the earlier stages of relapse and remission. The relationship between relapse and long 
tenn disability is unclear. 
Magnetic resonance imaging studies have confinned the association between acute 
relapses and the fonnation of sclerotic plaques50;60;135. Sclerotic plaques are 
characterised by demyelination, axonal loss and gliosis. Reparative mechanisms 
including remyelination, ion channel redistribution and plasticity, whilst fom1ing the 
basis of remission. are rarely complete. Neurological transmission through a sclerotic 
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plaque is therefore impaired. Intuitively sclerotic plaques should lead to the chronic 
neurological impairment that forms the basis of disability. 
It has long been noted, however, that the function of pathways that are involved in 
the sclerotic plaque survIves surprisingly well considering the evident 
histopathological devastation that has occurred. Charcot in 1877 noted7 : "Amblyopia 
is a persistent and frequent symptom of cerebro-spinal disseminated sclerosis but it 
rarely issues in complete blindness. This is worthy of notice since patches of 
sclerosis have been found after death occupying the whole thickness of the nerve 
trunk, in the optic nerve, in cases where during life an enfeeblement of sight simply 
had been noted. This discrepancy between symptom and lesion constitutes one of the 
most powerful arguments to show that the functional continuity of the nerve tubes is 
not absolutely interrupted although these, in their course through the sclerosed 
patches, have been despoiled of their medullary sheaths and reduced to axis 
cylinders." In comparison with other central nervous system lesions, such as 
infarction or trauma, individual episodes of multiple sclerosis type demyelination 
have an excellent prognosis. 
Muller reported on 810 Swedish patients with multiple sclerosis in 1949159. He 
categorised clinical episodes or 'bouts' into either remittent bouts (relapses) or 
progressIve bouts (disease progression). Muller noted (see Table 4-1) that the 
progressive bouts frequently involved motor disturbances (910/0) but rarely involved 
cranial nerves (9%) or sensory disturbance (20%). This is despite the fact that 
remittent bouts involving cranial nerves (440/0), motor disturbance (420/0) or sensory 
disturbance (33%) occurred with similar frequency. Also although 21 % of 
monosymptomatic remittent bouts feature an isolated disturbance of sensation they 
did not record a single progressive bout featuring sensory disturbance alone. This 
compares with isolated motor disturbance occurring in 26% of monosymptomatic 
remittent bouts but 86% of monosymptomatic progressive bouts. The conclusion that 
remitting bouts and progressive bouts appear to be unrelated phenomena was not 
made. According to this data it is hard to belie\·e that the relapses are acting as a 
template for secondary progression. Perhaps in the prevailing scientific climate such 
results might have been seen only as an indication of methodological flaws rather 
94 
Relapse and Disability in Multiple Sclerosis 
than a true dissociation between relapse and progression, a notion that has gained 
virtually unanimous support lO• 
Table 4-1: Frequency of certain symptom groups in progressive, remittent and 
first bouts in 810 Swedish patients159 
Symptom groups 
Cranial Motor Sensory(%) Sphincter(%) Other(%) Paretic( 00) Intention tremor 
nerves (%) (%) dysmetria (0 0 ) 
Progressive Bouts 
Total Bouts 707 9 91 20 33 15 74 24 
Mono 343 3 86 0 6 5 - -
symptomatic 
Poly- 364 15 96 40 55 23 -
symptomatic 
Reminent bouts 
Total Bouts 2957 44 42 33 8 2 29 
-' 
Mono 2196 46 26 21 5 2 - -
symptomatic 
Poly- 761 40 87 68 18 5 
- -
symptomatic 
The first bout 
Total bouts 793 49 47 28 5 2 33 3 
Mono- 590 51 31 16 1 1 - -
symptomatic 
Poly- 203 42 91 62 15 5 - -
symptomatic 
Notwithstanding what we would describe as these clear signposts, the widespread 
belief that "Secondary progressive multiple sclerosis tends to affect whichever 
system has borne the brunt of the disease earlier in the course,,7 remains as popular as 
it is intuitive. We hypothesise that individual episodes of relapse in multiple sclerosis 
are not the cause of chronic impairment and disability. We aim to explore this by 
companng the relapse history of a group of patients with multiple sclerosis and 
companng this with a contemporary clinical examination. Certainly (as Muller 
found) cranial nerve and sensory deficits rarely progress despite the fact that thcsc 
systems frequently bore the brunt of the earlier disease course. \ 1cAlpine and 
Compston 167 similarly found that isolated sensory symptoms were common during 
the relapsing-remitting disease phase (41 out of 146 patients) but were rare as an 
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A recent study30 sought to examme the effects of a relapse on disability. Data 
analysed from 224 patients randomized to placebo in previous therapeutic trials 
revealed that 420/0 of their patients had a worsening of at least 0.5 EOSS points at an 
average of 64 days post relapse. The average EOSS change amongst the whole group 
was an increase of 0.27 EOSS points. Although not commented upon their data also 
reveal that 58% of patients have a stable or improved EOSS following a relapse. The 
authors conclude3o that this demonstrates relapses produce a measurable and 
sustained effect on disability. This appears consistent with models suggesting that 
disability during the relapsing remitting phase is accrued by virtue of incomplete 
remission. This study has limitations however. A longer follow up with blinding of 
examiners to the clinical history and a control group of multiple sclerosis patients 
who had not suffered recent relapse would allow determination of whether relapses 
truly contribute to fixed disability at a population level, whether they merely 
camouflage an early progressive phase23 or prompt more detailed clinical 
examination of areas highlighted in the history. A history of optic neuritis obviously 
helps to reassure the examiner that slight disc pallor is a clinical sign rather a normal 
variant. The reliance placed on the EOSS for this study and not individual clinical 
signs, in contrast to our own study, means that it is difficult to be sure that the 
increase in post relapse EOSS is reflective of new deficits at the site of relapse. 
The optimum method to assess the clinical legacy of an acute plaque in multiple 
sclerosis would undoubtedly be a prospective study design involving regular clinical 
assessment and imaging starting many years prior to symptomatic disease onset. The 
temporal association of plaque formation with clinical relapse quality would allow 
assessment of not only the radiological appearances of the plaque but also its 
resultant clinical effects to be charted over time. This approach would prevent the 
disappearing plaque98 being disregarded. A plaque may presumably disappear by 
repair or atrophy. Single time point studies of MRI plaques and disability will 
obviously fail to register the disappearing plaque or the atrophied k~ion load and will 
necessarily underestimate the chronic effects of the acute plaque. 
The optimum study \Vas not possible within the available time frame. A ~tudy with a 
degree of retrospective assessment is necessary to assess a practically time unlimited 
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disease within a limited time frame. A purely clinical approach allows clinically 
eloquent acute plaques to be recorded in the form of a history of acute relapses. The 
clinical nature of the relapse indicates the affected pathways. One assumes that 
plaques can only appear or disappear but not move within the central nervous system 
over time. Therefore if acute plaques are to be held responsible for chronic disability 
then the chronic disability will match closely the quality of the combined acute 
relapses. 
The advantages of a historical clinical approach over a radiological approach to 
identifying the legacy of acute plaques are two-fold. Firstly the study is not 
confounded by disappearing plaques98 . Secondly problems of relating plaque 
structure to disability are avoided. This problem is partly technical. Clinically 
eloquent areas with multiple small pathways beyond the accurate resolution of the 
MRI scanner such as the spinal cordloo highlight this point. In the clinical study the 
chronic impairment should simply mimic the acute impairment. 
The acknowledged disadvantages of the clinical approach over the radiological 
approach are principally that there are many more plaques than relapses in patients 
with multiple sclerosis 72. However by assessing relapses one will identify the 
clinically eloquent plaques that are likely to represent more destructive acute 
pathology than the corresponding silent plaque. The caveat to the above is that 
historical data even when obtained from multiple overlapping sources including the 
patient history and hospital records is inherently imperfect. Despite extensive efforts 
it is clear that not every relapse will be recorded accurately. 
Methods 
The database described in chapter 2 was analysed. Briefly, patients with McDonald 
criteria 15 multiple sclerosis who were being assessed for their suitability for 
prescription of the disease modifying drugs beta-interferon and glatiramer acetate 
were examined and a clinical history and consent for the study was obtained. This 
infomlation was recorded in a password protected computer database. 150 patients 
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were recruited to the study. For the purposes of this analysis the 9 pnmary 
progressive patients were excluded leaving 141 patients. 
Statistical analysis 
Our primary aim was to analyse whether a history of relapse in a particular limb or 
eye was associated with the presence of an appropriate clinical deficit at assessment. 
For several reasons a linear approach was considered sub-optimal. The limb specific 
data was recorded as part of the functional systems score component of the EDSS 
and included other ordinal and non-linear scales such as the Medical Research 
Council scale for measuring limb strength. For this reason a binary logistic 
regression analysis was used with each target limb or eye either considered to be 
appropriately impaired or not. The definitions used to dichotomise the data for each 
of the four examined systems are outlined below. The number of relapses per 
limb/eye was not normally distributed with a high proportion of zeros (see table 4-2) 
and for this reason the relapse data were transformed into three categories: none, one 
and many (see table 4-2). Factors such as the patients age, disease duration, sex and 
whether the patient were in the secondary progressive phase of the disease as well as 
limb related factors - arm or leg - were considered to be potential confounders and 
so were entered into the regression. Statistical analysis was performed using SPSS 
version 12 (SPSS inc., Chicago, IL) statistical package. 
Binary impairment transformation 
Limb weakness was defined by any score of 4+ or less as judged by the Medical 
Research Council grading system within anyone or more of five separate 
movements in each limb. In the arm these included shoulder abduction, elbow 
flexion, elbow extension, wrist extension and wrist flexion. In the leg these included 
hip flexion, knee flexion, knee extension, ankle dorsi-flexion and ankle plantar 
flexion. 
The presence of cerebellar ataxia in a limb was defined by the presence of tremor or 
clumsy moyements seen easily with at least a minor interference with function and 
not felt to be attributable to a sensory ataxia. 
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The presence of sensory disturbance in a limb was defined by the patient being 
aware of impaired or absent light touch or pain on sensory testing. (Defined as mild 
abnormality or worse on Sensory Functional Systems Score component of EDSS). 
The superficial sensation component was chosen to defme sensory disturbance over 
vibratory or proprioceptive loss as we felt this was more likely to correspond with 
the patient's description of sensory disturbance during a relapse. In addition previous 
analysis suggested abnormality of superficial sensation (see table 2-4, chapter 2) was 
present in nearly 400/0 and would be a relatively good discriminator in comparison to 
vibratory (very common abnormality) or proprioceptive (rare abnormality) 
impairment. 
The presence of poor vision in an eye was defined by the presence of a corrected 
visual acuity of worse than 6/6 as defined by Snellen chart testing. 
99 
Relapse and Disability in Multiple Sclerosis 
Results 
A total of 150 patients with multiple sclerosis were recruited to the study, 9 of these 
were excluded from this analysis as they had primary progressive disease without 
relapse. The demographic and basic clinical details of this cohort are presented in 
Chapter 2 whilst further relapse data are presented in Chapter 3. 
Table 4-2: The frequency of relapse types in cohort (n=141 patients) 
Relapses per limb (n=564) Mean relapses per limb/eye 
Relapse type /eye (n=282) 
None One Many Range All Many relapse 2fOUP only 
Weakness 335 123 106 0-14 0.84 3.30 
Cerebellar Ataxia 438 88 38 0-8 0.34 2.79 
Sensory 168 181 215 0-11 1.56 3.10 
Optic neuritis 174 80 28 0-8 0.57 2.92 
Table 4-2 shows how many relapses of each type were suffered by each limb and eye 
in the cohort of 141 relapse onset MS patients. It largely echoes data presented in 
Chapter 3 which suggest that sensory relapses are more common than weakness 
relapses which are in turn more common than ataxic relapses. 
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Table 4-3: Multivariate analysis of potential risk factors for development of 
clinical impairment in multiple sclerosis (n=141) 
Clinical factor Clinical Impairment 
Weakness Cerebellar Sensory Poor 1 IOn 
Ataxia disturbance 
p- OR p- OR p- OR p- OR 
value value value value 
Relevant One 0.894 0.08 0.003 2.073 0.012 2.27 
relapse M any <0.001 4 .046 <0.001 6.15 0.001 2. 188 0.022 2.992 
Male sex 0.207 0.596 0.01 1.75 0.089 
Age 0.046 1.028 0.013 1.038 0.974 0. 858 
(years) 
Duration 0.479 0.163 0.052 0.02 1 1.06 
(years) 
SPMS <0.001 2.839 0.001 2.18 <0.001 3.253 0.01 2.29 
Leg <0.001 3.485 0.001 2.24 0.54 
. . Bmary lOgIstIC regressIOn used to compare limbs or eyes with a particular impairment 
(weakness, ataxia, sensory or visual) with unimpaired equivalents. Comparator group 
include female sex, RRMS and arm. 
P<O.05 primary outcome measure 
P<O.05 secondary outcome measure 
Figure 4-3 reveals the relationship between relapse and subsequent relevant 
impairment of an individual limb or eye. Other factors such as the age, disea e 
duration, sex, secondary progressive status and whether the limb is an arm or leg are 
entered into the analysis to try to account for these potential confounders. 
Interestingly a single relapse involving limb weakness or ataxia does not appear to 
predispose to relevant chronic impairment although multiple weakness or ataxia 
relapses in the same limb are associated with relevant chronic impairment. Thi 
resu lt suggests that it is more than one clinically eloquent plaque on an ind i idual 
motor pathway that causes, or is related to, chronic weakn e . An i olated clin ical l 
eloquent plaque does not appear to adversely affect the motor pathwa I ng-t rm 
functional integrity. However sen ory relaps and optic neuriti ar a 
rele ant chronic impairment after onl y the fir t relap alth ugh th a 
lightly tronger for multipl re lap e . 
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Of the secondary outcome measures the presence of secondary progressive disease 
shows a consistent and strong association with specific impairment across all -+ 
domains. 
Discussion 
Interestingly we begin to see a plausible explanation for the dissociation of relapse 
from disability as presented in the large natural history studies. In general our results 
confirm the received wisdom that relapses are associated with relevant chronic 
impairment although with significant caveats: the motor pathways (pyramidal and 
cerebellar) appear to be resistant to a single relevant relapse. However this is quite 
different from suggesting that relapses cause disability as measured by the EDSS. 
The large natural history studies do confirm a relationship between relapse rates and 
assignment of an EDSS of 4 although the relationship is lost at greater EDSS 
scores
lO
. Poignantly the EDSS is an impairment scale up to an EDSS of 4 but past 
this point it becomes a mobility scale. So these studies confirm our own findings that 
relapses are associated with impairment but they also suggest that relapse does not 
affect mobility: how can this be? 
Firstly certain relapse types even when effecting chronic impairment are unlikely to 
translate into a loss of mobility. Sensory and visual systems would fall into this 
category. It would require a severe impairment of vision in both eyes to affect 
mobility but even the blind patient with appropriate guidance (not support) is not 
distance limited. Similarly even a marked sensory impairment is unlikely to impact 
significantly on the ability to walk unless perhaps combined with severe impairment 
in other systems - such as is usually only found in the secondary progressive stage of 
the disease. Thus sensory relapses and optic neuritis are likely to have significant 
traction on the EDSS scale at its lower levels where it is an impairment scale but 
little or no traction on the mobility portions of the EDSS scale. This is highlighted by 
the work of Lublin30 who found that relapses did leave a sustained and measurable 
increase in EDSS but that there was a significant negative correlation between pre-
relapse EDSS and post relapse residual EDSS. in addition the Scripps Ncurological 
Rating ll :' scale detected post relapse residual in a greater proportion of patients than 
did the EDSS further emphasising the greater traction of relapses on impaim1cnt 
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over mobility. Indeed Lublin30 appears to have recognised that it may be the EDSS 
scale rather than multiple sclerosis that is insensitive to relapses at its later stages but 
he did not appear to relate this to the changeover from an impairment to mobility 
scale apparent in the EDSS. 
Secondly certain relapse types, particularly optic neuritis and sensory relapses. have 
previously been associated with a relatively good prognosis in multiple sclerosisl:'s. 
Accepting that reliable prospective indicators of 'benign multiple sclerosis' continue 
to prove elusive, this may suggest that there are further appropriate sub-diyisions of 
multiple sclerosis 184 to place alongside the widely accepted optic_spinaI 185;186 oriental 
variant of multiple sclerosis. Such subtypes may include sensory pre-dominant 
disease that may in any case be associated with a better prognosis. If this is the 
situation and one does not take into account the relapse quality but merely relapse 
counts then the situation is precarious: one patient may have many sensory relapses 
and low disability by virtue of their as yet undefined benign subtype and be 
compared with another patient who has had only two relapses, both of which 
involved leg weakness and who has a higher EDSS. Such an analysis whilst crude 
and illustrative might incorrectly conclude that relapses were inversely associated 
with disability in a dose related manner. 
Thirdly, weakness and ataxia, the relapse types which would be expected to have real 
traction on the mobility portions of the EDSS, appear to have increased resistance to 
the long term sequelae of relapse: an individual weakness or ataxia relapse in a limb 
is not associated with relevant chronic impairment. Whether this represents an 
evolutionary investment in a surfeit of luxury function in these particular pathways 
or an inherent resistance to inflammatory demyelination. perhaps by virtue of 
predominant axonal size187is unclear. However, whilst single weakness or ataxic 
relapses in our study did not appear to be associated with relevant impairment. 
multiple weakness or ataxic relapses were and the inability of these relapses to affect 
mobility and in tum EDSS disability in the large natural history studies is initially 
perplexing until one considers that these studies are describing a popUlation and not 
individual effect. Such multiple weakness or ataxic relapses in the same limb were an 
unusual phenomenon in our study: 18.8% of limbs had had multiple weakness 
relapses whilst only 6.7% of all limbs had had multiple ataxic relapses (see table 4-
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2). A non or single relapsed limb is much more likely. In addition whilst most of 
these mUltiple relapses will be affecting the legs a significant minority will be 
affecting the arms (see chapter 3, figure 3-7a) which will have little affect on 
mobility and by the time arm function regains significant traction on the EDSS scale 
(EDSS score of 8 and above) it is highly likely that the secondary progressiye phase 
will have supervened in any case. Thus it seems that multiple weakness or ataxic 
relapses coalescing in the same leg, whilst likely to be disabling to the individual, is 
sufficiently uncommon at the population level so as to allow any such disabling 
effect to be obscured in a morass of sensory, visual, mono-relapse weakness or 
ataxia, leg sparing relapse and EDSS idiosyncrasy before being completely lost in a 
tidal wave of secondary progression. 
But what of the possibility that "Secondary progressive multiple sclerosis tends to 
affect whichever system has borne the brunt of the disease earlier in the course,,7. 
There are in fact several reasons to suggest that the secondary progressive stage is 
independent of precedent relapse and our study supports and expands on such 
observations. Firstly in primary progressive disease there are often no relapses and 
therefore no dependence upon precedent relapses and the clinical character of 
disability and impairment is very similar to that of secondary progressive disease 
(see chapter 2). Secondly previously published work suggests independence of 
relapse and progression. In neuromyelitis optica where the relapses are generally 
more severe than in multiple sclerosis, secondary progressive transformation occurs 
much less frequently than in multiple sclerosis188• In 1949 Muller found that despite 
the heterogeneous nature of the relapsing disease phase the progressive disease phase 
was almost invariably characterised by motor disturbance159. However, it seems the 
prevailing scientific climate in 1949 was not conducive to Muller over emphasising 
his findings. Much more recently the London, Ontario group reported that the site of 
relapse and subsequent progression are largely unrelated173 . This group examincd 
single-attack progressive patients and found that whilst the site of relapse was 
heterogeneous, the site of progression was relatiyely stereotyped and appeared to 
have a predilection for the distal corticospinal tract. Howcyer whilst largely 
prospective methodology was employed, the attempt at localisation in this study was 
arguably less precise than our own and recorded only the neurological systems 
involved at onset and progression rather than localising them to a particular limb or 
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eye. Our study found that the presence of the secondary progressive phase was 
significantly associated with impairment across all 4 functional systems examined 
(see table 4-3) and that this association was independent of relevant relapse activity. 
Thus both relapses and progression are independently associated with chronic 
impairment but the relative resistance of motor pathways to relapse and their relative 
susceptibility to progression159;173forms a basis for explaining the disparate effects of 
relapse on disability reported by natural history studies6;10;22 and shorter tenn studies 
biased towards the earlier disease course reporting a recordable effect of relapse on 
EDSS3o. 
Thus we have shown that relapse is independently associated with relevant chronic 
impairment although motor pathways may be relatively preserved. We have also 
shown that the secondary progressive phase is independently associated with 
impairment in motor, cerebellar, sensory and visual pathways. We have also offered 
explanation as to why this is in fact entirely concordant with the large natural history 
studies of multiple sclerosis. But how might these fmdings be relevant to clinical 
practice? 
Firstly it may suggest that targeting of the presently available disease modifying 
drugs towards those patients who are at risk of relapse related disability is feasible. 
The Association of British Neurologists has recently updated their guidelines for 
prescription of Beta-interferon and glatiramer acetate. The new guidelines (March 
2007) now allow prescription of these drugs in CIS (clinically isolated syndromes) 
where McDonald MRI criteria for diagnosis ofMS is metIS as well as expanding the 
starting criteria and loosening the stopping criteria in established disease. These new 
guidelines broadly align UK practice with current European and United States 
practice which gives high regard to MRI monitoring of disease activity, despite the 
weak association between MRI activity and disability, and has confidence in the 
ability of these drugs to prevent long term disability despite a paucity of presently 
available evidenceI89. In an environment of imperative rationalisation our data begin 
to suggest a rationale basis for use of the disease modifying drugs that may be less 
ambiguous than existing guidelines that include terms such as 'clinically significant' 
and 'disabling' relapse. If the desired outcome is to prevent disability as measured by 
the EDSS it would seem sensible, based on our data, to aggressively target any 
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weakness or ataxic relapse, particularly involving the legs after only a single attack. 
The rationale being that it is not the frrst such relapse that is associated with chronic 
impairment but the second or subsequent relapses. Although our data does not 
include any CIS patients meeting McDonald criteria it would seem reasonable to 
consider treating these patients providing the CIS involved weakness or ataxia. 
Based on our data in isolation treating sensory relapses or optic neuritis would be 
less likely to have a long-term benefit on disability although our data suggest that 
their prevention may reduce relevant impairment - and indeed this has been reported 
in a trial of Natalizumab1 90with regards to visual acuity. 
Secondly our data highlight the critical importance of choice of outcome measure21 • 
This is already suggested by studies comparing various outcome measures that show 
poor longitudinal correlations in responsiveness over time191 ;192. Our study indicates 
that the multiple sclerosis relapse/progression paradox may at least partly be an 
artefact of imperfections in the EDSS. It is unlikely that any disability scale will ever 
be perfect but we need to recognise such imperfections when evaluating both natural 
history and therapeutic data to ensure we are recognising disease, and not scale, 
related phenomena. The mobility segment of the EDSS scale appears largely 
insensitive to the effect of relapse and we have highlighted possible reasons for this. 
Newer and probably more robust and sensitive disability scales may be found to be 
more sensitive to relapse related impairment and in turn give relatively favourable 
outcome data for the disease (relapse) modifying drugs - but this doesn't mean that 
the EDSS data are wrong or that newer outcomes are necessarily any more 
worthwhile. Partly it is a question of our own intuitive definition of disability and the 
EDSS, despite its inherent peculiarities, possibly reflects this quite well. 
Thirdly we have shown the importance of considering relapse quality in both natural 
history and therapeutic research in multiple sclerosis. In a condition such as multiple 
sclerosis where the underlying cause and effect are debated it seems appropriate to 
give precise consideration to the quality and location of the individual components of 
this argument. If the inflammatory component of this disease were the cause of the 
degenerative component of this disease then one would expect to see both sharing a 
very similar character separated in only in time but not space. Maintaining the chain 
of possible cause and effect in natural history studies requires localisation of both 
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relapse and progression. We believe that a prospective attempt to do this involving 
similar or greater detail in localisation than we have demonstrated would help further 
answer these questions and such techniques may become useful in therapeutic trials -
even possibly allowing shorter trials with fewer patients but using focused 'cause and 
effect' clinical outcomes without the heavy reliance on arguably questionable MRI 
surrogates. 
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Chapter 5: Plasma exchange in episodes of severe inflammatory 
demyelination of the central nervous system 
Introduction 
Severe acute inflammatory demyelination of the central nervous system (C1\'S) can 
occur in multiple sclerosis (MS), including the Marburg variant l93 . acute 
disseminated encephalomyelitis (ADEM), acute transverse myelitis and 
neuromyelitis optica. All of these conditions commonly respond to intravenous 
corticosteroids. With the exception of MS, they are infrequent disorders, and in MS 
individual episodes of inflammatory demyelination are often not severe and. 
moreover, are usually steroid responsive and followed by good clinical recovery in 
the short term l94. Therefore severe acute inflammatory demyelination of the CNS 
that does not respond well to intravenous corticosteroids is rare and large treatment 
trials have not been done. Consequently there is still doubt as to the best management 
of this condition. 
Early studies of plasma exchange for inflammatory demyelination concentrated on 
its possible role as a treatment for chronic progressive MS. Some studies suggested a 
benefitI95-198, but they were often confounded by concurrent immunosuppressant 
usage. Others did not demonstrate a benefitl99-202 including two randomised, blinded, 
sham controlled studies I99;200. However reports on the value of plasma exchange for 
I h 0 'd h 203-205 h b severe, acute MS re apses t at are resIstant to sterOl t erapy ave een more 
promising. Similarly case reports of successful use of plasma exchange in oth~r 
episodes of severe, inflammatory demyelinating CNS disease. including acute 
o • d h I 10 0 (ADEM)206-208 d DO, d 209 t th t dlssemmate encep a omye ItlS an eVlc s syn rome sugges a 
plasma exchange could be useful across the full spectrum of sever~ acute 
inflammatory demyelinating CNS disease. 
A sham controlled double blind randomised crossover trial of plasma exchang~ in 22 
adult patients with acute central nervous system int1ammatory demyelinating dis~asc 
who had not responded to corticosteroid therapy210 found moderate or great~r 
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neurological improvement occurred in 42.1 % of patients receiving plasma exchange 
(7 exchanges over 14 days) compared with 5.9% in the sham exchange group 
(p=O.OII). A subsequent reporrll of the effects of plasma exchange in 59 cases, 
including the 22 patients involved in the aforementioned trial2IO, has continued to 
support its use in acute severe inflammatory CNS demyelination. Both of these 
studies2l0;211 that support the use of plasma exchange specifically in acute severe 
demyelination of the CNS issue from the same centre (the Mayo clinic). 
In this chapter we describe six consecutive patients with acute severe inflammatory 
CNS demyelination who failed intravenous corticosteroid therapy and were treated 
with plasma exchange. 
Methods 
From 2001 to 2003, a total of 6 adult patients with severe acute steroid-insensitive 
inflammatory demyelinating CNS disease have undergone plasma exchange at the 
National Blood Service Apheresis Unit in Bristol. This chapter summarises the 
results and progress of all six patients. These are the only patients we have treated 
with plasma exchange for severe acute steroid-insensitive inflammatory 
demyelinating CNS disease at this centre. 
For inclusion into this retrospective analysis patients were at least 16 years old at the 
time of plasma exchange, had a clinically and radiologically secure diagnosis of 
severe acute inflammatory CNS demyelination and other therapeutic options - which 
always included intravenous methylprednisolone (Ig daily for at least 3 days) - had 
proven unsatisfactory. Plasma exchange was performed using Gambro-BCT ® 
Spectra TM apheresis machines. A single plasma volume exchange was performed 
on each occasion. Each individual patient's plasma volume was calculated by the 
program software based upon patient height, weight, gender and haematocrit. Human 
albumin solution and saline were used as replacement fluids and citrate as 
anticoagulant. 
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To assess the significance of plasma exchange on estimated Expanded Disability 
Status Score (EDSS) and relapse rate in the surrounding year we applied the sign 
test, as the datasets were small and non-parametric. 
Case Reports 
Patient! 
A 35 year old male presented with a rapidly progressive spastic paraparesis with a 
sensory level at T4. Blood examination was unremarkable. Cerebrospinal fluid 
examination revealed normal opening pressure, protein, glucose, negative oligoclonal 
bands, 5 lymphocytes and 70 red cells per mm3• Brain MRI was normal but MRI of 
the spinal cord revealed swelling, with T2 hyperintensity and some gadolinium 
enhancement from C617 to T2. Biopsy of the MRI denoted cord lesion revealed 
acutely reactive and oedematous spinal cord white matter. There was comparable 
loss ofaxons and myelin, prominent microglial activation but no macrophages and 
very few lymphocytes. There was no evidence of infection, granulomatous reaction, 
tumour or vasculitis. A diagnosis of acute transverse myelitis was made. 
Clinically he rapidly lost all power in his legs despite two courses of intravenous 
methyl-prednisolone. He was stable for 3 months before slowly recovering some 
movement and sensation in his legs but remaining wheelchair dependent. After a 
further 2 months his myelitis extended proximally and he developed weakness and 
numbness in his arms that again proved refractory to intravenous steroids. He 
received a course of 5 plasma exchanges. Following the first plasma exchange he 
reported an improvement in his arms and following the second plasma exchange the 
improvement was noted objectively. He also noted an increased rate of improvement 
in his legs. Five months later he had near-normal function in his arms and walks with 
a pair of crutches. 
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Patient 2 
A 35 year old Chinese male presented with a I day history of bilateral blurred vision 
and weak legs. Neurological examination revealed an asymmetrical· spastic 
paraparesis with a sensory level at T8. Routine blood tests and chest X ray were 
normal. Brain MRI revealed multiple T2 hyperintense lesions involving both cerebral 
hemispheres, the internal capsule, corpus callosum, basal ganglia, brainstem and 
cerebral hemispheres. Spinal MRI revealed three T2 hyperintense lesions in the cord 
at C7, T 1-7 and TIl respectively. Cerebrospinal fluid was normal apart from a raised 
protein ofO.74g/dl. No intrathecal synthesis of immunoglobulin was detected. 
The patient was initially treated with intravenous methylprednisolone 1 gram daily 
for 3 days. His leg weakness was unaffected by the methylprednisolone. His vision 
improved during the course of methylprednisolone but deteriorated 2 days after the 
last dose and within a week his visual acuity was only sufficient for finger counting 
in either eye. His deteriorating vision at this stage was accompanied by new 
neurological deficits including diplopia, right arm weakness, urinary retention and 
worsening paraparesis such that he was only able to mobilise slowly with the aid of a 
walking frame. A further 3 day course of intravenous methylprednisolone was 
temporally associated with an objective improvement in limb power and visual 
acuity. 2 days after finishing this course of methylprednisolone the patient's limb 
strength deteriorated and was followed by deteriorating vision such that within 6 
days of finishing steroids he was finger counting only in either eye and walking 
slowly with a wheeled frame. 
The patient had a course of 5 plasma exchanges over the following 10 days. An 
improvement in limb strength was objectively noted within a day of the first plasma 
exchange and improved visual acuity was demonstrated the following day. On the 
day of the final exchange he had a steady gait without any support and his visual 
acuities improved to 6/6 and 6/12 in the right and left eyes respectively. His visual 
acuities relative to his treatment can be seen in Chart 1. He was discharged home at 
this point. At follow up 6 months later he was found to be well and normally mobile 
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whilst his vision was reported as satisfactory. Neurological examination at this stage 
was nonnal apart from pale optic discs. 
Patient 3 
A 41 year old female with a 3 year history of aggressive progressive multiple 
sclerosis with continuing superimposed relapses presented with rapidly accumulating 
disability. Her diagnosis had been made on the basis of the clinical presentation, a 
typical MRI brain scan, positive oligoclonal bands, delayed visual evoked potentials 
and absence of confounding results. 
In the 3 years preceding the use of plasma exchange she experienced progressi\'l~ 
accumulation of disability and had required 5 courses of intravenous 
methylprednisolone (lg/day for 3 days) for 5 separate relapses, each with sub-
optimal response. Because of her progressing disability, frequent relapses and 
perceived lack of response to intravenous steroids a course of intravenous 
mitoxantrone (12mg/m2 every 4 months) was started fourteen months prior to the 
first plasma exchange. The evidence for this dosing regime is from a stud/12 that 
used 12mg/m2 every 3 months but to allow the patient to recover from inter-dose 
relapses we were only able to achieve this dose every 4 months. Mitoxantrone was 
stopped after the 3rd dose and considered a treatment failure for the following 
reasons: (1) no clinical improvement had been noted at any stage during the course, 
(2) the patient had suffered a clinically significant relapse within 6 weeks of each of 
the three doses of mitoxantrone, (3) the patient was poorly tolerant of the mouth 
ulceration that followed each course, (4) the patient's disability continued to progress 
during the course of mitoxantrone such that following the third dose she had poor 
vision, a painful asymmetrical spastic tetraparesis, marked ataxia and vertigo. Her 
gait deteriorated markedly over the next 3 months such that she was unable to walk 
without a wheeled frame. In view of her previous treatment failures and her rapid 
disability progression she received a course of 5 plasma exchanges over 8 days. 
Immediately following her final plasma exchange limited but definite objective 
improvement in her gait was observed; her vertigo and pain howe\cr remained 
unimproved. In the 19 months of follow up she has had only one definite relapse (left 
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sided deafness), and her gait has remained stable although her vertigo and pain have 
deteriorated. 
Patient 4 
A 26 year old lady with a history of 'neurotic depression' presented with an acute 
onset of tetraparesis, more marked in the legs than arms and diplopia. Neurological 
examination revealed impaired upgaze in her left eye and partial tetraparesis and 
sensory loss in face and body but with normal tone, reflexes and flexor plantar 
responses. A CT scan of her head at this stage was normal. Routine bloods including 
inflammatory markers were normal. The patient showed spontaneous improvement 
and was discharged with no definite diagnosis. Six weeks later she was readmitted 
with worsening right sided limb weakness, diplopia, nausea and vomiting. 
Neurological examination at this stage revealed very hesitant speech, an inability to 
look to the right and a right hemiparesis with associated brisk tendon reflexes more 
marked in the arm than leg. Plantar reflexes remained flexor. Routine blood tests 
were again normal. Brain MRl revealed multiple T2 hyperintense lesions mostly in 
the white matter of the upper hemispheres, many of which were in the corona radiata 
and close to the ventricles. Lesions were also present in the medial temporal lobes 
and in the left cerebellar hemisphere. CSF examination revealed oligoclonal bands 
and negative herpes PCR. The patient was treated with intra venous 
methylprednisolone 1 g/day for 5 days followed by a 7 week tapering course of oral 
prednisolone. The patient actually deteriorated during the course of intravenous 
steroids: she developed visual disturbance on the first day of the course and was 
noted to have visual acuities of 6/9 in both eyes. On the final day of intravenous 
steroid administration her acuities had deteriorated to 6/36 in the right eye and she 
had lost light perception in the left eye. Slow improvement in vision and right 
hemiparesis coincided with the commencement of the oral prednisolone tapering 
course such that after 2 weeks of oral steroids the patient was reliant on a walking 
frame for mobility and visual acuities were 6/12 and 6124 in the right and left eye 
respectively. 
OYer the next 13 months she was admitted to hospital on 6 separate occasions for a 
total of 126 days. Three of these were 'emergency' admissions for disabling relapse 
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whilst the remaining 3 admissions were on an elective basis for administration of 
intravenous immunoglobulin for recent relapse. In total during this period she had 2 
courses of intravenous methylprednisolone (1 g per day for 3 days) with tapering oral 
prednisolone to a lowest dose of 7.5mg per day, 4 courses of intravenous 
immunoglobulin (O.4mglkg/day for 5 days) and was commenced on azathioprine 
150mg per day. There was sub-optimal improvement with the steroid courses and 
improvement that lasted less than 1 month following each course of intravenous 
immunoglobulin. 
The last of these admissions was for a further disabling clinical relapse that left her 
requiring the support of 2 people to walk where previously she had been mobile with 
a walking frame. Following an ineffective course of intravenous methylprednisolone 
she received a course of 5 plasma exchanges over 13 days. On the day following the 
final exchange she was able to walk independently with a walking frame and after a 
further six weeks she was able to walk about 20 metres with 2 walking sticks. She 
has remained well for the twenty-four month follow up period and her walking has 
continued to improve such that 21 months after her course of plasma exchange she 
reports that she is able to walk a quarter of a mile with one stick. She has had no 
relapses during this period. 
PatientS 
An asymptomatic 16 year old male attended his opticians for routine review of his 
short sightedness and a non correctable deterioration in his vision was noted. He was 
referred to an ophthalmologist who noted corrected acuities of 6/9 in both eyes with 
normal fundoscopy and a 'subtle eye movement disorder'. Over the following three 
months the patient developed headaches, blurred vision, a clumsy gait with 
occasional falls and a tendency to drop things. An MRI brain scan at this stage 
showed multiple T2 hyperintensities within the cerebral white matter, most marked 
within the peri ventricular white matter, anterior temporal lobes, pons and medulla. 
CSF examination revealed oligoclonal bands. Further blood investigations were 
unremarkable and a diagnosis of multiple sclerosis was made. His ataxia responded 
well to a three day course of intravenous methylprednisolone. However four weeks 
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after the course of steroids his disease continued to progress. His neurological 
deterioration subsequently accelerated rapidly such that ten months after his first 
symptom he had become dependent upon a wheeled frame to take just a few steps. 
Neurological examination at this stage revealed a partial left internuclear 
ophthalmoplegia, a spastic paraparesis and cerebellar ataxia. 
In view of his rapidly accumulating disability and young age a course of plasma 
exchange was instituted. He received 5 plasma exchanges over a 2 week period. By 
the end of the course was able to walk 15 metres without support. In the 14 months 
since his plasma exchanges he has progressively improved, despite suffering 3 
superimposed relapses (1 episode of ataxia, 2 episodes of right optic neuritis), such 
that at the end of his follow up period he is able to walk 500 metres without any 
support. 
Patient 6 
A 17 year old male presented with slowly progressive personality change, seizure 
disorder, cognitive decline, intermittent episodes of optic neuritis and gait 
disturbance. Full neurological investigation revealed a diagnosis of multiple sclerosis 
based on the clinical history, typical MRI brain appearances, positive oligoclonal 
bands, delayed visual evoked potentials and lack of confounding results. He 
improved following initial courses of intravenous methylprednisolone. Over the 3 
years from presentation his disease course was progressive with 3 superimposed 
relapses. At this stage he was markedly ataxic and required the support of one carer 
to stand. Over the next 3 months he deteriorated rapidly despite a course of 
intravenous corticosteroids such that at the end of this time he was bed bound with 
quadriparesis, bulbar dysfunction and cognitive decline. A decision was taken to treat 
him using plasma exchange. Due to an MRS A colonisation of his central line he 
received only 3 of 5 planned exchanges. Following plasma exchange his family said 
he had improved. Clinically there was some improvement in cognitive function and 
speech but this was sub-optimal and the patient has remained quadriparetic and fully 
dependent. No relapses were recorded in the 12 months of follow up. 
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Results 
Table 5-1: Patient and disease characteristics 
Iouration at PE (months' 
Patient !Age Sex lDiagnosis lOisease ~cute 
~umber (vrs) episode Major involvement 
1 135 Male IAcute transverse myelitis [5 15 RWldriparesis 
2 ~5 Male ~linically isolated optico-spinal 1 1 Paraparesis 
~yndrome 
~ [43 Female Secondary progressive MS with 64 6 Paraparesis 
elapses 
~ ~7 Pemale lRelapsing remitting MS 17 1 Paraparesis 
5 17 Male lRelapsing remitting MS 10 1 ~erebellar 
~ 120 Male Secondary progressive MS with [45 f4 Ruadriparesis 
Irelapses 
Table 5-2: Treatment and Response 
Patient Plasma ~ime (days) IEstimated EDSS lRelapse rate 1P01l0w up 
Inumber ~xchan2es Ifrom last i v relapses/year) months) 
~o. Period ~teroids to PE lBefore IAfter IEDSS IY ear before lYear 
days) chang:e PE £'ollowing: PE 
I ~ 11 38 ~.5 ~.5 2 NA NA 5 
2 ~ 10 ~ 6.5 ~ ~.5 NA NA 6 
~ rs 8 176 6.5 ~.5 1 3 I 19 
~ ~ 11 ~4 7.5 ~.5 1 ~ P ~4 
~ 14 8 114 rf.5 14 3.5 ~ ~ 16 
6 13 14 108 ~.5 ~ 0.5 ~ P 12 
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Days after admission 
A summary of the patient and disease characteristics is shown in Table 5-1 , whil t 
the results of plasma exchange in these patients is shown in Table 5-2. There were 4 
men and 2 women. Age at time of plasma exchange ranged from 16 to 41 year 
(mean 29.5 years). Four of the patients were suffering from multiple sclero i with a 
disease duration of between 10 and 45 months (mean 26.5 months) whilst there wa 
one case of acute transverse myelitis and one case of clinically isolated optico-spinal 
demyelination. The follow up period averaged 13.7 months and ranged from 5 to 24 
months. 
Of the six acute episodes that led to a course of plasma exchange five principally 
involved probable spinal cord lesions whilst one episode principally in 01 ed 
cerebellar dysfunction. The number of plasma exchanges given to each patient 
ranged from 3 to 5 (mean 4.5) and were given over 4 to 11 days (mean 8.7). Four of 
the patients had a sub-optimal response to at least one cour 
methylprednisolone during the same admission where pia rna 
admini teredo Two patients did not recei e teroid during th ir admi 
xchang : In one of these cases (patient 3) thi wa du to a I 
un ucc ful t roid r pon e and in another ca (pati nt 5) thi wa 
logical d t riorati n in a ung pati nt \ h pr 
r p n t intr ter id had la t d ~ r nl 4 'vV k . 
11 7 
of intra n u 
chang a 
n D r pI a rna 
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intravenous steroid course to plasma exchange ranged from 9 to 176 days (see table 
5-2). Only patient 4 was receiving concurrent immunotherapy at the time of their 
plasma exchange (azathioprine 150mg/day). The case notes allowed retrospective 
estimation of EDSS scores and these ranged from between 6.5 and 9.5 (median 7.5) 
before plasma exchange and between 2 and 9 (median 5.5) after plasma exchange 
(p=O.031, sign test). The four patients with multiple sclerosis in the study 
experienced a combined total of 10 relapses in the year prior to plasma exchange 
compared to a total of 3 relapses in the year following plasma exchange (p=O.25, 
sign test). 
Our complications of plasma exchange were as follows. All patients required central 
venous access despite an initial attempt to complete the course of plasma exchange 
via peripheral access in two patients. Two patients developed an infection of their 
central venous (CV) line, both cases responded well to CV line removal and 
antibiotic therapy. One patient had their planned course of plasma exchange curtailed 
due to CV line infection. One patient required their CV line to be replaced due to 
poor line patency. One patient reported light-headedness for a few hours following 
each plasma exchange. No patient developed anaemia or systemic infection. 
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Discussion 
This study although retrospective and uncontrolled, nevertheless provides further 
clinical support for the value of plasma exchange in steroid resistant acute se\'ere 
inflammatory demyelination of the central nervous system. The 6 patients described 
had received a total of 9 courses of intravenous methylprednisolone in the 6 months 
prior to plasma exchange; two had also been treated \\'ith intravenous 
immunoglobulin and with mitoxantrone respectively without objective benefit. 
Although the extent of the response varied, all improved following plasma exchange. 
The possibility that improvement in some patients was at least partially a delayed 
effect of intravenous corticosteroid therapy cannot be excluded, though since the 
mean period between last steroid dose and plasma exchange was over 78 days, this 
seems unlikely. None of our patients had the number of plasma exchanges (seven) 
given in the May0210 study, perhaps suggesting that fewer than seven plasma 
exchanges may be efficacious. Further research is required to clarify this issue. 
Acute relapses in MS are thought to be inflammatory in origin, progressive disability 
the result of accumulating axon loss. The mechanisms of action of plasma exchange 
remain obscure213, but are far more likely to affect immunological and inflammatory 
processes than neurodegeneration. Many neurological diseases are indeed 
characterised by the presence of a specific auto-antibody: Myasthenia Gravis, 
Lambert-Eaton Myasthenic syndrome, Stiff Person Syndrome and Miller-Fisher 
syndrome to name but a few. In MS however a single specific auto-antibody has yet 
to be described and given the relative abundance of MS and the quantity of research 
into MS when compared to the often much rarer conditions outlined above one must 
doubt whether such an entity exists. Antibodies against myelin basic protein (MBP) 
and myelin oligodendrocyte glycoprotein (MOG) have been described in MS but are 
limited to sub-groups only214 and it is unclear whether they are causative or reactive, 
The responses exhibited by our patients usefully illustrate these various aspects of 
the activity of plasma exchange. Patients 3 and 6, for example. both suffered an 
inexorable gradual deterioration over a 3 month period prior to their plasma 
exchanges. Clinically it was difficult to exclude aggressive, subacute relapsing 
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disease (rather than secondary progression), hence the trial of plasma exchange. The 
favourable response of Patient 3 supports inflammation rather than 
neurodegeneration as the basis for her deterioration. The relatively poor outcome of 
Patient 6 may imply irreversible axonal loss and secondary progressive disease had 
already commenced. The occasional difficulty, illustrated by these two patients, of 
clinically distinguishing between sub-acute frequent relapses and secondary 
progression, together with the clinicians desire to offer seyerely affected patients 
every possible therapeutic support, may on a larger scale help to explain the variable 
and ultimately inconclusive outcome of studies195-202 examining the role of plasma 
exchange in progressive multiple sclerosis. 
Within the group of patients with more unambiguous inflammatory action, our 
results help suggest two separate actions of plasma exchange: the immediate 
suppression of acute inflammation, and longer term prevention of further 
inflammatory relapses. Previously published trials21O:211 have concentrated more on 
the former, emphasising recovery from relapse, than the latter. 
Thus, in our case of acute transverse myelitis (patient 1) a complete spastic 
paraparesis began to ascend after several months and threatened a tetraparesis. 
Plasma exchange in this case was closely associated temporally with resolution of 
arm symptoms and rapidly accelerated improvement in the legs. The response to 
plasma exchange even at this very late stage suggests that neurological cord 
dysfunction was at least partly due to reversible conduction block215 not irreversible 
axonal loss. 
In our case of clinically isolated optico-spinal demyelination (patient 2) in a Chinese 
gentleman, which may in time prove to be the first relapse of an oriental phenotype 
MS216, a significant improvement in vision followed each course of intravenous 
methylprednisolone but lasted only 1-2 days. Plasma exchange was followed by 
dramatic but also sustained improvement (see figure 5-1). This again suggests a rok 
for ren~rsible conduction block caused by agents sensitiye to but not abolished by 
steroids. 
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Beyond the immediate effects on acute relapse, we noted in our four patients with 
mUltiple sclerosis a lower relapse rate following plasma exchange. Whilst further 
prospective, blinded and sham controlled studies are required to examine whether 
this tentative observation is valid, or either a result of sub-optimal trial design or 
merely regression to the mean in a popUlation selected for high relapse rate it does at 
least suggest the possibility that the plasma exchange may not only promote recovery 
from acute relapse but also prospectively reduce further attacks for a period of time. 
Indeed of three studies217-219 which have looked at the effects of plasma exchange on 
brain MRI gadolinium-enhancing lesions one found a reduction217 in the number of 
gadolinium-enhancing lesions following PE; one found no change218 and the other 
reports an increase219. It is therefore suggested that PE may modify the overall 
inflammatory process219. The mechanisms by which plasma exchange may bring 
about a sustained effect are not clear but previous observations of a beneficial effect 
of plasma exchange on cellular immunity 220 in addition to the immediate effects on 
humoral response in multiple sclerosis may be pertinent. In our and other studies, 
patients are selected by virtue of a very severe clinical relapse and a more aggressive 
and inflammatory MS phenotype: therefore the possible reduction in relapse rate may 
not be generalisable to all cases of relapsing remitting MS. 
Subsequent to our study the importance of the four distinct immunopathological 
patterns of MS lesion 42 (see Chapter 1) with regard to response to plasma exchange 
has been described. In 19 MS patients in whom brain biopsy was performed prior to 
plasma exchange there was a strong correlation between favourable response and the 
presence of pattern II lesions (antibody and complement mediated) at biopsy43. 
Whilst biopsy was not performed in any of our 4 MS patients their generally 
favourable response may be more than pure fortune: pattern II lesions appear to be 
more common than the three other pattern types combined42. Whether with hindsight 
one would have perfonned brain biopsy prior to plasma exchange in these cases to 
assess whether pattern II lesions were present is also doubtful as the risks of brain 
biopsy probably exceed the risks of plasma exchange, especially when there is little 
or no doubt about the diagnosis of MS based on clinical and para-clinical parameters. 
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Our findings from chapter 4 suggest that recurrent motor relapses isolated in C~S 
space do cause relevant chronic impairment and it is likely that such motor 
impairment would translate effectively into chronic disability. However such 
recurrent motor relapse activity is relatively uncommon and is likely to be a 
significant cause of disability in only a minority of patients, howe\'er it is these very 
patients in whom we would tend to consider more aggressive anti-inflammatory 
therapies, such as plasma exchange, and our work suggests this is appropriate. The 
finding that motor relapses probably do contribute to chronic disability is supported 
by a trial of the humanised monoclonal antibody Campath 1-H which suppressed 
relapses in patients with relapsing remitting disease and led to an improvement in 
disability. It was suggested that suppression of the inflammatory environment 
protects axons from secondary degeneration which can cause disabilitylo9, although 
our own observations suggest that relapse suppression alone in the case of aggressive 
relapsing motor disease would probably be enough to ameliorate disability 
independent of any action on secondary progressive disease and this is highlighted 
further by the observation that effective suppression of relapse and MRI surrogates 
by Campath-l H in those with secondary progression did not halt progression of 
disability or CNS atrophy 12. 
The complications our SIX patients experienced from plasma exchange, whilst 
fortunately not resulting in lasting morbidity, highlight that it is not to be undertaken 
lightly or until less risky interventions such as intravenous methylprednisolone have 
been exhausted. 
Our study supports the use of plasma exchange in cases of severe acute steroid-
insensitive inflammatory demyelination of the CNS. 
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Chapter 6: Conclusions 
What has this work contributed to our understanding of multiple sclerosis? 
Whilst multiple sclerosis undoubtedly involves inflammatory demyelination in the 
central nervous system of humans there is an emerging controversy as to whether this 
is a primary or secondary disease phenomenon. Does inflammation cause 
neurodegeneration or does neurodegeneration cause inflammation? The latter 
possibility represents a potential paradigm shift in multiple sclerosis theory22U22. 
Early clinical and pathological studies of multiple sclerosis gave rise to the 
intuitively attractive primary inflammatory model driven by a Th 1 lymphocyte 
dependent, macrophage mediated auto-immune response directed against myelin 
derived antigen. However, subsequent therapeutic, radiological, clinical and 
pathological studies have arguably done more to question than support the primary 
inflammatory model. The key cornerstones of this debate include clinical, MRI and 
pathological information. 
Whilst the pathology is the disease, access to the most revealing early disease stages 
is limited. Thus potentially critical observations of oligodendrocyte apoptosis 
preceding inflammation in the earliest stages of the disease3 should be tempered by 
the knowledge that severe disease necessitating biopsy or facilitating post mortem 
pathology is unusual and it is difficult to be sure that this is representative of the 
more abundant, milder disease forms where tissue from early stage disease is 
ethically unobtainable. For this reason there has been a great interest in non-invasi\'e 
neuro-imaging, principally magnetic resonance imaging. 
Whilst MRI rapidly established a role in the diagnosis of multiple sclerosis 15, the 
technique was less proficient in terms of prognosis: there is a relatively poor 
correlation between conventional MRI indices and disability69:223. Subsequent studies 
have shown a profound effect of disease modifying drugs on conventional ~1RI 
indices 107 but this translated into a weaker effect on relapse rates and no discernible 
dfect on disease progression 12. At this stage multiple sclerosis was perhaps telling us 
rather more about MRI than MRI was about multiple sclerosis and this was realized 
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when subsequent studies of the much less visually captivating 'normal appearing' 
white and grey matter revealed that these tissues are far from nonnal39-
41;49;53;54;80;82;83;85;86;88;91;93;224-226 Th' 'd th 'b'l'ty th t th ' Itt' I 
, IS raise e POSSI I I a e mu p e 
scleroses' are the equivalent of the cherry on the hitherto invisible cake, Additional 
evidence for the growing discrepancy in the primary inflammatory model included 
natural history data suggesting a fundamental dissociation between relapse and 
chronic disability6;10;11;23;120;173 and the realization that the 'immune system' is not 
bound by any job description and is more a 'cell based survival system' that may 
have evolved a potent neuro-protective and regenerative capaciti6;227 within the now 
massive and latterly long lived human brain, 
I I 'th hr ' d' b'l' 120·138 Paradox abounds: relapses corre ate poor y WI c ornc Isa llty . , 
conventional MRI indices correlate poorly with disabiliti23, pathological features 
can not be accurately determined with conventional MRI indices81 and obvious 
pathological change may not be clinically eloquent67, Thus the relationship between 
clinical, radiological and pathological features of multiple sclerosis appears tortuous 
at best (see figure 6-1). 
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Figure .6-1: M.~. ~sher's Penrose Triangle figurativel) illustrates the 
paradoxIcal relationshIp between clinical, radiological and pathological feature 
of multiple sclerosis 
The debate over the pnmary cause of multiple sclerosi continue without 
satisfactory resolution228·229 . In this new cognitive climate of pathogenic uncertainty 
we believed that a return to the study of the living patient with the traditional tool of 
the neurologist, which was so much in evidence prior to, but increasingly scarce 
since the advent of MRl may reveal information useful in advancing our 
understanding of multiple sclerosis. 
The reader will recall that the aims of this thesis were as follows : 
1. To describe the relationship between relapse and disability in multipl 
sclerosis. 
2. To describe the neurological deficits encountered during r lap e of 
multiple sclerosis. 
3. To describe in detail the neurological deficit at pr valence in a defined 
population of patient with multiple clero i . 
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In chapter 2 we have described in detail the neurological deficits at prevalence in 
150 patients with multiple sclerosis. Furthermore we have examined the relationship 
between clinical signs and both patient related (sex and age) and disease related 
(disease sub type and disease duration) factors. Our findings show that a progressin~ 
disease sub-type is the major risk factor for the appearance of the majority of clinical 
signs and this correlates well with natural history data that find that progressiyc 
disease is associated with disability. However certain clinical signs appear with 
increasing disease duration and not the onset of the secondary progressive phase. 
This raises the possibility that neurological tracts and functions may degenerate and 
so contribute to the secondary progressive phase at different times rather than 
simultaneously. Diagnosis of secondary progressive multiple sclerosis usually 
requires a sustained increase in EDSS H'ithin its mobility range and so if non-
mobility related functions, such as a disturbance of vibratory sensation were to 
progress before this time it is unlikely that the patient would be identified as 
secondary progressive. However when a tract with high influence on mobility enters 
the secondary progressive phase, such as the cortico-spinal tracts, a sustained 
increase in EDSS, and thus a label of secondary progressive multiple sclerosis is 
likely. In this way the important observation that the progressive phase is stereotyped 
and related to degeneration of the distal cortico-spinal tractl73 should be viewed in 
the knowledge that this may at least partially be an effect of the definitions used. It 
has previously been suggested 138 that the presence of certain clinical signs, such as 
the Babinski reflex, may indicate imminent conversion to the secondary progressive 
phase of the disease by noting sub-clinical damage to the cortico-spinal tracts. Our 
observations extend this: if varying tracts degenerate in a relatively predictable order 
in multiple sclerosis then the identification of clinical signs unrelated to the cortico-
spinal tract may give even earlier warning of classical disease progression than is 
currently appreciated. The applications of such data in therapeutic studies, 
particularly where relapses are effectively suppressed, could be invaluable. Whilst 
our study with its cross sectional design has exposed this question a prospectin~ 
study would be required to answer it. 
In chapter 3 we have described the neurological deficits encountered during relapse 
in our cohort and compared it with data from other studies. \Vhilst the task of 
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retrospective relapse assessment was performed rigorously we believe this is likely to 
represent the weakest link in our methodology and therefore a detailed presentation 
of these results, with appropriate comparison and discussion, was necessary. The 
assessment of clinical signs was performed prospectively and therefore, 
notwithstanding known problems of inter and intra-rater variability23o, less likely to 
be confounding. We found some useful and to our knowledge previously unreported 
data suggesting that motor and sensory relapses become increasingly common 
distally (face:arm:leg ratio of 1 :5: 10), whilst the character of relapses varies in the 
ratio of 1 :3:5 for ataxia:motor:sensory in our study. Accepting the heterogeneous 
reporting techniques found in the literature with regards to relapses, we believe our 
own relapse data are comparable with previous studies and this suggests that rigorous 
retrospective relapse ascertainment, whilst unquestionably inferior to diligent 
prospective assessment, is satisfactory. 
In chapter 4 we have described the relationship between relapse and chronic 
disability in multiple sclerosis. We have shown that relapse is independently 
associated with relevant chronic impairment although in a manner that is in fact, we 
believe, consistent with natural history studies that suggest relapse number and rate 
are not associated with long term disability. The major explanation for this paradox 
is that whilst the human central nervous system appears to be relatively resistant to 
the chronic effects of motor relapse, the EDSS is heavily predicated upon motor 
impairment and thus relapses at the population level fail to translate into meaningful 
longterm disability. Our data also show that progressive disease states are associated 
with impairment and this impairment is independent of relapse activity. In addition 
the motor pathway's apparent partial resistance to relapse does not protect against 
progressive disease that in turn translates effectively into EDSS measured disability. 
Further reasons that may amplify the apparent paradox between relapse and disability 
include relapses from presently unidentified disease sub types with a relatively 
benign relapse character (ie sensory) being compared in a quantitative fashion with 
relapses from a less favourable (ie motor) phenotype. Thus relapses do appear to 
cause relevant impairment, and probably short term disability at lower EDSS 
levels 138, but not EDSS measured disability in the longer term. 
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In chapter 5 we have reported on the role of plasma exchange in severe. acute. 
inflammatory, demyelinating disease, including our own experience with 6 patients, 
4 of whom had multiple sclerosis231 . We found a varying benefit throughout all 6 
patients which supported previous work suggesting a potential role for plasma 
exchange in inflammatory, demyelinating disease2I o. These patients were largdy 
selected for treatment with plasma exchange by virtue of unequivocally disabling 
steroid insensitive relapses. In combination with our work (Chapter 4) showing that 
repeated motor relapses coalescing in CNS space do indeed cause appropriate 
impairment this suggests that aggressive anti-inflammatory relapse therapy, if 
appropriately targeted to the relatively small subset of patients who are at risk of 
relapse related disability, is likely to have a significant long term beneficial effect on 
disability. 
Thus we would argue that we have both met and exceeded our original thesis aims 
outlined in the introduction and re-iterated above. Our findings in conjunction with 
recent advances by other researchers allow us to speculate further on the nature of 
multiple sclerosis: 
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(1) Disability and impairment in multiple sclerosis 
If the EDSS scale defines disability then disease progression is a dominant cause of 
disability in multiple sclerosis and this effect is independent of relapse activity. 
Relapses are associated with relevant impainnent and at the early disease stag~s 
(where EDSS is an impainnent scale) this probably explains and supports the idea 
that disability is accrued in a stepwise fashion3o. However the impairment caused by 
relapses does not translate well into chronic disability because motor functions 
appear to have a relative resistance to the chronic effects of relapse and the mobility 
portion of the EDSS is relatively insensitive to non-motor impairment. In this way 
our work appears to resolve the conflicts between studies showing no effect of 
relapses on disability in the longer term6;IO;22:23 and a study showing residual 
disability following relapse in the shorter term at lower EDSS30 (and thus 
impainnent) levels. This may suggest that McAlpine's original schemata l16 (see 
figure 6-2a) is an oversimplification and that disability cannot be accurately 
expressed in only two dimensions. Our findings from chapter 2 and chapter 4 suggest 
that different neurological tracts may have their own susceptibilities to the different 
disease processes involved in multiple sclerosis and therefore an expansion of 
McAlpine's original schemata can be proposed (figure 6-2b). 
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they found a significant reduction in cortico-spinal fibres at all spinal cord leyels 
when compared with controls, this was only the case for sensory fibres in the upper 
levels of the cervical cord. Sensory fibres appeared to be better preserved in chronic 
multiple sclerosis than cortico-spinal fibres. This reflects clinical studies that suggest 
sensory symptoms are a relatively uncommon, or perhaps overlooked. component of 
. I' I I . 159'167 . . . 187 progressIve mu tIp e sc erOSIS ' . In addItIOn an eloquent pathologIcal study of 
the anterior optic pathways in multiple sclerosis confirmed previous findings 136;233 
suggesting that small diameter axons may be more susceptible to damage and loss 
than larger diameter axons. They found that there were significantly fewer small 
diameter axons (parvocellular) preserved in the anterior optic pathways of multiple 
sclerosis patients whilst there was relative preservation of large diameter axons 
(magnocellular). This observation corresponds with clinical experience: colour vision 
is mainly served by small diameter axons and is often affected early in multiple 
sclerosis. Surprisingly with regards to the sensori-motor system pathways we could 
find no information relating axonal size with function and found that others had 
encountered the same unanticipated information void (personal communication -
Esiri MM). Another problem would be that axonal diameter in sensory pathways 
such as dorsal columns is compromised by the fact that these pathways contain a 
considerable number of efferent fibres. Efferent fibres are well described in optic234 
and auditory235 nerves but their existence in spinal 'sensory' pathways is becoming 
increasingly realised236. Their function is not entirely clear but they may act as a 
peripheral sensory switch - you were likely unaware of the soles of your feet prior to 
this sentence. Any pathological study where the axonal diameter in certain pathways 
were measured would be compromised as one could never be sure whether each axon 
was technically going 'up' or 'down'. For these reasons we are presently unable to 
test the hypothesis that chronic impairment secondary to relapses is partially 
dependent upon the size ofaxons in particular eNS pathways but intuitively it 
remains an attractive theory. The fact that unmyelinated eNS axons may be as large 
as 0.8 micrometres in diameter whilst myelinated eNS fibres are often as small as 
0.2 micrometres in diameter237 further suggests that one needs to consider that 
patterns of axonal loss may appear to be demyelination dependent when they are in 
fact dependent upon axonal size. 
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(2) MRI in multiple sclerosis 
Whilst our work did not involve the use of MRllimited inferences can be made \\"ith 
regard to use of this imaging modality. A major difference between an MRI and 
clinical study is the fact that MRI lesions are about ten times as common as episodes 
of acute clinical relapse. Our study suggests that these acutely eloquent MRl lesions 
are associated with relevant impairment in the fashion already described for relapses. 
The fact that correlations between T2 lesion load and disability are generally 
weak
69
;223 may suggest that these acutely eloquent relapse associated lesions are the 
sole agents responsible for such a correlation. In tum this may infer that the clinically 
silent majority of MRI lesions remain clinically silent in the longer term and do not 
contribute towards chronic disability. This may help explain the comparatively 
greater effect of disease modifying drugs on MRI activity compared with relapse 
rates and their failure to provide unequivocal evidence of amelioration of chronic 
disability - they may be preferentially eliminating relatively benign or adaptive white 
matter lesions. This is further compounded by the fact that even in the heavily 
sclerosed central nervous system the majority of tissue is macroscopically normal 
appearing and so even a relatively subtle functional deficit in these normal appearing 
tissues may be more relevant to overall dysfunction and disability than a relatively 
marked deficit in lesional tissue. 
. I . I I . 6·H7·68 1 38· d·fr. I I The possible role of asymptomatIc mu tIp e sc erOSIS ' , .- IS I lICU t to eva uate 
for obvious reasons of ascertainment but further support the dissociation between 
conventional MRI lesion loads and disability and suggest that therapeutically 
targeting MRI markers of disease in isolation may be ineffective and possibly 
harmful in individual cases. Is it possible that asymptomatic multiple sclerosis is a 
well-adapted response to an as yet unidentified primary pathology and that 
symptomatic multiple sclerosis represents a spectrum of failure at this attempt? 
(3) A realistic alternative to inflammation as the primary patholoe;y in multiple 
sclerosis? 
Perhaps the most considered non-inflammatory pnmary mechanism in multiple 
sclerosis is oligodendrocyte apoptosis). The triggering factor for this apoptosis is still 
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unclear, although possibilities include locally generated pro-inflammatory c)10kines. 
oxidative and nitrative stress, excito-toxicity and persistent viral 
. fl . 239·240 Wh' In arnmatlOn ' . lIst there are many factors that need to be explained in any 
convincing model of multiple sclerosis it seems of at least some interest that multiple 
sclerosis only convincingly affects an organism that has recently evoh·ed a massive 
cerebrum and an even more recent prolongation of life expectancy past the age at 
which mUltiple sclerosis usually starts. Evidently the oligodendrocyte has coped with 
humanity's increasing longevity and the presumptive mechanism is an increased 
oliogodendroglial life expectancy to exceed that of the host. However a significant 
number of human cell types cope with increasing host life expectancies not by 
increasing their own life expectancy but by a process of apoptosis and replacement 
by younger cells241 . It has recently been realised that even human neurons have the 
ability to regenerate in adults242 and so the possibility that oligodendrocytes employ 
this technique, not only exceptionally to repair obvious pathological damage, but also 
routinely to maintain a healthy, functioning, central nervous system over time is 
worthy of some consideration. 
If this fundamental model of cycling rather than static oligodendrocyte cell 
populations were correct then a number of secondary (and necessarily even more 
tentative) observations can be made. Importantly a clear role for oligodendrocyte 
progenitor cells is immediately evident. It is unlikely that such cells would be there 
just in case the host were to develop multiple sclerosis and in any case they seem 
relatively ineffective when this is the case243 . Such apoptosis and replacement of 
cells as large as oligodendrocytes would present its own difficulties. In particular 
concealing large amounts of apoptotic myelin from the attentions of the Immune 
system would represent a technical challenge, and this task probably falls to 
endogenous microglia. The process of oligodendrocyte apoptosis would need to be 
carefully regulated to avoid microglia and oligodendrocyte progenitor cells becoming 
overwhelmed and thus prevent significant functional impairment of the nervous 
system during routine maintenance. Thus such oligodendrocyte apoptosis should be 
well dispersed in time and space and difficult to detect in pathological studies unless 
perhaps specifically looked for. If the useful lifespan of an oligodendrocyte is up to 
20 -30 years then relatively few oligodendrocytes would need to be undergoing 
apoptosis at any given point in time. Dysregulation of oligodendrocyte apoptosis 
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may therefore explain at least some of the pathological42 and even clinical 
expressions of multiple sclerosis. Failed diffuse apoptosis may lead to axons 
becoming slowly suffocated by functionally decrepit oligodendrocytes with partially 
adaptive venocentric focal apoptosis leading to the formation of the acute multiple 
sclerosis lesion3, providing the opportunity for useful remyelination but also 
overwhelming the microglia and attracting T -lymphocyte and macrophage attention. 
Conversely a primary progressive phenotype may represent the same model without 
significant maladaptive focal apoptotic rescue mechanisms resulting in persisting 
axonal impairmenr24 by dysfunctional oligodendrocytes and relatively less focal 
infiammation72: a studi33 of axonal loss in multiple sclerosis found that there was 
relatively little axonal damage in primary progressive disease suggesting that the 
degree of dysfunction in such disease is greater than can be explained on the basis of 
axon loss alone. We accept this proposed model is finely balanced on supposition 
with relatively few supporting facts, however it seems likely that any accurate model 
of multiple sclerosis would have to explain a lower than expected contribution 
towards disability from lesional matter and a higher than previously expected 
·b· fr 1 . h·t d tt 40;41;54;82;91;224 contn utlOn om norma appeanng w 1 e an grey rna er . 
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Summary of Conclusions 
• Relapses do cause relevant chronic impairment but for a number of disease 
and scale related reasons this fails to translate into chronic disability. 
• Secondary progression is not dependent upon prior relevant relapse actiyity. 
• Varying neurological functions and pathways may haye yarymg 
susceptibilities and resistances to the different pathological components of 
multiple sclerosis. 
• Many contemporary observations and paradox relating to multiple sclerosis 
may tell us as much about the tools used to make those observations, 
principally MRI and disability scales, as they do about the underlying disease. 
• A model of multiple sclerosis based on a failure to maintain a physiological, 
dynamic oligidendrocyte population may have some merits. 
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Appendices 
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Appendix 2: Kurtzke's Expanded Disability Status Scale 
(i) Definitions 
• EDSS steps below 4 refer to patients who are fully ambulatory (able to 
walk >500 metres). The precise step is defined by the Functional System 
(FS) scores . 
• EDSS steps between 4.0 and 5.0 are defined by both the FS scores and the 
walking range. In general, the more severe parameter determines the 
EDSS step. 
• EDSS steps 5.5 to 8.0 are exclusively defined by the ability to ambulate and 
type of assistance required, or the ability to use a wheelchair. 
• From steps 0 to 4.0, the EDSS should not change by 1.0 step, unless there is 
a similar change in FS score by 1 grade. 
• The EDSS step should not be lower than the score of any individual FS, 
with the expetion of the Visual and BowellBladder FS. 
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(ti) Expanded Disability Status Scale 
o Normal neurological exam (all FS grade 0) 
1.0 No disability, minimal signs in one FS (one FS grade 1) 
1.5 No disability, minimal signs in more than one FS (more than one FS grade 
1) 
2.0 Minimal disability in one FS (one FS grade 2, others 0 or 1) 
2.5 Minimal disability in two FS (two FS grade 2, others 0 or 1) 
3.0 Moderate disability in one FS (one FS grade 3, others 0 or 1) though fully 
ambulatory; or mild disability in three or four FS (three/four grade 2, others 
o or 1) 
3.5 Fully ambulatory but with moderate disability in one FS (one FS grade 3) 
and mild disability in one or two FS (one/two FS grade 2) and others 0 or 1; 
or fully ambulatory with two FS grade 3 (others 0 or 1); or fully ambulatory 
with five FS grade 2 (others 0 or 1) 
4.0 Ambulatory without aid or rest for >500 metres; up and about some 12 
hours a day, characterised by relatively severe disability consisting of one 
FS grade 4 (others 0 or 1) or combinations of lesser grades not exceeding 
limits of previous steps 
4.5 Ambulatory without aid or rest for >300 metres; up and about much of the 
day, characterised by relatively severe disability usually consisting of one 
FS grade 4 and combinations of lesser grades exceeding limits of previous 
steps 
5.0 Ambulatory without aid or rest for >200 metres (usual FS equivalents 
include at least one FS grade 5, or combinations of lesser grades usually 
exceeding specifications for step 4.5) 
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5.5 Ambulatory without aid or rest> 100 metres 
6.0 Unilateral assistance (cane or crutch) required to walk at least 100 metres 
with or without resting 
6.5 Constant bilateral assistance (cane or crutches) required to walk at least 20 
metres without resting 
7.0 Unable to walk 5 metres even with aid, essentially restricted to wheelchair: 
wheels self and transfers alone~ up and about in wheelchair some 12 hours a 
day 
7.5 Unable to take more than a few steps: restricted to wheelchair; may need 
some help in transferring and wheeling self 
8.0 Essentially restricted to bed or chair or perambulated in wheelchair: but out 
of bed most of day; retains many self care functions; generally has effective 
use of arms 
8.5 Essentially restricted to bed much of the day; has some effective use of 
arm(s)~ retains some self care functions 
9.0 Helpless bed patient~ can communicate and eat 
9.5 Totally helpless bed patient; unable to communicate effectively or 
eat/swallow 
10 Death due to MS 
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Appendix 3: Functional System Scores 
(i) Visual (Optic) Functions 
Visual Acuity: The visual acuity score is based on the line in the Snellen chart at 
20 feet (5 metres) for which the patient makes no more than one error (use best 
available correction). Alternatively, best corrected near vision can be assessed, 




1 Signs only: deficits present only on formal (confrontational) testing 
2 Moderate: Patient aware of deficit, but incomplete hemianopsia on 
examination 
3 Marked: complete homonymous hemianopsia or equivalent 
Scotoma 
o None 
1 Small: detectable only on formal (confrontational) testing 
2 Large: spontaneously reported by patient 
Disc Pallor 
o Not present 
1 Present 
Note: When determining the EDSS step the Visual FS score is converted to a 
lower score as follows: 
(Visual FS Score - Converted Visual FS score) 
1-1, 2-2, 3-2, 4-3, 5-3, 6-4. 
Visual FSS 
o Normal 
Disc pallor and/or mild scotoma and/or visual acuity of worse eye less than 
20/20 but better than 20/30 
.., Worse eye with large scotoma and/or maximal visual acuity (corrected) of 
20,30 to 20/59 
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3 Worse eye with large scotoma or moderate decrease in fields and/or maximal 
visual acuity of 20/60 to 20/99 
4 Worse eye with marked decrease of fields and/or maximal visual acuity of 
20/100 to 20/200; grade 3 plus maximal acuity of better eye of 20 /60 or less 
5 Worse eye with maximal visual acuity (corrected) less than 20.'200: grade -l 
plus maximal visual acuity of better eye of 20/60 or less 
6 Grade 5 plus maximal visual acuity of better eye of 20/60 or less 
(ii) Brainstem Functions 
Extraocular movements impairment 
o None 
1 Signs only: subtle and barely clinically detectable EOM weakness, patient 
does not complain of blurry vision, diplopia or discomfort 
2 Mild: subtle and barely clinically detectable weakness of which patient is 
aware; or obvious incomplete paralysis of any eye movement of which 
patient is not aware 
3 Moderate: obvious incomplete paralysis of any eye movement of which 
patient is aware; or complete loss of movement in one direction of gaze in 
either eye 




1 Signs only or mild: gaze evoked nystagmus below the limits of "moderate" 
2 Moderate: Sustained nystagmus on horizontal or vertical gaze at 30 degrees, 
but not in primary position, patient mayor may not be aware of the 
disturbance 
3 Severe: sustained nystagmus III prImary position or coarse persistent 
nystagmus in any direction that interferes with visual acuity; complete 
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1 Signs only 
2 Mild: clinically detectable numbness of which patient is aware 
3 Moderate: impaired discrimination of sharp/dull in one, two or three 
trigeminal branches; trigeminal neuralgia (at least one attack in last 24 
hours) 
4 Marked: unable to discriminate between sharp/dull or complete loss of 
sensation in entire distribution of one or both trigeminal nerves 
Facial Weakness 
o None 
I Signs only 
2 Mild: clinically detectable facial weakness of which patient is aware 
3 Moderate: incomplete facial palsy, such as weakness of eye closure that 
requires facial patching overnight or weakness of mouth closure that results 
in drooling 
4 Marked: complete unilateral or bilateral facial palsy with lagophthalmus or 
difficulty with liquids 
Hearing loss 
o None 
I Signs only 
2 Mild 
3 Moderate: cannot hear finger rub and/or misses several whispered numbers 
4 Marked: misses all or nearly all whispered numbers 
Dysarthria 
o None 
I Signs only 
2 Mild: Clinically detectable dysarthria of which patient is aware 
3 Moderate: obvious dysarthria during ordinary conversation that nnparrs 
comprehensibility 
4 Marked: incomprehensible speech 
5 Inability to speak 
Dysphagia 
o None 
1 Signs only 
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2 Mild: difficulty with thin liquids 
3 Moderate: difficulty with liquids and solid food 
4 Marked: sustained difficulty with swallowing; requires a pureed diet 
5 Inability to swallow 
Other Bulbar functions 
o Normal 
1 Signs only 
2 Mild disability: clinically detectable deficit of which patient is usually aware 
3 Moderate disability 
4 Marked disability 
Brainstem Functional system Score 
0 Normal 
1 Signs only 
2a Moderate nystagmus 
2b Other mild disability 
3a Severe nystagmus 
3b Marked extra-ocular weakness 
3c Moderate disability of other cranial nerves 
4a Marked dysarthria 
4b Other marked disability 
5 Inability to swallow or speak 
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4 Nonsustained clonus 
5 Sustained clonus 
Plantar Response 
o Flexor 
1 Neutral or equivocal 
2 Extensor 
Limb Strength - BMRC Rating Scale 
o No muscle contraction detected 
1 Visible contraction without visible joint movement 
2 Visible movement only on the plane of gravity 
3 Active movement against gravity 
4 Active movement against resistance, but not full strength 
5 Normal strength 
LIMB SPASTICITY (AFTER RAPID FLEXION OF THE EXTREMITY) 
o None 
1 Mild: barely increased muscle tone 
2 Moderate: moderately increased muscle tone that can be overcome and full 
range of motion is possible 
3 Severe: severely increased muscle tone that is extremely difficult to 





2 Evident: minor interference with function 
.3 Permanent shuffling: major interference with function 
Pyramidal Function system Score 
1~5 
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o Normal 
1 Abnormal signs without disability 
2 Minimal Disability: Patient complains of fatiguability or reduced 
performance in strenuous motor tasks and/or BMRC grade 4 in one or two 
muscle groups 
3a Mild to moderate paraparesis or hemiparesis: usually BMRC grade 4 in 
more than two muscle groups or BMRC grade 3 in one or two muscle 
groups; movements against gravity are possible 
3b Severe monoparesis: BMRC grade 2 or less in one muscle group 
4a Marked paraparesis or hemiparesis: usually BMRC grade 2 in two limbs 
4b Moderate tetraparesis: BMRC grade 3 in three or more limbs 
4c Monoplegia: BMRC grade 0 or 1 on one limb 
5a Paraplegia: BMRC grade 0 or 1 in all muscle groups of the lower limbs 
5b Hemiplegia 
5c Marked tetraparesis: BMRC grade 2 or less in three or more limbs 
6 Tetraplegia: BMRC grade 0 or 1 in all muscle groups of the upper and lower 
limbs 
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(iv) Cerebellar Functional System Score 
Truncal Ataxia 
o None 
1 Signs only 
2 Mild: Swaying with eyes closed 
3 Moderate: Swaying with eyes open 
4 Severe: unable to sit without assistance 
Limb Ataxia (tremor/dysmetria and rapid alternating movements) 
o None 
1 Signs only 
2 Mild: tremor or clumsy movements easily seen, minor interference with 
function 
3 Moderate: tremor or clumsy movements interfere with function III all 
spheres 
4 Severe: most functions are very difficult 
Tandem (straight line) walking 
o Normal 
1 Impaired 
2 Not possible 
Gait ataxia 
o None 
1 Signs only 
2 Mild: abnormal balance only with tandem walking 
3 Moderate: abnormal balance with ordinary walking 
4 Severe: unable to walk more than a few steps unassisted or requIres a 
walking aid or assistance by another parson because of ataxia 
Romberg test 
o Normal 
Mild: mild instability with eyes closed 
2 Moderate: not stable with eyes closed 
3 Severe: not stable with eyes open 
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Note: The presence of severe gait ataxia alone (without severe truncal ataxia and 
sever ataxia in three or four limbs) results in a Cerebellar FS score of 3. 
If weakness interferes with the testing of ataxia, score the patient's actual 
performeance, but also indicate the possible role of weakness by marking an 'X' 
after the cerebellar FS score. 
Cerebellar Functional Systems Score 
o Normal 
1 Abnormal signs without disability 
2 Mild ataxia 
3a Moderate truncal ataxia 
3b Moderate limb ataxia 
3c Moderate or severe gait ataxia 
4 Severe truncal ataxia and severe ataxia in 3 or 4 limbs 
5 Unable to perform coordinated movements due to ataxia 
X Pyramidal weakness (BMRC grade 3 or worse in limb strength) interferes 
with cerebellar testing 
(v) Sensory Functions 
Superficial Sensation (Light touch and pain) 
o Normal 
1 Signs only: slightly diminished sensation (temperature, figure writing) on 
formal testing of which patient is not aware 
2 Mild: patient is aware of impaired light touch or pam, but IS able to 
discriminate sharp/dull 
3 Moderate: impaired discrimination of sharp/dull 
4 Marked: unable to discriminate between sharp/dull and/or unable to feel 
light touch 
5 Complete loss: anaesthesia 
Vibration Sensation (at the most distal joint) 
o Normal 
Mild: graded tuning fork 5-7 of 8~ alternatively, detects more than 10 
seconds but less than examiner 
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2 Moderate: graded tuning fork 1-4 of 8; altematiYely, detects between 2 and 
10 seconds 
3 Marked: complete loss of vibration sensation 
Position sense 
o Normal 
1 Mild: 1-2 incorrect responses, only distal joints affected 
2 Moderate: misses many movements of fingers or toes; proximal joints 
affected 
3 Marked: no perception of movement, astasia 
Sensory Function System Score 
o Normal 
1 Mild vibration or figure writing or temperature decrease only in one or two 
limbs 
2a Mild decrease in touch or pain or position sense and/or moderate decrease in 
vibration in one or two limbs 
2b Mild vibration or figure writing or temperature decrease alone in three or 
four limbs 
3a Mild decrease in touch or pam or position sense and/or essentially lost 
vibration in one or two limbs 
3b Mild decrease in touch or pam and/or moderate decrease m all 
proprioceptive tests in three or four limbs 
4a Marked decrease in touch or pain or loss of proprioception, alone or 
combined, in one or two limbs 
4b Moderate decrease in touch or pain and/or severe proprioceptive decrease in 
more than two limbs 
5a Loss (essentially) of sensation in one or two limbs 
5b Moderate decrease in touch or pain and/or loss of proprioception for most of 
the body below the head 
6 Sensation essentially lost below the head 
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(vi) Bowel and Bladder Functions 
Urinary hesitancy and retention 
o None 
1 Mild: no major impact on lifestype 
2 Moderate: urinary retention; frequent urinary tract infections 
3 Severe: requires catheterisation 
4 Loss of function: overflow incontinence 
Urinary urgency and incontinence 
o None 
1 Mild: no major impact on lifestype 
2 Moderate: rare incontinence occurring no more than once a week~ must wear 
pads 
3 Severe: frequent incontinence occurring from several times a week to more 
than once a day; must wear urinal or pads 
4 Loss of function: loss of bladder control 
Bladder catheterisation 
o None 
1 Intermittent self catheterisation 
2 Constant catheterisation 
Bowel dysfunction 
o None 
1 Mild: no incontinence, no major impact on lifestyle, mild constipation 
2 Moderate: must wear pads or alter lifestyle to be near lavatory 
3 Severe: in need of enemata or manual measures to evacuate bowel 






4 Loss of function 
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Note: When determining the EDSS step the bladder and bowel FS score IS 
converted to a lower score as follows: 
FS score - Converted FS score 
1-1, 2-2, 3-3, 4-3, 5-4, 6-5. 
Bowel and Bladder functional system score 
o Normal 
1 Mild urinary hesitancy and/or urgency and/or rare unnary incontinence 
and/or severe constipation 
2 Moderate urinary hesitancy and/or urgency and/or rare urinary incontinece 
and/or severe constipation 
3 Frequent urinary incontinence or intermittent self-catheterisation; needs 
enemata or manual measures to evacuate bowel 
4 In need of almost constant catheterisation 
5 Loss of bladder or bowel function: external or indwelling catheter 
6 Loss of bowel and bladder function 
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(vii) Cerebral Functions 
Depression and Euphoria 
o None 
1 Present: patient complains of depression or is considered depressed or 
euphoric by the investigator or significant other 
Decrease in Mentation 
o None 
1 Signs only: not apparent to patient and/or significant other 
2 Mild: Patient and/or significant other report mild changes III mentation. 
Examples include: impaired ability to follow a rapid course of association 
and in surveying complex matters; impaired judgement in certain 
demanding situations; capable of handling routine daily activities, but 
unable to tolerate additional stressors; intermittently symptomatic even to 
normal levels of stress; reduced performance; tendency toward negligence 
due to obliviousness or fatigue. 
3 Moderate: definite abnormalities on brief mental status testing, but still 
oriented to person, place and time 
4 Marked: not oriented in one or two spheres (person, place or time), marked 
effect on lifestyle 
5 Dementia, confusion and/or complete disorientation 
Note: the presence of depression and/or euphoria alone results in a Cerebral FS 
score of 1 a, but does not affect the EDSS step. However a Cerebral FS score of 
1 b due to mild fatigue and/or signs only decrease in mentation contributes to the 
determination of the EDSS step 
Functional System Score 
o Normal 
1 a Mood alteration (depression and/or euphoria) alone (does not affect EDSS 
step) 
1 b Mild fatigue; signs only decrease in mentation 
,., Mild decrease in mentation; moderate or se\'ere fatigue 
3 Moderate decrease in mentation 
4 Marked decrease in mentation 
5 Dementia 
152 
Relapse and Disability in Multiple Sclerosis 
References 
1. Sadovnick AD, Ebers GC. Epidemiology of multiple sclerosis: a critical 
overview. Can.J Neurol Sci 1993;20: 17-29. 
2. Lublin FD, Reingold SC. Defining the clinical course of multiple 
sclerosis: results of an international survey. National Multiple Sclerosis 
Society (USA) Advisory Committee on Clinical Trials of New Agents in 
Multiple Sclerosis. Neurology 1996;46:907-11. 
3. Barnett MH, Prineas lW. Relapsing and remitting multiple sclerosis: 
pathology of the newly forming lesion. Ann. Neurol 2004;55:458-68. 
4. Bruck W. Inflammatory demyelination is not central to the pathogenesis 
of multiple sclerosis. Journal of Neurology 2005 ;252: y 1 O-v 15. 
5. Cottrell DA, Kremenchutzky M, Rice GP. Koopman WJ, Hader W, 
Baskerville J, Ebers GC. The natural history of multiple sclerosis: a 
geographically based study. 5. The clinical features and natural history of 
primary progressive multiple sclerosis. Brain 1999;122 ( Pt 4):625-39. 
6. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and 
progression of irreversible disability in multiple sclerosis: an amnesic 
process. Brain 2003;126:770-82. 
7. Compston A, Ebers GC, Lassmann H, McDonald \\1, Matthews B. 
Wekerle H. McAlpine's Alulriple Sclerosis. Churchill Liyingstone, 199X. 
153 
Relapse and Disability in Multiple Sclerosis 
8. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM. Richert JR, Salazar 
AM, Fischer JS, Goodkin DE, Granger CV, Simon JH. Alam JJ, 
Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle C~1, Coats ~tE. 
Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, III, 
Priore RL, Pullicino PM, Scherokman BJ, Whitham RH .. Intramuscular 
interferon beta-la for disease progression in relapsing multiple sclerosis. 
The Multiple Sclerosis Collaborative Research Group (MSCRG). 
A nn. Neuro I 1996;39:285-94. 
9. Coles A. Can the course of multiple sclerosis be modified? Practical 
Neurology 2005;5:278-87. 
10. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and 
progression of disability in multiple sclerosis. N.Engl.J Med. 
2000;343: 1430-8. 
11. Ebers GC. Natural history of multiple sclerosis. J Neurol Neurosurg 
Psychiatry 2001;71 Suppl 2:ii 16-ii 19. 
12. Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M, MacManus D, 
Barker GJ, Compston DA, Miller DH. Quantitative MRI in patients with 
secondary progressive MS treated with monoclonal antibody Campath 
IH. Neurology 1999:53:751-7. 
13. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, 
Johnson KP, Sibley WA. Silberberg DH, Tourtellotte W\\'. New 
diagnostic criteria for multiple sclerosis: guidelines for research 
protocols. Ann .. VclIroI1983J3:227-31. 
15.+ 
Relapse and Disability in Multiple Sclerosis 
14. Uthoff W. Untersuchungen fiber bei multiplen Herdsklerose 
vorkommenden Augenstorungen. Arch Psychiatr Nervenkrankh 
1890;21:303-410. 
15. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin 
FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-
Wollheim M, Sibley W, Thompson A, van den NS, Weinshenker BY, 
Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: 
guidelines from the International Panel on the diagnosis of multiple 
sclerosis. A nn. Neuro I 200 1 ;50: 121-7. 
16. Schumacher GA, Beebe GW, Kibler RF, et al. Problems of experimental 
trials of therapy in multiple sclerosis; report by the panel on the 
evaluation of experimental trials of therapy in multiple sclerosis. 
Ann.N y'Acad.Sci 1965;122:552-68. 
17. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, 
Baskerville J, Ebers GC. The natural history of multiple sclerosis: a 
geographically based study. I. Clinical course and disability. Brain 
1989;112 ( Pt 1): 133-46. 
18. Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. 
Neurology 1955;5:580-3. 
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an 
expanded disability status scale (EDSS). Neurology 1983;33:1444-52. 
20. Hobart J, Kalkers N, BarkhofF, Uitdehaag B, Polman C, Thompson A. 
Outcome measures for multiple sclerosis clinical trials: relative 
155 
Relapse and Disability in Multiple Sclerosis 
measurement precision of the Expanded Disability Status Scale and 
Multiple Sclerosis Functional Composite. Mult.Scler. 2004;10:41-6. 
21. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Ho\\' 
responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A 
comparison with some other self report scales. J Neurol Neurosurg 
Psychiatry 2005;76: 1539-43. 
22. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W. 
Baskerville J, Ebers GC. The natural history of multiple sclerosis: a 
geographically based study. 2. Predictive value of the early clinical 
course. Brain 1989;112 ( Pt 6): 1419-28. 
23. Ebers GC. The natural history of multiple sclerosis. Neurol Sci 
2000;21:S815-S817. 
24. Ebers GC. Prognostic factors for multiple sclerosis: the importance of 
natural history studies. J Neuro12005;252 Sup pi 3:iii 15-iii20. 
25. Hader WJ, Elliot M, Ebers GC. Epidemiology of multiple sclerosis in 
London and Middlesex County, Ontario, Canada. Neurology 
1988;38:617-21. 
26. Martino G, Adorini L, Rieckmann P, Hillert J, Kallmann B, Comi G, 
Filippi M. Inflammation in multiple sclerosis: the good, the bad, and the 
complex. The Lancet Neurology 2002;1:499-509. 
27. Foote AK, Blakemore WF. Inflammation stimulates remyelination in 
areas of chronic demyelination. Brain 2005:128:528-39. 
156 
Relapse and Disability in Multiple Sclerosis 
28. Maggs FG, Palace J. The pathogenesis of multiple sclerosis: is it really a 
primary inflammatory process? Mult.Seler. 2004;10:326-9. 
29. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson 
AI. EDMUS, a European database for multiple sclerosis. J Neurol 
Neurosurg Psychiatry 1992;55:671-6. 
30. Lublin FD, Baier M, Cutter G. Effect of relapses on development of 
residual deficit in mUltiple sclerosis. Neurology 2003 ;61: 1528-32. 
31. Sudlow CL, Counsell CEo Problems with UK government's risk sharing 
scheme for assessing drugs for multiple sclerosis. BMJ 2003;326:388-92. 
32. Chadwick D, Gray R. Shared scheme for assessing drugs for multiple 
sclerosis: dealing with uncertainties about cost effectiveness of treatments 
is difficult problem. BMJ2003;326:1212-3. 
33. Burton JL, Wells M. The Alder Hey affair: implications for pathology 
practice. J Clin.Pathol. 2001;54:820-3. 
34. Mason K, Laurie G. Consent or property? Dealing with the body and its 
parts in the shadow of Bristol and Alder Hey. Mod.Law Rev. 
2001 ;64:710-29. 
35. Frohman EM, Filippi M, Stuve 0, Waxman SG, Corboy J, Phillips IT, 
Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De 
Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BA, Hauser S, 
Racke MK. Characterizing the mechanisms of progression in multiple 
157 
Relapse and Disability in .\/ultiple Sclerosis 
sclerosis: evidence and new hypotheses for future directions. Arch ~Veurol 
2005;62: 1345-56. 
36. Scolding N, Franklin R. Axon loss in multiple sclerosis. Lancet 
1998;352:340-1. 
37. Trapp BD, Peterson J, RansohoffRM, Rudick R, Mork S, Bo L. Axonal 
Transection in the Lesions of Multiple Sclerosis. N Engl J Med 
1998;338:278-85. 
38. Chard DT, Griffin CM, Rashid W, Davies GR, Altmann DR, Kapoor R, 
Barker GJ, Thompson AJ, Miller DH. Progressive grey matter atrophy in 
clinically early relapsing-remitting multiple sclerosis. Mult.Seler. 
2004;10:387-91. 
39. Miller DH, Thompson AJ, Filippi M. Magnetic resonance studies of 
abnormalities in the normal appearing white matter and grey matter in 
multiple sclerosis. J Neurol 2003 ;250: 1407 -19. 
40. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis 
GS, Antel JP, Wolfson C, Arnold DL. Imaging axonal damage of normal-
appearing white matter in multiple sclerosis. Brain 1998;121 (Pt 1):103-
13. 
41. Gallo A, Rovaris M, Riva R, Ghezzi A, Benedetti B, Martinelli V, Falini 
A, Comi G, Filippi M. Diffusion-Tensor Magnetic Resonance Imaging 
Detects Normal-Appearing White Matter Damage Unrelated to Short-
term Disease Activity in Patients at the Earliest Clinical Stage of Multiple 
Sclerosis. Arch /'IleuroI2005:62:803-8. 
158 
Relapse and Disability in Multiple Sclerosis 
42. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez ~ Lassmann 
H. Heterogeneity of multiple sclerosis lesions: implications for the 
pathogenesis of demyelination. Ann.NeuroI2000;47:707-17. 
43. Keegan M, Konig F, McClelland R, Bruck W, Morales Y, Bitsch A, 
Panitch H, Lassmann H, Weinshenker B, Rodriguez M, Parisi J, 
Lucchinetti CF. Relation between humoral pathological changes in 
multiple sclerosis and response to therapeutic plasma exchange. Lancet 
2005;366:579-82. 
44. BROWNELL B, HUGHES IT. The distribution of plaques in the 
cerebrum in mUltiple sclerosis. J Neurol Neurosurg Psychiatry 
1962;25:315-20. 
45. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, 
apoptotic neurons, and reduced inflammation in cortical multiple 
sclerosis lesions. Ann.NeuroI2001;50:389-400. 
46. Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. Intracortical multiple 
sclerosis lesions are not associated with increased lymphocyte infiltration. 
Mult.Seler. 2003;9:323-31. 
47. Bo L, Vedeler CA, Nyland Ill, Trapp BD, Mork S1. Subpial 
demyelination in the cerebral cortex of multiple sclerosis patients. J 
Neuropathol. Exp. Neuro I 2003;62:723-32. 
48. Kutzelnigg A, Lassmann H. Cortical lesions and brain atrophy in MS. J 
Neurol Sci 2005;233:55-9. 
159 
Relapse and Disability in Multiple Sclerosis 
49. He J, Inglese M, Li BS, Babb JS, Grossman RJ, Gonen O. Relapsing-
remitting multiple sclerosis: metabolic abnormality in nonenhancing 
lesions and normal-appearing white matter at MR imaging: initial 
experience. Radiology 2005;234:211-7. 
50. Ormerod IE, Miller DH, McDonald WI, du Boulay EP, Rudge P, Kendall 
BE, Moseley IF, Johnson G, Tofts PS, Halliday AM, . The role ofNMR 
imaging in the assessment of multiple sclerosis and isolated neurological 
lesions. A quantitative study. Brain 1987;110 ( Pt 6): 1579-616. 
51. Davies GR, Altmann DR, Hadjiprocopis A, Rashid W, Chard DT, Griffin 
eM, Tofts PS, Barker GJ, Kapoor R, Thompson AJ, Miller DH. 
Increasing normal-appearing grey and white matter magnetisation 
transfer ratio abnormality in early relapsing-remitting multiple sclerosis. J 
NeuroI2005;252:1037-44. 
52. Allen IV, McKeown SR. A histological, histochemical and biochemical 
study of the macroscopically normal white matter in multiple sclerosis. J 
Neurol Sci 1979;41:81-91. 
53. Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative 
pathological evidence for axonal loss in normal appearing white matter in 
multiple sclerosis. Ann.NeuroI2000;47:391-5. 
54. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. Axonal loss in 
normal-appearing white matter in a patient with acute MS. Neurology 
2001 ;57: 1248-52. 
160 
Relapse and Disability in Multiple Sclerosis 
55. Bjartmar C, Trapp BD. Axonal degeneration and progressive neurologic 
disability in multiple sclerosis. Neurotox.Res. 2003;5: 157-6-+. 
56. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in 
acute multiple sclerosis lesions. Brain 1997;120 ( Pt 3):393-9. 
57. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal 
damage in multiple sclerosis is most extensive in early disease stages and 
decreases over time. Brain 2002:125:2202-12. 
58. Frisen L, Quigley HA. Visual-Acuity in Optic Atrophy - A Quantitative 
Clinicopathological Analysis. Graefes Archive for Clinical and 
Experimental Ophthalmology 1984;222:71-4. 
59. Youl BD, Turano G, Miller DH, Towell AD, MacManus DG, Moore SG, 
Jones SJ, Barrett G, Kendall BE, Moseley IF, . The pathophysiology of 
acute optic neuritis. An association of gadolinium leakage with clinical 
and electrophysiological deficits. Brain 1991;114 (Pt 6):2437-50. 
60. Miller DH, McDonald WI, Blumhardt LD, du Boulay GH, Halliday AM, 
Johnson G, Kendall BE, Kingsley DP, MacManus DG, Moseley IF, . 
Magnetic resonance imaging in isolated noncompressive spinal cord 
syndromes. A nn. Neurol 1987;22:714-23. 
61. Filippi M, Rocca M. MRI evidence for multiple sclerosis as a diffuse 
disease of the central nervous system. Journal of Neurology 
2005;252:v 16-v24. 
161 
Relapse and Disability in Multiple Sclerosis 
62. Rovaris M, Filippi M. Magnetic resonance techniques to monitor disease 
evolution and treatment trial outcomes in multiple sclerosis. 
Curr.Opin.NeuroI1999;12:337-44. 
63. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359: 1221-3l. 
64. O'Riordan JI, LosseffNA, Phatouros C, Thompson AJ, Moseley IF, 
MacManus DG, McDonald WI, Miller DH. Asymptomatic spinal cord 
lesions in clinically isolated optic nerve, brain stem, and spinal cord 
syndromes suggestive of demyelination. ] Neurol Neurosurg Psychiatry 
1998;64:353-7. 
65. Lynch SG, Rose JW, Smoker W, Petajan JH. MRI in familial multiple 
sclerosis. Neurology 1990;40:900-3. 
66. Engell T. A clinical patho-anatomical study of clinically silent multiple 
sclerosis. Acta Neurol Scand 1989;79:428-30. 
67. Ghatak NR, Hirano A, Lijtmaer H, Zimmerman HM. Asymptomatic 
demyelinated plaque in the spinal cord. Arch NeuroI1974;30:484-6. 
68. Knecht S, Frank B. Latent or truly asymptomatic multiple sclerosis. Acta 
Neurol Scand 1990;81 :363. 
69. Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DP, 
Moseley IF, McDonald WI. Patterns of disease actiyity in multiple 
sclerosis: clinical and magnetic resonance imaging study. BM] 
1990;300:631-4. 
162 
Relapse and Disability in Multiple Sclerosis 
70. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of 
magnetic resonance techniques in understanding and managing multiple 
sclerosis. Brain 1998;121 (Pt 1):3-24. 
71. Filippi M, Paty DW, Kappos L, BarkhofF, Compston DA, Thompson 
AJ, Zhao GJ, Wiles CM, McDonald WI, Miller DH. Correlations 
between changes in disability and T2-weighted brain MRI activity in 
multiple sclerosis: a follow-up study. Neurology 1995;45:255-60. 
72. Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, 
Kingsley DP, McDonald WI. Major differences in the dynamics of 
primary and secondary progressive multiple sclerosis. Ann.Neurol 
1991 ;29:53-62. 
73. Nijeholt GJ, van Walderveen MA, Castelijns JA, van Waesberghe JH, 
Polman C, Scheltens P, Rosier PF, Jongen PJ, BarkhofF. Brain and 
spinal cord abnormalities in multiple sclerosis. Correlation between MRI 
parameters, clinical subtypes and symptoms. Brain 1998;121 (Pt 4):687-
97. 
74. Filippi M, Rocca MA, Falini A, Caputo D, Ghezzi A, Colombo B, Scotti 
G, Comi G. Correlations between structural CNS damage and functional 
MRI changes in primary progressive MS. Neuroimage. 2002;15:537-46. 
75. Rovarls M, Bozzali M, Santuccio G, Ghezzi A, Caputo D, Montanari E, 
Bertolotto A, Bergamaschi R, Capra R, Mancardi G, Martinelli V, Comi 
G, Filippi M.1n vivo assessment of the brain and cervical cord pathology 
163 
Relapse and Disability in MUltiple Sclerosis 
of patients with primary progressive multiple sclerosis. Brain 
2001 ;124:2540-9. 
76. van Walderveen MA, Kamphorst W, Scheltens P, van \Vaesberghe JH, 
Ravid R, Valk J, Polman CH, BarkhofF. Histopathologic correlate of 
hypointense lesions on Tl-weighted spin-echo MRI in multiple sclerosis. 
Neurology 1998;50:1282-8. 
77. Truyen L, van Waesberghe JH, van Walderveen MA, van Oosten BW, 
Polman CH, Hommes OR, Ader HJ, BarkhofF. Accumulation of 
hypointense lesions ("black holes") on T 1 spin-echo MRI correlates with 
disease progression in multiple sclerosis. Neurology 1996;47: 1469-76. 
78. Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, Herndon RM, 
Richert JR, Salazar AM, Sheeder J, Miller D, McCabe K, Serra A, 
Campion MK, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Wende 
K, Martens-Davidson A, Kinkel RP, Munschauer FE, III. A longitudinal 
study ofTI hypointense lesions in relapsing MS: MSCRG trial of 
interferon beta-I a. Multiple Sclerosis Collaborative Research Group. 
Neurology 2000;55: 185-92. 
79. Filippi M, Cercignani M, Inglese M, Horsfield MA, Comi G. Diffusion 
tensor magnetic resonance imaging in multiple sclerosis. Neurology 
2001;56:304-11. 
80. Cercignani M, Bozzali M, Iannucci G, Comi G, Filippi M. Magnetisation 
transfer ratio and mean diffusiyity of normal appearing white and grey 
164 
Relapse and Disability in Multiple Sclerosis 
matter from patients with multiple sclerosis. J Neurol Neurosurg 
Psychiatry 2001;70:311-7. 
81. Cercignani M, Iannucci G, Rocca MA, Comi G, Horsfield MA, Filippi 
M. Pathologic damage in MS assessed by diffusion-weighted and 
magnetization transfer MRI. Neurology 2000;54: 1139-44. 
82. Chard DT, Griffm CM, McLean MA, Kapeller P, Kapoor R, Thompson 
AJ, Miller DH. Brain metabolite changes in cortical grey and normal-
appearing white matter in clinically early relapsing-remitting multiple 
sclerosis. Brain 2002;125:2342-52. 
83. Filippi M, Campi A, Dousset V, Baratti C, Martinelli V, Canal N, Scotti 
G, Comi G. A magnetization transfer imaging study of normal-appearing 
white matter in multiple sclerosis. Neurology 1995;45:478-82. 
84. Iannucci G, Tortorella C, Rovaris M, Sormani MP, Comi G, Filippi M. 
Prognostic value of MR and magnetization transfer imaging fmdings in 
patients with clinically isolated syndromes suggestive of multiple 
sclerosis at presentation. AJNR Am.J Neuroradiol. 2000;21: 1034-8. 
85. Traboulsee A, Dehmeshki J, Brex PA, Dalton CM, Chard D, Barker GJ, 
Plant GT, Miller DH. Normal-appearing brain tissue MTR histograms in 
clinically isolated syndromes suggestive of MS. Neurology 2002;59:126-
8. 
86. Tortorella C, Viti B, Bozzali M, Sormani MP, Rizzo G, Gilardi MF, 
Comi G, Filippi M. A magnetization transfer histogram study of normal-
appearing brain tissue in MS. Neurology 2000;54: 186-93. 
165 
Relapse and Disability in Multiple Sclerosis 
87. Bozzali M, Cercignani M, Sormani MP, Comi G, Filippi M. 
Quantification of brain gray matter damage in different MS phenotypes 
by use of diffusion tensor MR imaging. AJNR Am.J Neuroradiol. 
2002;23:985-8. 
88. Rovaris M, Bozzali M, Iannucci G, Ghezzi A, Caputo D, Montanari E, 
Bertolotto A, Bergamaschi R, Capra R, Mancardi GL, Martinelli V, Comi 
G, Filippi M. Assessment of normal-appearing white and gray matter in 
patients with primary progressive multiple sclerosis: a diffusion-tensor 
magnetic resonance imaging study. Arch Neuro/2002;59:1406-12. 
89. Rovaris M, Agosta F, Sormani MP, Inglese M, Martinelli V, Comi G, 
Filippi M. Conventional and magnetization transfer MRI predictors of 
clinical multiple sclerosis evolution: a medium-term follow-up study. 
Brain 2003;126:2323-32. 
90. Santos AC, Narayanan S, De Stefano N, Tartaglia MC, Francis SJ, 
Amaoutelis R, Caramanos Z, Antel JP, Pike GB, Arnold DL. 
Magnetization transfer can predict clinical evolution in patients with 
multiple sclerosis. J Neurol 2002;249:662-8. 
91. Tartaglia MC, Narayanan S, De Stefano N, Arnaoutelis R, Antel SB, 
Francis SJ, Santos AC, Lapierre Y, Arnold DL. Choline is increased in 
pre-Iesional normal appearing white matter in multiple sclerosis. J Neurol 
2002;249:1382-90. 
92. Wilson M, Tench CR, Morgan PS, Blumhardt LD. Pyramidal tract 
mapping by diffusion tensor magnetic resonance imaging in multiple 
166 
Relapse and Disability in Jlultiple Sclerosis 
sclerosis: improving correlations with disability. 1 Neurol Xeurosurg 
Psychiatry 2003;74:203-7. 
93. Ciccarelli 0, Werring DJ, Wheeler-Kingshott CA, Barker GJ, Parker GJ, 
Thompson AJ, Miller DH. Investigation ofMS normal-appearing brain 
using diffusion tensor MRl with clinical correlations. Neurology 
2001 ;56:926-33. 
94. Inglese M, Ghezzi A, Bianchi S, Gerevini S, Sormani MP, Martinelli V, 
Comi G, Filippi M. Irreversible Disability and Tissue Loss in Multiple 
Sclerosis: A Conventional and Magnetization Transfer Magnetic 
Resonance Imaging Study of the Optic Nerves. Arch Neurol 
2002;59:250-5. 
95. Miller DH, Khan OA, Sheremata WA, Blurnhardt LD, Rice GP, Libonati 
MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW. A 
controlled trial of natalizumab for relapsing multiple sclerosis. N.Engl.l 
Med. 2003;348: 15-23. 
96. Edwards SG, Gong QY, Liu C, Zvartau ME, Jaspan T, Roberts N, 
Blurnhardt LD. Infratentorial atrophy on magnetic resonance imaging and 
disability in multiple sclerosis. Brain 1999;122 ( Pt 2):291-301. 
97. Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC, Miller 0, 
Weinstock-Guttman B, Mass MK, Dougherty OS, Simonian NA. Eight-
year follow-up study of brain atrophy in patients with MS. Vcurology 
2002:59: 1412-20. 
167 
Relapse and Disability in Multiple Sclerosis 
98. Balassy C, Bernert G, Wober-Bingol C, Csapo B, Kornek B, Szeles J, 
Fleischmann D, Prayer D. Long-term MRI observations of childhood-
onset relapsing-remitting multiple sclerosis. Neuropediatrics 2001;32:28-
37. 
99. Behan, C. M. H., Hickman, S. J., Scolding, N. 1., Miller, D. H., and 
Compston, D. A. S. Identification of the clinically symptomatic lesion in 
multiple sclerosis - implications for remyelination therapy. Rev.Neurol 
(Paris) 156(3),28. 2000. 
Ref Type: Abstract 
100. Lycklama G, Thompson A, Filippi M, Miller D, Polman C, Fazekas F, 
Barkhof F. Spinal-cord MRI in multiple sclerosis. The Lancet Neurology 
2003;2:555-62. 
101. Double-masked trial of azathioprine in multiple sclerosis. British and 
Dutch Multiple Sclerosis Azathioprine Trial Group. Lancet 1988;2: 179-
83. 
102. Noseworthy JH, O'Brien P, Erickson BJ, Lee D, Sneve D, Ebers GC, 
Rice GP, Auty A, Hader WJ, Kirk A, Duquette P, Carter J, Francis G, 
Metz L, Shuster E. The Mayo Clinic-Canadian Cooperative trial of 
sulfasalazine in active multiple sclerosis. Neurology 1998;51: 1342-52. 
103. Berger JR, Sheremata W A, Resnick L, Atherton S, Fletcher MA, 
Norenberg M. Multiple sclerosis-like illness occurring with human 
immunodeficiency virus infection. Neurology 1989;39:324-9. 
168 
Relapse and Disability in Multiple Sclerosis 
104. The IFNB Multiple Sclerosis Study Group and The University of British 
Columbia MSIMRI Analysis Group. Interferon beta-l b in the treatment 
of mUltiple sclerosis: final outcome of the randomized controlled trial. 
Neurology 1995;45:1277-85. 
105. Paty DW, Li DK. Interferon beta-lb is effective in relapsing-remitting 
mUltiple sclerosis. II. MRI analysis results of a multicenter, randomized, 
double-blind, placebo-controlled trial. UBC MSIMRI Study Group and 
the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-7. 
106. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, 
Myers LW, Panitch HS, Rose JW, Schiffer RB. Copolymer 1 reduces 
relapse rate and improves disability in relapsing-remitting multiple 
sclerosis: results of a phase III multicenter, double-blind placebo-
controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. 
Neurology 1995;45:1268-76. 
107. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS 
trial: a randomized, double-blind, placebo-controlled study of interferon-
beta 1 a in relapsing-remitting multiple sclerosis. Prevention of Relapses 
and Disability by Interferon-betala Subcutaneously in Multiple Sclerosis. 
Ann.NeuroI1999;46: 197-206. 
108. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D'Amico R, 
Rice GP. Interferons in relapsing remitting multiple sclerosis: a 
systematic review. Lancet 2003;361:545-52. 
169 
Relapse and Disability in Multiple Sclerosis 
109. Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S. ~Iiller 
DH, Hale G, Waldmann H, Compston DA. The window of therapeutic 
opportunity in multiple sclerosis Evidence from monoclonal antibody 
therapy. J Neuro12005. 
110. Alvarez-Cermeno JC, Masjuan J, Villar LM. Progressive multi focal 
leukoencephalopathy, natalizumab, and multiple sclerosis . . VEngl.J .\/cd 
2005;353: 1744-6. 
Ill. Berger T, Deisenhammer F. Progressive multi focal leukoencephalopathy, 
natalizumab, and multiple sclerosis. N.EngIJ A/cd 2005;353: 174.t-6. 
112. Buljevac D, van Doomum GJ, Flach HZ, Groen J, Osterhaus AD. Hop 
W, van Doom PA, van der Meche FG, Hintzen RQ. Epstein-Barr virus 
and disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 
2005;76: 1377-81. 
113. Swingler RJ, Compston DA. The morbidity of multiple sclerosis. QJ 
Med. 1992;83:325-37. 
114. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J. 
Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, 
Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E. 
Development of a multiple sclerosis functional composite as a clinical 
trial outcome measure. Brain 1999;122 ( Pt 5):871-82. 
115. Sipe JC, Knobler RL, Braheny SL, Rice GP, Panitch HS. Oldstone MB. 
A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 
1984~34: 1368-72. 
170 
Relapse and Disability in Multiple Sclerosis 
116. Course and prognosis of multiple sclerosis. In: McAlpine D, Compston 
NO, Lumsden CE, eds. Multiple Sclerosis. Edinburgh: Livingstone 1955: 
147. 
117. McAlpine D. Multiple sclerosis: a review. Br.Med J 1973;2:292-5. 
118. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis 
pathogenesis: implications for diagnosis and therapy. Trends Mol.Med 
2001;7:115-21. 
119. DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a 
pathological survey of the corticospinal and sensory tracts. Brain 
2004;127: 1 009-18. 
120. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a 
unifying concept. Brain 2006;129:606-16. 
121. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple 
sclerosis assessed by the computerized data processing of 349 patients. 
Brain 1980;103:281-300. 
122. Shepherd DI. Clinical features of multiple sclerosis in north-east 
Scotland. Acta Neurol Scand 1979;60:218-30. 
123. Napier JC, Francis R, Wright G. Shared scheme for assessing drugs for 
mUltiple sclerosis: Cost effective provision of effective treatments for 
multiple sclerosis. BM/2003 ;326: 1212. 
124. Khatri BO, McQuillen MP. Disease modifying therapies in multiple 
sclerosis. Neurology 2002;59:472-3. 
171 
Relapse and Disability in Multiple Sclerosis 
125. Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical 
picture of mUltiple sclerosis: comparison between British and Japanese 
patients. J Neurol Sci. 1981;49:253-71. 
126. Poser S, Wikstrom J, Bauer H. Clinical data and the identification of 
special forms of multiple sclerosis in 1271 cases studied with a 
standardised documentation system. J Neurol Sci 2004;40:159-68. 
127. Dujmovic I, Mesaros, Pekmezovic T, Levic Z, Drulovic J. Primary 
progressive multiple sclerosis: clinical and paraclinical characteristics 
with application of the new diagnostic criteria. European Journal of 
Neurology 2004;11:439-44. 
128. Minderhoud 1M. On the pathogenesis of multiple sclerosis. A revised 
model of the cause(s) of multiple sclerosis, especially based on 
epidemiological data. Clin.Neurol Neurosurg 1994;96: 135-42. 
129. Ebers GC. Natural history of primary progressive multiple sclerosis. 
Mult.SeIer. 2004;10 Suppll:S8-13. 
130. Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH. 
Brain atrophy in clinically early relapsing-remitting multiple sclerosis. 
Brain 2002;125:327-37. 
131. Chard DT, Brex PA, Ciccarelli 0, Griffin CM, Parker GJ, Dalton C, 
Altmann DR, Thompson AJ, Miller DH. The longitudinal relation 
between brain lesion load and atrophy in multiple sclerosis: a 14 year 
follow up study. J Neurol Neurosurg Psychiatry 2003;74: 1551-4. 
172 
Relapse and Disability in Multiple Sclerosis 
132. Davies GR, Ramio-Torrenta L, Hadjiprocopis A, Chard DT, Griffin CM, 
Rashid W, Barker GJ, Kapoor R, Thompson AJ, Miller DH. Evidence for 
grey matter MTR abnormality in minimally disabled patients with early 
relapsing-remitting mUltiple sclerosis. J Neurol Neurosurg Psychiatry 
2004;75:998-1002. 
133. Lycke J, Tollesson PO, Frisen L. Asymptomatic visual loss in multiple 
sclerosis. J NeuroI2001;248:1079-86. 
134. Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stem Y, Lavie 
M, Gurevich M, Dolev M, Magalashvili D, Barak Y. Intravenous 
Immunoglobulin Treatment Following the First Demyelinating Event 
Suggestive of Multiple Sclerosis: A Randomized, Double-Blind, Placebo-
Controlled Trial. Arch NeuroI2004;61:1515-20. 
135. Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, 
Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner JL, 
Kupersmith MJ, Miller NR, Moke PS, Nazarian S, Orengo-Nania S, 
Savino PJ, Shults WT, Smith CH, Trobe JD, Wall M, Xing D. Visual 
function more than 10 years after optic neuritis: experience of the optic 
neuritis treatment trial. Am.J Ophthalmol. 2004;137:77-83. 
136. Ganter, Prince, Esiri. Spinal cord axonal loss in multiple sclerosis: a post-




Relapse and Disability in Multiple Sclerosis 
137. BONDUELLE M, BOUYGUES P, CHAUMONT P. [AMYOTROPHY 
AND ABOLITION OF REFLEXES IN MULTIPLE SCLEROSIS]. 
Sem.Hop. 1964;40:814-21. 
138. Ebers GC. Disease evolution in multiple sclerosis. J Neuro/2006;253 
Suppl 6:vi3-vi8. 
139. Baker AB, Baker LH. Diseases of the cerebellum. In: Clinical Neurology. 
Harper & Row 1995. 
140. Alusi SH, Worthington J, Glickman S, Bain PG. A study of tremor in 
mUltiple sclerosis. Brain 2001 ;124:720-30. 
141. Kurtzke JF. Clinical manifestation of multiple sclerosis. In: Vinken P, 
Bruyn G, eds. Handbook of Clinical Neurology. 1970: 161-216. 
142. Kakigi R, Kuroda Y, Neshige R, Endo C, Shibasaki H. Physiological 
study of the spinothalamic tract conduction in multiple sclerosis. J Neurol 
Sci 1992;107:205-9. 
143. Bergers E, Bot JCJ, De Groot CJA, Polman CH, Nijeholt GJ, Castelijns 
JA, van der Valk P, BarkhofF. Axonal damage in the spinal cord ofMS 
patients occurs largely independent of T2 MRI lesions. Neurology 
2002;59: 1766-71. 
144. Miller AE. Clinical Features. In: Cook S, ed. Handbook of Multiple 
Sclerosis. 2001. 
145. Voskuhl RR. Gender issues and multiple sclerosis. Cu".Neurol Neurosci 
Rep. 2002;2:277-86. 
174 
Relapse and Disability in Multiple Sclerosis 
146. Hall ED, Pazara KE, Linseman KL. Sex differences in postischemic 
neuronal necrosis in gerbils. J Cereb.Blood Flow Metab 1991;11:292-8. 
147. Alley J, Khasabov S, Simone D, Beitz A, Rodriguez M, Njenga MK. 
More severe neurologic deficits in SJL/J male than female mice following 
Theiler's virus-induced CNS demyelination. Exp.NeuroI2003;180:14-24. 
148. Hauben E, Mizrahi T, Agranov E, Schwartz M. Sexual dimorphism in the 
spontaneous recovery from spinal cord injury: a gender gap in beneficial 
autoimmunity? Eur J Neurosci 2002;16: 1731-40. 
149. Weatherby SJ, Mann CL, Davies MB, Fryer AA, Haq N, Strange RC, 
Hawkins CP. A pilot study of the relationship between gadolinium-
enhancing lesions, gender effect and polymorphisms of antioxidant 
enzymes in multiple sclerosis. J NeuroI2000;247:467-70. 
150. Pozzilli C, Tomassini V, Marinelli F, Paolillo A, Gasperini C, Bastianello 
S. 'Gender gap' in multiple sclerosis: magnetic resonance imaging 
evidence. EurJ NeuroI2003;IO:95-7. 
151. Wilder RL. Neuroimmunoendocrinology of the rheumatic diseases: past, 
present, and future. Ann.N. y'Acad.Sci 2002;966: 13-9. 
152. Da Silva JA, Hall GM. The effects of gender and sex hormones on 
outcome in rheumatoid arthritis. Baillieres Clin.Rheumatol. 1992;6: 196-
219. 
153. Whitacre CC, Reingold SC, O'Looney PA. A gender gap in 
autoimmunity. Science 1999;283:1277-8. 
175 
Relapse and Disability in Multiple Sclerosis 
154. Nankin HR, Calkins JH. Decreased bioavailable testosterone in aging 
normal and impotent men. J Clin.Endocrinol.Metab 1986;63:1418-20. 
155. Tomassini V, Onesti E, Mainero C, Giugni E, Paolillo A, Salvetti M, 
Nicoletti F, Pozzilli C. Sex hormones modulate brain damage in multiple 
sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry 2005;76:272-5. 
156. Detels R, Clark VA, Valdiviezo NL, Visscher BR, Malmgren RM, 
Dudley JP. Factors associated with a rapid course of multiple sclerosis. 
Arch Neuro/1982;39:337-41. 
157. Panelius M. Studies on epidemiological, clinical and etiological aspects 
of multiple sclerosis. Acta Neurol Scand 1969;Suppl-82. 
158. Runmarker B, Andersen o. Prognostic factors in a multiple sclerosis 
incidence cohort with twenty-five years of follow-up. Brain 1993;116 ( 
Pt 1):117-34. 
159. Muller R. Studies on disseminated sclerosis with special reference to 
symptomatology, course and prognosis. Acta Med Scand 1949;133:1-214. 
160. Gravel C, Gotz R, Lorrain A, Sendtner M. Adenoviral gene transfer of 
ciliary neurotrophic factor and brain-derived neurotrophic factor leads to 
long-term survival ofaxotomized motor neurons. Nat Med 1997;3:765-
70. 
161. Rapalino 0, Lazarov-Spiegler 0, Agranov E, Velan GJ, Voles E, 
Fraidakis M, Solomon A, Gepstein R, Katz A, Belkin M, Hadani M, 
176 
Relapse and Disability in Multiple Sclerosis 
Schwartz M. Implantation of stimulated homologous macrophages results 
in partial recovery of paraplegic rats. Nat Med 1998;4:814-21. 
162. Van Q, Elliott J, Snider WD. Brain-derived neurotrophic factor rescues 
spinal motor neurons from axotomy-induced cell death. Nature 
1992;360:753-5. 
163. Matthews PM. Primary progressive multiple sclerosis takes centre stage. 
J Neurol Neurosurg Psychiatry 2004;75: 1232-a. 
164. Grossman RI, Gonzalez-Scarano F, Atlas SW, Galetta S, Silberberg DH. 
Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology 
1986;161:721-5. 
165. Fog T, Linnemann F. The course of multiple sclerosis in 73 cases with 
computer-designed curves. Acta Neurol Scand SuppI1970;47:3-17S. 
166. Gudmundsson KR. Clinical studies of multiple sclerosis in Iceland. A 
follow-up of previous survey and reappraisal. Acta Neurol Scand Suppl 
1971 ;48: 1-78. 
167. McAlpine D, COMPSTON N. Some aspects of the natural history of 
disseminated sclerosis. Q.J Med 1952;21:135-67. 
168. Patzold U, Pocklington PRo Course of multiple sclerosis. First results ofa 
prospective study carried out of 102 MS patients from 1976-1980. Acta 
Neurol Scand 1982;65:248-66. 
169. Handbook of Multiple Sclerosis. New York: Marcel Dekker, 2001. 
177 
Relapse and Disability in Multiple Sclerosis 
170. Interferon beta-Ibis effective in relapsing-remitting multiple sclerosis. I. 
Clinical results of a multicenter, randomized, double-blind, placebo-
controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 
1993;43:655-61. 
171. Randomised double-blind placebo-controlled study of interferon beta-l a 
in relapsing/remitting multiple sclerosis. PRISMS (prevention of 
Relapses and Disability by Interferon beta-l a Subcutaneously in Multiple 
Sclerosis) Study Group. Lancet 1998;352:1498-504. 
172. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, 
Miller DH, Phillips IT, Lublin FD, Giovannoni G, Wajgt A, Toal M, 
Lynn F, Panzara MA, Sandrock A W. A randomized, placebo-controlled 
trial of natalizumab for relapsing multiple sclerosis. N.Engl.J Med 
2006;354:899-910. 
173. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk OM, Ebers GC. 
The natural history of multiple sclerosis: a geographically based study 9: 
observations on the progressive phase of the disease. Brain 
2006;129:584-94. 
174. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, 
Ebers GC. The natural history of multiple sclerosis: a geographically 
based study. 3. Multivariate analysis of predictive factors and models of 
outcome. Brain 1991;114 (Pt 2):1045-56. 
178 
Relapse and Disability in Multiple Sclerosis 
175. Sundstrom P, Svenningsson A, Nystrom L, Forsgren L. Clinical 
characteristics of mUltiple sclerosis in Vasterbotten County in northern 
Sweden. J Neurol Neurosurg Psychiatry 2004;75:711-6. 
176. Kurtzke JF, Beebe GW, Nagler B, Auth TL, Kurland LT, Nefzger MD. 
Studies on natural history of multiple sclerosis. 4. Clinical features of the 
onset bout. Acta Neurol Scand. 1968;44:467-94. 
177. McDonald WI. Relapse, remission, and progression in multiple sclerosis. 
N.Engl.J Med. 2000;343:1486-7. 
178. Rovaris M, Comi G, Ladkani D, Wolinsky JS, Filippi M. Short-term 
correlations between clinical and MR imaging findings in relapsing-
remitting multiple sclerosis. AJNR Am.J Neuroradiol. 2003;24:75-81. 
179. Held U, Heigenhauser L, Shang C, Kappos L, Polman C. Predictors of 
relapse rate in MS clinical trials. Neurology 2005;65: 1769-73. 
180. Sweeney VP, Sadovnick AD, Brandejs V. Prevalence of multiple 
sclerosis in British Columbia. Can.J Neurol Sci 1986;13:47-51. 
181. Swingler RJ, Compston DA. The prevalence of multiple sclerosis in south 
east Wales. J Neurol Neurosurg Psychiatry 1988;51:1520-4. 
182. Poser S, Raun NE, Poser W. Age at onset, initial symptomatology and the 
course of multiple sclerosis. Acta Neurol Scand 1982;66:355-62. 
183. Visscher BR, Liu KS, Clark VA, Detels R, Malmgren RM, Dudley JP. 
Onset symptoms as predictors of mortality and disability in multiple 
sclerosis. Acta Neurol Scand 1984;70:321-8. 
179 
Relapse and Disability in Multiple Sclerosis 
184. Zarei M, Chandran S, Compston A, Hodges J. Cognitive presentation of 
mUltiple sclerosis: evidence for a cortical variant. J Neurol Neurosurg 
Psychiatry 2003;74:872. 
185. Ochi H, Wu XM, Osoegawa M, Horiuchi I, Minohara M, Murai H, 
Ohyagi Y, Furuya H, Kira 1. TclITc2 and ThllTh2 balance in Asian and 
Western types of multiple sclerosis, HTLV-I-associated 
myelopathy/tropical spastic paraparesis and hypedgEaemic myelitis. J 
Neuroimmunol. 2001;119:297-305. 
186. Nakashima I, Fukazawa T, Ota K, Nohara C, Warabi Y, Ohashi T, 
Miyazawa I, Fujihara K, Itoyama Y. Two subtypes of optic-spinal form 
of mUltiple sclerosis in Japan: clinical and laboratory features. J Neurol 
2007. 
187. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Size-
selective neuronal changes in the anterior optic pathways suggest a 
differential susceptibility to injury in multiple sclerosis. Brain 
2001;124:1813-20. 
188. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker 
BG. A secondary progressive clinical course is uncommon in 
neuromyelitis optica. Neurology 2007;68:603-5. 
189. Kieseier BC. Assessing long-term effects of disease-modifying drugs. J 
Neuro12006;2S3 Suppl 6:vi23-vi30. 
190. Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, 
Havrdova E, Hutchinson M, Kappos L, Lublin FD, Miller DH, O'Connor 
180 
Relapse and Disability in Multiple Sclerosis 
PW, Phillips IT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt 
A, Weinstock-Guttman B, Wynn DR, Lynn F, panzara MA. Natalizumab 
reduces visual loss in patients with relapsing multiple sclerosis. 
Neurology 2007;68:1299-304. 
191. Costelloe L, O'rourke K, Kearney H, McGuigan C, Gribbin L, Duggan 
M, Tubridy N, Daly L, Hutchinson M. The patient knows best; significant 
change in the physical component of the multiple sclerosis impact scale 
(MSIS-29 physical). J Neurol Neurosurg Psychiatry 2007. 
192. Hoogervorst EL, Kalkers NF, Uitdehaag BM, Polman CH. A study 
validating changes in the multiple sclerosis functional composite. Arch 
NeuroI2002;59: 113-6. 
193. Marburg O. Die sogennante "akute multiple sklerose". Jarbucher fur 
Psychiatre und Neurologie 1906;27:211-312. 
194. Kurtzke JF, Beebe GW, Nagler B, Auth TL, Kurland LT, Nefzger MD. 
Studies on the natural history of multiple sclerosis. 7. Correlates of 
clinical change in an early bout. Acta Neurol Scand 1973;49:379-95. 
195. Dau PC, Petajan JH, Johnson KP, Panitch HS, Bomstein MB. 
Plasmapheresis in multiple sclerosis: preliminary findings. Neurology 
1980;30: 1023-8. 
196. Khatri BO, McQuillen MP, Hoffmann RG, Harrington GJ, Schmoll D. 
Plasma exchange in chronic progressive multiple sclerosis: a long-term 
study. Neurology 1991;41:409-14. 
181 
• 
Relapse and Disability in Multiple Sclerosis 
197. Weiner HL, Dawson DM. Plasmapheresis in multiple sclerosis: 
preliminary study. Neurology 1980;30:1029-33. 
198. Khatri BO, McQuillen MP, Harrington GJ, Schmoll D, Hoffmann RG. 
Chronic progressive mUltiple sclerosis: double-blind controlled study of 
plasmapheresis in patients taking immunosuppressive drugs. Neurology 
1985;35:312-9. 
199. The Canadian cooperative trial of cyclophosphamide and plasma 
exchange in progressive multiple sclerosis. The Canadian Cooperative 
Multiple Sclerosis Study Group. Lancet 1991;337:441-6. 
200. Gordon PA, Carroll DJ, Etches WS, Jeffrey V, Marsh L, Morrice BL, 
Olmstead D, Warren KG. A double-blind controlled pilot study of plasma 
exchange versus sham apheresis in chronic progressive multiple sclerosis. 
Can.J Neurol Sci. 1985;12:39-44. 
201. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, 
Mills JA, Weiner HL. Intensive immunosuppression in progressive 
multiple sclerosis. A randomized, three-arm study of high-dose 
intravenous cyclophosphamide, plasma exchange, and ACTH. N.Engl.J 
Med. 1983;308:173-80. 
202. Tindall RS, Walker JE, Ehle AL, Near L, Rollins J, Becker D. 
Plasmapheresis in multiple sclerosis: prospective trial of pheresis and 
immunosuppression versus immunosuppression alone. Neurology 
1982;32:739-43. 
182 
Relapse and Disability in Multiple Sclerosis 
203. Valbonesi M, GarelH S, Mosconi L, Zerbi D, Forlani G. Plasma exchange 
in the management of patients with multiple sclerosis: preliminary 
observations. Vox Sang. 1981;41:68-73. 
204. Weiner HL, Dau PC, Khatri BO, Petajan J, Birnbaum G, McQuillen MP, 
Fosburg MT, Feldstein M, Orav J. Double-blind study of true vs. sham 
plasmapheresis in patients being treated with immunosuppression for 
acute attacks of multiple sclerosis. Prog.Clin.Biol.Res. 1990;337:283. 
205. Rodriguez M, Karnes WE, Bartleson JD, Pineda AA. Plasmapheresis in 
acute episodes of fulminant CNS inflammatory demyelination. Neurology 
1993;43:1100-4. 
206. Dodick DW, Silber MH, Noseworthy JH, Wilbright WA, Rodriguez M. 
Acute disseminated encephalomyelitis after accidental injection of a hog 
vaccine: successful treatment with plasmapheresis. Mayo Clin.Proc. 
1998;73: 1193-5. 
207. Kanter DS, Horensky D, Sperling RA, Kaplan JD, Malachowski ME, 
Churchill WH, Jr. Plasmapheresis in fulminant acute disseminated 
encephalomyelitis. Neurology 1995;45:824-7. 
208. Stricker RB, Miller RG, Kiprov DD. Role of plasmapheresis in acute 
disseminated (postinfectious) encephalomyelitis. J Clin.Apheresis. 
1992;7: 173-9. 
209. Aguilera AJ, Carlow TJ, Smith 10, Simon TL. 
Lymphocytaplasmapheresis in Devic's syndrome. Transfusion 
1985;25:54-6. 
183 
Relapse and Disability in Multiple Sclerosis 
210. Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, 
Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M. A 
randomized trial of plasma exchange in acute central nervous system 
inflammatory demyelinating disease. Ann.NeuroI1999;46:878-86. 
211. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, 
Weinshenker BG. Plasma exchange for severe attacks of CNS 
demyelination: predictors of response. Neurology 2002;58: 143-6. 
212. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey 
SP, Krapf H, Zwingers T. Mitoxantrone in progressive multiple sclerosis: 
a placebo-controlled, double-blind, randomised, multi centre trial. The 
Lancet 2002;360:2018-25. 
213. Khatri BO. Therapeutic apheresis in multiple sclerosis and other central 
nervous system disorders. Ther.Apher. 2000;4:263-70. 
214. Archelos JJ, Storch MK, Hartung HP. The role ofB cells and 
autoantibodies in multiple sclerosis. Ann.NeuroI2000;47:694-706. 
215. Koller H, Buchholz J, Siebler M. Cerebrospinal fluid from multiple 
sclerosis patients inactivates neuronal Na+ current. Brain 1996;119:457-
63. 
216. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 
2003;2:117-27. 
184 
Relapse and Disability in Multiple Sclerosis 
217. Jacquerye P, Ossemann M, Laloux P, Dive A, De Coene B. Acute 
fulminant multiple sclerosis and plasma exchange. Eur.Neurol 
1999;41:174-5. 
218. Sorensen PS, Wanscher B, Szpirt W, Jensen CV, Ravnborg M, 
Christiansen P, Schreiber K, Nordenbo A. Plasma exchange combined 
with azathioprine in multiple sclerosis using serial gadolinium-enhanced 
MRI to monitor disease activity: a randomized single-masked cross-over 
pilot study. Neurology 1996;46:1620-5. 
219. Pericot I, Rio J, Rovira A, Castella MD, Tintore M, Montalban X. Serial 
gadolinium-enhanced MRI in acute attack of multiple sclerosis treated 
with plasma exchange. J NeuroI2003;250:243-4. 
220. Khatri BO, Koethe SM, McQuillen MP. Plasmapheresis with 
immunosuppressive drug therapy in progressive multiple sclerosis. A 
pilot study. Arch NeurolI984;41:734-8. 
221. Barnett MH, Sutton I. The pathology of multiple sclerosis: a paradigm 
shift. Curro Op in. Neuro 1 2006;19:242-7 . 
222. Schwartz M, Kipnis J. Multiple sclerosis as a by-product of the failure to 
sustain protective autoimmunity: a paradigm shift. Neuroscientist. 
2002;8:405-13. 
223. Brex PA, Ciccarelli 0, O'Riordan TI, Sailer M, Thompson AJ, Miller DH. 
A longitudinal study of abnormalities on MRI and disability from 
multiple sclerosis. N.Engl.J Med 2002;346: 158-64. 
185 
Relapse and Disability in Multiple Sclerosis 
224. Manfredonia F, Ciccarelli 0, Khaleeli Z, Tozer DJ, Sastre-Garriga J, 
Miller DH, Thompson AI. Normal-appearing brain tl relaxation time 
predicts disability in early primary progressive multiple sclerosis. Arch 
NeuroI2007;64:411-5. 
225. Davies GR, Altmann DR, Hadjiprocopis A, Rashid W, Chard DT, Griffin 
CM, Tofts PS, Barker GJ, Kapoor R, Thompson AJ, Miller DH. 
Increasing normal appearing grey and white matter magnetisation transfer 
ratio abnormality in early relapsing remitting multiple sclerosis. Journal 
o/Neurology 1900. 
226. Griffm CM, Chard DT, Parker GJ, Barker GJ, Thompson AI, Miller DH. 
The relationship between lesion and nonnal appearing brain tissue 
abnormalities in early relapsing remitting multiple sclerosis. J Neurol 
2002;249: 193-9. 
227. Schwartz M, Kipnis J. Protective autoimmunity and neuroprotection in 
inflammatory and noninflammatory neurodegenerative diseases. J Neurol 
Sci 2005;233:163-6. 
228. Weiner HL. Multiple Sclerosis Is an Inflammatory T-Cell-Mediated 
Autoimmune Disease. Arch NeuroI2004;61:1613-5. 
229. Chaudhuri A, Behan PO. Multiple Sclerosis Is Not an Autoimmune 
Disease. Arch NeuroI2004;61:1610-2. 
230. Amato MP, Fratiglioni L, Groppi C, Siracusa G, Amaducci L. Interrater 
reliability in assessing functional systems and disability on the Kurtzke 
scale in multiple sclerosis. Arch NeuroI1988;45:746-8. 
186 
Relapse and Disability in Multiple Sclerosis 
231. Bennetto L, Totham A, Healy P, Massey E, Scolding N. Plasma exchange 
in episodes of severe inflammatory demyelination of the central nervous 
system. A report of six cases. J Neuro/2004;251: 1515-21. 
232. Lovas G, Szilagyi N, Majtenyi K, Palkovits M, Komoly S. Axonal 
changes in chronic demyelinated cervical spinal cord plaques. Brain 
2000;123 (Pt 2):308-17. 
233. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. Acute 
axonal injury in multiple sclerosis. Correlation with demyelination and 
inflammation. Brain 2000;123 (Pt 6):1174-83. 
234. Gastinger MJ, Tian N, Horvath T, Marshak DW. Retinopetal axons in 
mammals: emphasis on histamine and serotonin. Curr.Eye Res. 
2006;31:655-67. 
235. Guinan JJ, Jr. Olivocochlear efferents: anatomy, physiology, function, 
and the measurement of efferent effects in humans. Ear Hear. 
2006;27:589-607. 
236. Lacroix S, Havton LA, McKay H, Yang H, Brant A, Roberts J, Tuszynski 
MH. Bilateral corticospinal projections arise from each motor cortex in 
the macaque monkey: a quantitative study. J Comp Neuro/2004;473:147-
61. 
237. Grey's Anatomy. Churchill Livingstone, 1989. 
238. De Stefano N, Cocco E, Lai M, Battaglini M, Spissu A, Marchi P, Floris 
G, Mortilla M, Stromillo ML, Paolillo A, Federico A, Marrosu MG. 
187 
Relapse and Disability in Multiple Sclerosis 
Imaging brain damage in frrst-degree relatives of sporadic and familial 
multiple sclerosis. Ann.NeuroI2006;59:634-9. 
239. Barnett MH, Henderson AP, Prineas IW. The macrophage in MS: just a 
scavenger after all? Pathology and pathogenesis of the acute MS lesion. 
Mult.Seler. 2006;12: 121-32. 
240. Aktas 0, Prozorovski T, Zipp F. Death ligands and autoimmune 
demyelination. Neuroscientist. 2006;12:305-16. 
241. Lang KS, Roll B, Myssina S, Schittenhelm M, Scheel-Walter HG, Kanz 
L, Fritz J, Lang F, Huber SM, Wieder T. Enhanced erythrocyte apoptosis 
in sickle cell anemia, thalassemia and glucose-6-phosphate 
dehydrogenase deficiency. Cell Physiol Bioehem. 2002;12:365-72. 
242. Yamashita T, Ninomiya M, Hernandez AP, Garcia-Verdugo 1M, 
Sunabori T, Sakaguchi M, Adachi K, Kojima T, Hirota Y, Kawase T, 
Araki N, Abe K, Okano H, Sawamoto K. Subventricular zone-derived 
neuroblasts migrate and differentiate into mature neurons in the post-
stroke adult striatum. J Neurosci 2006;26:6627-36. 
243. Camara J, Ffrench-Constant C. Lessons from oligodendrocyte biology on 
promoting repair in multiple sclerosis. J NeuroI2007;254 Suppll:I15-
122. 
188 
\NVERSrTY CIF 
BRISTOL 
UBRAR'f 
